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Abstract
Despite massive efforts to develop effective therapeutic options for the treatment
of asthma, disease prevalence continues to increase. Approximately 300 million people
worldwide have been estimated to be affected by asthma, and it remains a leading cause
of childhood hospitalization. While environmental as well as genetic causative agents
have been identified, the heterogeneous nature of the disease has proven difficult to
effectively treat. Asthma is characterized as chronic inflammation of the airway
characterized by increased airway hyperreactivity, increased goblet cell hyperplasia, and
airway remodeling. While these effects are traditionally regarded to be mediated through
the actions of CD4+ Th2 cells, recent advances have suggested that underlying innate
immune cell populations within the airway mucosa might exert a critical role in the
development of asthma. However, the inflammatory mediators and respective
mechanisms responsible for this role remain poorly understood. In this study, we attempt
to elucidate the role of two mucosal-associated inflammatory mediators, Snitrosoglutathione and prostaglandin I2 in the pathogenesis of asthma in two distinct
mouse models of allergic asthma. In our first study, we demonstrated that therapeutic
treatment using SPL-334, a specific inhibitor of S-nitrosoglutathione reductase,
significantly reduced the development of allergic airway inflammation. In our second
study, we demonstrated that loss of prostaglandin I2 signaling resulted in significant
alterations in pulmonary NK cells. Using an in vivo depletion method, we demonstrated
that pulmonary NK cells are responsible for attenuated development of house dust-mite
induced allergic airway inflammation. In our third and final study, we demonstrated that
loss of prostaglandin I2 signaling leads to substantial reduction in the production of nonantigen-specific IgG2b and IgA via an undetermined mechanism. The results of this
dissertation strongly suggest that regulation of mucosal immunity by inflammatory
mediators such as S-nitrosoglutathione and prostaglandin I2 can have profound effects on
the development of mucosal-associated diseases, and offer novel insights into potential
future therapeutic targets for the treatment of diseases such as asthma.
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CHAPTER ONE
Introduction and General Background
1.0

Introduction
In the past 40 years, the prevalence of asthma has continued to increase steadily,

and current estimates indicate that approximately 300 million people worldwide are
currently affected by asthma (Masoli, Fabian et al. 2004). The high cost associated with
morbidity and mortality in patients suffering from asthma reflects the severity of the
disease and the need for effective therapeutic approaches. In particular, the development
of asthma in young children has been shown to result in significant numbers of
hospitalizations and deaths, particularly in patients afflicted by poverty and inadequate
access to medical care (Mitchell 1985; Evans, Mullally et al. 1987; Beasley 2002). The
heterogeneous nature of the disease has made effective treatment of asthma extremely
difficult, as a wide variety of both environmental and genetic factors contribute to asthma
pathogenesis (Holloway, Yang et al. 2010). The most prevalent clinically recognized
form of asthma is allergic, or atopic, asthma (Kim, DeKruyff et al. 2010). This form of
asthma is predominantly mediated through adaptive immune responses, specifically
through the actions of CD4+ Th2 cells and IgE-producing B cells. These immune cells
are capable of extensive recognition and specificity towards a diverse array of antigens,
resulting in potent effector function and long-lasting immunological memory (Sakaguchi,
Yamaguchi et al. 2008). Recognition of environmental antigens, referred to as allergens,
by immune cells resident in airway mucosal tissue results in extensive activation of the
adaptive immune system that can pose a serious threat to the host. Animal models of
asthma, particularly rodent models, have been used to great effect to elucidate the
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underlying cellular and molecular mechanisms responsible for pathogenesis of asthma,
and most of our current understanding of the Th2-associated nature of asthma is a result
of extensive use of animal models (Bates, Rincon et al. 2009; Holmes, Solari et al. 2011).
However, while the role of the adaptive immune system in the regulation of asthma
pathogenesis has been widely studied, the role of the innate immune system remains
underappreciated (Holtzman 2012). In particular, our understanding of the mediators
responsible for regulation of innate immunity in response to allergen exposure remains
unresolved. The objective of the studies described in this dissertation are to expand our
current knowledge of the regulatory role of inflammatory mediators present in mucosal
tissue, and how regulation of innate immunity by these inflammatory mediators alters the
pathogenesis of asthma. The work presented herein can be divided into two distinct aims.
Our first aim was to utilize a specific inhibitor of S-nitrosoglutathione reductase, SPL334, to characterize the role of S-nitrosoglutathione in the regulation of an animal model
of allergic asthma. Our second aim was to determine whether loss of prostaglandin I2
signaling resulted in alteration of innate immune cells that had the capacity to affect the
development of asthma pathogenesis in an animal model of allergic asthma.
1.1

Pathophysiology of Asthma
Allergic asthma is a complex, heterogeneous disease defined as chronic

inflammation of the airway clinically associated with breathlessness, wheezing, and
coughing following exposure to allergen. These clinical manifestations arise from the
activation of the immune system resulting in increased airway levels of IgE, infiltration
of the airways by inflammatory immune cells such as eosinophils, airway hyperreactivity
(AHR), goblet cell hyperplasia resulting in increased airway mucus production, and
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airway remodeling (Strachan 1989; Robinson, Hamid et al. 1992; Cohn, Elias et al. 2004;
Kowalski 2007). Classically, CD4+ T cells are considered the primary orchestrator of
asthma-associated inflammatory responses. However, in addition to CD4+ T cells,
infiltration of the airway by macrophages, dendritic cells, eosinophils, and mast cells
leads to exacerbation of the inflammatory response resulting in a milieu of cytokines,
chemokines, and cytotoxic mediators that ultimately culminate in airway hyperreactivity,
mucus production, and airway remodeling (Mukherjee and Zhang 2011).
1.1.1

Airway Hyperreactivity and Airway Remodeling
Airway hyperreactivity (AHR) is defined as increased bronchoconstriction in

response to nonspecific stimulus of the airway (Boushey 1982). While the precise
mechanism underlying AHR is poorly understood, it has been recognized that there is a
close correlation between the degree of AHR and levels of airway inflammation (Jeffery,
Wardlaw et al. 1989). The consequences of AHR include a reduction in airway diameter,
increased smooth muscle contractility, increased microvascular permeability, and
generation of inflammatory mediators that can result in epithelial injury (Skoogh 1984;
Fryer, Lein et al. 2004). The damage to epithelial cells triggers enhanced mucus
production and shedding of epithelial cells into the airway (Holgate 2008). Attempts by
epithelial and stromal cells to repair the damage caused by inflammatory mediators
results in remodeling of the airway through the deposition of collagen (type I, II, III) and
fibronectin, and subsequent thickening of the airway epithelial layer from 10 to 300%
(Roche, Beasley et al. 1989; Homer and Elias 2000).
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Figure 1.1
Airway Remodeling. Inflammatory mediators induced by allergen exposure result in
smooth muscle contractility, epithelial shedding, goblet cell hyperplasia, and collagen deposition that
severely restrict airflow (Doeing and Solway 2013).

1.2

Immune Cells Involved in Asthma-associated Inflammation

1.2.1

CD4+ T Cells
As CD4+ T cells are the hallmark immune cell responsible for mediating the

inflammatory effects observed in allergic asthma, understanding the effector functions of
this immune population is critical in understanding asthma pathogenesis. Th2 cells are
characterized based on the expression of a specific cytokine profile which include IL-4,
IL-5, and IL-13 that are capable of aiding the differentiation and activation of humoral
responses in order to generate antigen-specific responses. IL-4 has been recognized to
have the greatest influence in driving Th2 differentiation, as IL-4 signaling via the
STAT6 pathway induces transcription factor GATA3 and subsequent commitment to the
Th2 lineage, resulting in a cascade effect responsible for the expansion of a large
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population of Th2 cells from naïve T cells (Swain, Weinberg et al. 1990; Zheng and
Flavell 1997). The production of IL-4 by CD4+ T cells promotes direct and indirect
recruitment of eosinophils into the airway, as IL-4 signaling has been shown to activate
endothelial and epithelial cells that subsequently produce chemokines responsible for
eosinophil recruitment (Dubois, Schweizer et al. 1998; Nakamura, Luster et al. 2001).
Additionally, IL-4 has been shown to induce the synthesis of IgE by activated B cells, as
well as promote IgG1 and IgE isotype switching (Hasbold, Hong et al. 1999). IL-13
shares a significant number of similarities in the signaling role involved in the
pathogenesis of asthma. However, IL-13 has been shown to be a more potent inducer of
AHR and chronic remodeling changes in the airway via smooth muscle hyperplasia and
subepithelial fibrosis (Grunig, Warnock et al. 1998; Wills-Karp, Luyimbazi et al. 1998;
Zhu, Homer et al. 1999). IL-5 is a highly effective and necessary eosinophil recruitment
and survival factor during allergic lung inflammation, capable of driving eosinophils in
the bone marrow to enter into the periphery (Huffnagle, Boyd et al. 1998).

Figure 1.2
The effector functions of Th2-associated cytokines in Allergic Asthma. Th2associated cytokines produce a wide range of effector functions that drive the inflammatory response
observed following allergen exposure (Finkelman, Hogan et al. 2010).
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1.2.2 Eosinophils
While CD4+ T cells retain the most influence in the orchestration of asthma
pathogenesis, the most distinctive immune cells associated with allergic asthma are
eosinophils. They are found not only in significantly increased numbers in the lung
tissue of asthmatic patients, but found to be expanded out into the sputum and
bronchoalveolar lavage fluid as well (Bousquet, Chanez et al. 1990; Lemiere, Ernst et al.
2006). The contribution of eosinophils to allergic airway inflammation is regarded as
primarily a release of pro-inflammatory cytotoxic granule proteins such as EPO as well
as through release of lipid mediators (Weller, Lim et al. 1996; Gleich 2000). The levels
of eosinophils and eosinophil-derived products found in the airways remain the standard
for indicating the severity of allergic asthma inflammation (Venge 2004).
Eosinophils display a prodigious capacity for the synthesis and secretion of inflammatory
mediators, and approximately 35 inflammatory cytokines, chemokines, cytotoxic factors,
and growth factors have been described, and the storage of these compounds in
intracellular granules means activation of eosinophils results in immediate and
indiscriminate inflammation directly at the site of activation (Lacy and Moqbel 2000;
Hogan, Rosenberg et al. 2008).
1.2.3

Dendritic Cells
In order to induce a CD4+ T cell-mediated immune response following allergen

exposure, the processing and presentation of allergen must occur. In the airway, three
subsets of dendritic cells have been identified that are capable of sampling the airway for
the presence of inhaled antigens. These subsets are derived from Ly-6C-expressing
peripheral monocytes, and are characterized as CD11b-CD103+, CD11bhiCD103-, and
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CD11bloCD103- (Masten and Lipscomb 1999; Sung, Fu et al. 2006; Condon, Sawyer et
al. 2011). While all subsets are capable of the internalization and processing of antigen,
differential pathogen receptor expression suggests that these dendritic cells are capable of
inducing responses to highly specific antigens (Condon, Sawyer et al. 2011). Processing
of antigen results in loading antigenic peptide onto the MHC class II or HLA (mouse and
human, respectively) receptor, allowing for subsequent presentation to T cells (Riese and
Chapman 2000). The presentation is accomplished via migration to the draining lymph
nodes of the lung, where engagement of the MHC/antigen complex binds to the T cell
receptor in addition to several additional co-receptors, resulting in allergen sensitization
and subsequent memory response (Humrich, Humrich et al. 2006; Smit and Lukacs 2006)

Figure 1.3
Overview of Th2-mediated development of allergic inflammation. Activation of Th2
cells following allergen presentation by dendritic cells results in cytokine production capable of
regulating a wide variety of cell types. This regulation results in inflammation of the airway as a
response to allergen exposure.

	
  

7	
  

1.3

Animal Models of Asthma
Using animal models to further our understanding of human diseases is a

universal practice in biomedical research. In regard to allergic asthma, animal models
have a long history of use to elucidate the basic immunological biology and mechanisms
responsible for pathogenesis (Karol, Cormier et al. 1994). Mouse models of allergic
asthma are the most commonly utilized animal model, as genetic variability and ease of
use create a powerful tool for deeper understanding of the role of the immune system in
the development and progression of allergic asthma. This section highlights two highly
utilized mouse models of allergic asthma, the traditional Ovalbumin-sensitized mouse
model and the more recently adopted House dust mite-induced mouse model of allergic
asthma.
1.3.1

Ovalbumin-induced Mouse Model
Ovalbumin (OVA) is a water-soluble protein that comprises the majority of egg

white. Vaz et al demonstrated that intraperitoneal injection of low dose OVA was
capable of inducing an antibody response in inbred mouse strains (Vaz, Vaz et al.
1971). A few years later, Van Hout & Johnson demonstrated that aerosolized OVA was
capable of inducing IgE antibody production in rats following initial sensitization
utilizing Bordetella pertussis heat-killed vaccine (Van Hout and Johnson 1972). The use
of adjuvants such as B. pertussis in the induction of allergic reactions led to some dispute
amongst researchers, and Ahlstedt et al demonstrated that aerosolized OVA alone was
capable of producing a robust inflammatory response in the airways without the use of
adjuvants (Ahlstedt and Bjorksten 1983). These early studies led to the development of
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the OVA-induced protocols utilized today for the induction of allergic lung inflammation
in mice.
Acute models of asthma typically involve intraperitoneal injection of OVA with
or without the addition of an adjuvant such as alum or AlOH3 over the course of two
weeks followed by daily OVA aerosol challenge for 3 – 7 days (McMillan and Lloyd
2004). This model has been shown to reproduce several key characteristics of asthma,
including elevated IgE, infiltration of the airways by inflammatory immune cells, goblet
cell hyperplasia, as well as the development of airway-hyperreactivity and
bronchoconstriction (Kumar, Herbert et al. 2008). However, it has been described
previously that repeated OVA aerosol and intravenous challenged mice will develop
tolerance rather than sensitization (Van Houten and Blake 1996; Pape, Merica et al.
1998).
For the study presented in Chapter 3 of this dissertation, in order to facilitate the
analysis of the CD4+ T cell response to inhaled OVA, we utilized the DO11.10 adoptive
transfer model similar to that described by Kearney et al (Kearney, Pape et al.
1994). Naïve CD4+ T cells from DO11.10 mice express a transgenic αβ T cell receptor
specific for OVA323-339 peptide presented by the I-Ad class II MHC that can be detected
using the anti-clonotypic antibody KJ1-26 (Haskins, Kubo et al. 1983). DO11.10 T cells
have been shown to undergo clonal expansion following antigen exposure, as well as
display resistance to the development of tolerance (Kearney, Pape et al. 1994). Adoptive
transfer of DO11.10 CD4+ T cells into Balb/c mice and subsequent exposure to OVA has
been shown to induce airway inflammation that closely mimics that seen in asthma (Lee,
Jaffar et al. 1999). The availability of the anti-clonotypic antibody KJ1-26 provides a
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method for the identification of OVA-specific donor T cells in vivo. The lack of
development of T cell tolerance in response to OVA exposure, combined with the
biologically relevant clonal expansion of an antigen-specific T cell population that results
in the characteristic immune responses observed in asthma make the DO11.10 adoptive
transfer model highly attractive for use in studying asthma pathogenesis.
1.3.2

House Dust Mite Allergen-induced Mouse Model
Although the traditional OVA-induced animal model of allergic asthma has

provided an impressive amount of relevant data over the last several decades, there are
concerns with the model that have led researchers to continue the search for models that
more closely mimic clinical features and relevancy to human disease. Primary among
these concerns is that the systemic delivery and immune activation of OVA and
additional adjuvants does not mimic human exposure and sensitization. Additionally, the
development of tolerance following prolonged exposure to OVA results in studies
skewed towards acute development rather than chronic development of asthma. Recent
efforts to address these concerns have resulted in the adoption of mouse models utilizing
house dust mite allergen exposure to mimic asthma development.
House dust mites (HDM) are members of the family Pyroglyphidae, and two
primary species have been the focus of intense interest in the development of asthma, the
European house dust mite (Dermatophagoides pteronyssinus) and the American house
dust mite (D. farinae). Several studies have indicated that asthmatic patients exhibit
significantly elevated HDM-specific IgE in airways and serum compared to control
patients, indicating a role for HDM in the development of asthma in humans (Shimojo,
Hirano et al. 1992; Nahm, Kim et al. 2000). Additionally, exposure to HDM in asthmatic
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patients resulted in development of airway hyperreactivity and increased airway
inflammation (Roche, Chinet et al. 1997). Analysis of HDM has revealed an impressive
array of allergens, primarily proteases, present in the HDM gastrointestinal tract that have
been subdivided into 24 major groups based on molecular category, immunological
activity, and quantitative allergenicity (Calderon and Cox 2014). Of these, Group 1 and
Group 2 (Der p/f 1 and Der p/f 2, respectively) have been generally accepted to be the
most clinically relevant, and the development of recombinant protein reagents for these
allergens has led to increased focus on the mechanisms involved in HDM-induced asthma
pathogenesis. It is particularly noteworthy that mice can be sensitized by HDM extracts
entering the airway and hence serve as a close approximation to the natural route of
allergen sensitization. Although the ultimate outcome of sensitization to HDM is the
development of a CD4+ Th2-driven IgE-dependent allergic response, research into the
mechanisms of HDM-induced asthma has revealed an expanded role for the involvement
of the innate immune system in the development of asthma. Specifically, it has been
described that HDM has the capacity to directly activate alveolar macrophages, mast
cells, and epithelial cells through PAR and TLR signaling and induce Th2-associated
cytokine responses without previous sensitization (Jacquet 2013; Wang 2013).
For the study described in Chapter 4 of this dissertation, we utilized a chronic
HDM-induced model of allergic asthma in order to address some of the concerns
regarding the OVA-induced model of allergic asthma as well as to maintain relevance
following wider adoption of HDM-induced models in asthma-related research. It has
been described previously that continuous intransal exposure to HDM in Balb/c mice
elicited eosinophilic and CD4+ T cell airway infiltration, increased production of Th2-
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associated cytokines by in vitro stimulated splenocytes, and airway remodeling not
observed in OVA-exposed Balb/c mice (Johnson, Wiley et al. 2004). Additionally, the
increased relevance of innate immunity in the development of HDM-induced asthma that
has been observed in other studies has tantalizing potential as an area for further research
interest that could lead to clinically relevant results.
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CHAPTER 2
MATERIALS & METHODS
2.0

Materials & Methods

2.0.1

Cell Culture Media
Cells were cultured in Complete RPMI (CRPMI) media comprised of L-

glutamine(-) RPMI 1640 media supplemented with 5% fetal bovine serum (FBS), Lglutamine (Life Technologies, Carlsbad CA), penicillin and streptomycin (Life
Technologies), Hepes (Life Technologies), Sodium Pyruvate (Life Technologies), and 2mercaptoethanol (Sigma Aldrich, St. Louis, MO).
2.0.2

Animals
DO11.10, Balb/c, IP-/-, and C57BL/6 mice were purchased from Jackson Labs,

Bar Harbor ME (The Jackson Laboratory) and were bred and housed in pathogen-free
conditions in the animal facilities at the University of Montana (Missoula, MT). IP-/mice were originally a generous gift of Dr. Garret A. Fitzgerald (University of
Pennsylvania, Philadelphia, PA). All experiments described in this dissertation were
performed to the guidelines of the National Institutes of Health, Bethesda, NIH, IACUC.
2.0.3

Animal Sensitization

2.0.3.1 Preparation of DO11.10 CD4+ Th2 Cells
Peripheral lymph nodes obtained from DO11.10 mice were depleted of CD8+
using MACS beads (Miltenyi Biotech, Auburn CA) and incubated in CRPMI (5x105
cells/ml) in the presence of OVA323-339 (1 µg/ml; Mimotopes, San Diego, CA), IL-4 (2
µg/ml; R&D Systems, Minneapolis, MN), and mAb anti-IFN-γ (5 µg/ml clone R4-6A2;
American Type Tissue Collection [ATTC], Manassas, VA) for 4 days at 37°C.
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Following incubation, cells were restimulated in identical culture conditions with the
addition of IL-2 (10 ng/ml; R&D Systems) for 4 days at 37°C. On day 8, cells were
depleted of class II+ cells by treating with mAb anti-class II (5 µg/ml clone M5/114;
ATTC) for 30 min, followed by incubation with 10 µg/ml plate-bound mouse anti-rat IgG
(Jackson ImmunoResearch, West Grove, PA) for 1 hr. Non-adherent (class II- cells)
CD4+ Th2 cells (>98% purity) were collected for analysis and transfer experiments.
2.0.3.2 Transfer of Polarized DO11.10 CD4+ Th2 Cells and OVA Aerosol Challenge
Eight-day polarized DO11.10 CD4+ Th2 cells generated as described in section
2.0.3.1 were adoptively transferred (6x106 cells/mouse) into Balb/c animals via
intravenous injection (100 µl of suspension). Mice (four to six per group) were then
challenged by exposure in a chamber to aerosolized solutions of OVA (0.5%, Grade V;
Sigma-Aldrich) for 20 min/day, over 7 consecutive days using a Wright’s nebulizer
(Buxco). Control mice were exposed to OVA aerosols but did not receive DO11.10 Th2
cells or received Th2 cells but were exposed to aerosolized PBS.
2.0.3.3 Intranasal Sensitization to Derp House Dust Mite Allergen
IP-/- and WT mice (four to six per group) were intranasally sensitized with 30 µl
whole Derp house dust mite (HDM) allergen (100 µg/mouse; Greer, Lenoir, NC) on day
0. Following sensitization, mice received subsequent challenge with HDM (50 µg/mouse
in 30 µl volume PBS; Greer) on day 7 and day 14. Three days following final HDM
challenge, mice were analyzed for development of allergic lung inflammation. Control
mice received intranasal 30 µl PBS on day 0, day 7, and day 14.
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2.0.4

Cell Purification

2.0.4.1 Isolation of Lung Mononuclear Cells
Lung tissue was mechanically dissociated into small fragments using a pair of
scissors followed by chemical dissociation using 0.1% collagenase (Type IV, SigmaAldrich) for 60 min at 37°C in CRPMI. Fragments were vigorously shaken every 15
minutes. Following dissociation, lung digest was filtered through a 70 µm nylon cell
strainer (Falcon) and washed in CRPMI by centrifugation at 1350 RPM at 4°C for 10
minutes. Viable mononuclear cells were isolated from the lung digest over a Percoll
density step gradient (41.7% and 67.6%).
To prepare the Percoll density step gradient, the stock solution of Percoll (GE
Healthcare, Piscataway, NJ) was made by adding 3.5 ml of 10X PBS into 35 ml Percoll.
The heavy (67.6%) and light (41.7%) density Percoll were made by combining 20 ml
stock Percoll with 9.6 ml CRPMI and 15 ml stock Percoll with 21 ml CRMPI,
respectively. Lung digest was resuspended in 7 ml of light density Percoll and carefully
layered on top of 7 ml of heavy density Percoll. Finally, 7 ml CRPMI was carefully
layered on top of the resuspended lung digest. This Percoll density gradient was
centrifuged at 1900 RPM at 4°C for 30 minutes with acceleration and brake set to the
lowest available setting. The mononuclear cells were removed using Pasteur pipette
(Alpha Laboratories, Hampshire, UK) and washed with HBSS (Life Technologies) at
1350 RPM at 4°C for 10 minutes, and resuspended in CRPMI.
2.0.4.2 Isolation of Peyer’s Patch Mononuclear Cells
The small intestines of IP-/- and WT mice were removed and the fecal content
removed by flushing with 5 ml of CRPMI. Peyer’s patches were removed from the
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intestinal wall using scissors and chemically dissociated using 0.5 mg/ml collagenase
(Type IV, Sigma-Aldrich) for 40 min at 37°C in CRPMI. After 40 min, 125 µl 0.5 M
EDTA (Sigma) was added for 5 minutes at 37°C to halt collagenase activity. Following
dissociation, Peyer’s patch digest was filtered through a 70 µm nylon cell strainer
(Falcon) and washed in CRPMI by centrifugation at 1350 RPM at 4°C for 10 minutes,
and resuspended in CRPMI.
2.0.4.3 Isolation of Splenic Mononuclear Cells
The spleens of IP-/- and WT mice were removed, mechanically dissociated by
forcing through a 70 µm nylon cell strainer (Falcon), and washed in CRPMI by
centrifugation at 1350 RPM at 4°C for 10 minutes. Splenic cells were resuspended in 7
ml media, layered on top of 7 ml Lympholyte Mouse Cell Separation Media (Cedarlane,
Burlington, NC), and centrifuged at 2000 RPM for 20 min at 4°C with acceleration and
brake set to the lowest available setting. The lymphocytes were removed, washed in
HBSS at 1350 PRM for 10 minutes at 4°C, and resuspended in CRPMI.
2.0.4.4 Isolation of Lymph Node Mononuclear Cells
The brachial and mesenteric lymph nodes were removed from IP-/- and WT mice,
mechanically dissociated by forcing through a 70 µm nylon cell strainer (Falcon), and
washed in CRPMI by centrifugation at 1350 RPM at 4°C for 10 minutes. Lymph node
lymphocytes were resuspended in CRPMI.
2.0.4.5 Isolation of Bone Marrow Mononuclear Cells
The femurs of IP-/- and WT mice were removed using scissor and the bone
marrow flushed out with 5 ml CRPMI using a syringe (BD Biosciences, Franklin Lakes,
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NJ). Bone marrow was then washed in CRPMI by centrifugation at 1350 RPM at 4°C for
10 minutes, then resuspended in CRPMI.
2.0.4.6 Collection of Bronchoalveolar Lavage Fluid
Bronchoalveolar lavage fluid (BALF) was collected by cannulation of the trachea
of euthanized mice (100 µl Euthasol) and washing the airways with 3 X 0.5 ml of PBS.
BALF was centrifuged to yield pelleted cells, which were pooled. The soluble phase
BALF was used for cytokine determination. BAL cells of four to six animals were used
for flow cytometry analysis, cell differential counts, and determination of eosinophil
peroxidase levels as described below.
2.0.4.7 Collection of Serum Samples for Immunoglobulin Quantification
Individual serum samples were collected from euthanized (100 µl Euthasol) IP-/and WT mice by cardiac puncture and placed in 1.5 ml Eppendorf tubes (VWR, Radnor,
PA) containing 50 µl of EDTA (Sigma). Individual samples were allowed to sit on ice
for 20 min, followed by centrifugation at 14000 RPM for 10 min at 4°C. Serum was
carefully collected and frozen down at -20°C for immunoglobulin quantification as
described below.
2.0.4.8 Collection of Fecal Content for sIgA Quantification
The small intestines of IP-/- and WT mice were removed and flushed as described
in Chapter 2 section 2.0.4.2. Flushed fecal contents were collected individually and
centrifuged at 2000 RPM for 10 min at 4°C, and supernatant was collected for sIgA
quantification as described below.
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2.0.5

Natural Killer Cell Protocols

2.0.5.1 Natural Killer Cell Depletion Utilizing mAb anti-NK1.1
Systemic depletion of natural killer (NK) cells in IP-/- and WT mice was
accomplished by intraperitoneal (i.p.) injection of 150 µl anti-NK1.1 monoclonal
antibody (mAb)(250 µg PK136, ATCC) one day prior (day -1) to HDM challenge (day 0)
as described in Chapter 2 Methods section 2.0.3.3. Mice received subsequent i.p.
injections of 150 µl mAb anti-NK1.1 (250 µg PK136, ATCC) on day 3, day 6, day 10,
and day 13. Control mice received i.p. injection of 150 µl PBS on day -1, day 3, day 6,
day 10, and day 13.
2.0.5.2 Oral-pharyngeal Adoptive Transfer of Natural Killer Cells
Splenic mononuclear cells were isolated from IP-/- and WT mice as described in
section 2.0.4.3, and NK cells purified by magnetic cell sorting (MagCellect,
R&DSystems). Sorted NK cells were selected on the basis of being CD3-NK1.1+ and
purity was determined by measuring the proportion of CD3-NK1.1+ cells (87-92% over
three experiments). Sorted NK cells were resuspended (5x105 cells/ml) in RPMI lacking
FBS but supplemented with 10 ng/ml IL-2, and 30 µl was instilled by oral-pharyngeal
administration (four mice per group) 24 hours following HDM administration (100
µg/mouse; Greer).
2.0.6

Intranasal Administration of SPL-334
Prior to administration, SPL-334 (SAJE Pharma, Baltimore, MD) was dissolved

in PBS by sonication for 5 min. DO11.10 Th2 cell-recipient mice (four to six per group)
were lightly anesthetized with isofluorane to allow for intranasal administration of 30 µl
SPL-334 (0.1 mg/kg or 1 mg/kg) for 7 consecutive days. Administration of SPL-334
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occurred 5 hours prior to OVA aerosol exposure as detailed in Chapter 2 Methods section
2.0.3.2. Control animals received intranasal administration of 30 µl PBS for 7
consecutive days, 5 hours prior to OVA aerosol exposure.
2.0.7

Cytokine & Chemokine Quantification

2.0.7.1 In vitro Stimulation of Cells Isolated from Dissociated Lung Tissue
Immune cells isolated from dissociated tissue as described in Chapter 2 Methods
section 2.0.4 were stimulated in vitro with either plate-bound mAb or recombinant
cytokines.
For plate-bound stimulation, mAb anti-CD3 (2 µg/ml clone 2C11; ATCC) mAb
anti-NK1.1 (20 µg/ml clone PK136; ATCC), or mAb anti-NKp46 (10 µg/ml clone
29A1.4; Biolegend) was added to 24 well cell culture plates (Greiner Bio-One, Monroe,
NC) and incubated for 24 hours at 37°C. Following incubation, cells (1x106 cells/ml)
were added and incubated for 24 hours at 37°C, with subsequent collection of
supernatants. In the case of mAb anti-NK1.1 and mAb anti-NKp46, recombinant IL-2
(10 ng/ml; Biolegend) was added to wells in conjunction with addition of cells.
Supernatants were frozen down at -20°C for further cytokine quantification
For recombinant protein stimulation, recombinant IL-2 (10 ng/ml; Biolegend),
recombinant IL-23 (20 ng/ml; R&D Systems), OVA323-339 peptide (1 µg/ml; Mimotopes,
San Diego, CA) or HDM (20 µg/ml; Greer) were added to 24 well cell culture plates
(Greiner Bio-One) in conjunction with cells from isolated tissue (1x106 cells/ml) and
incubated for 24 hours at 37°C. Supernatants were frozen down at -20°C for further
cytokine quantification.
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2.0.7.2 ELISA Cytokine & Chemokine Quantification: CX3CL1, CCL2, CCL11, GMCSF, IFN-γ, TNF-α, IL-22, IL-4, IL-5, IL-13, IL-17
To examine cytokine production, enzyme-linked immunosorbant assay (ELISA)
was performed using commercial kits. CX3CL1, CCL2, CCL11, IL-4, IL-5, IL-13, and
IL-22 were quantified using R&D systems kits. GM-CSF, IFN-γ, and TNF-α were
quantified using Biolegend kits.
The general protocol for ELISA assay is as follows: 100 µl of capture antibody
diluted in coating buffer (either PBS or bicarbonate buffer) was added to 96 well plates
(Greiner Bio-One) and stored at 4°C overnight followed by 3 washes on Thermo Electron
Wellwash 5 MK2 Plate washer (Fisher Scientific) with ELISA wash buffer (WB) (0.05%
Tween PBS). Following washing, 200 µl of blocking buffer (1% bovine serum albumin
(Sigma) in PBS) was added and incubated at room temperature for a minimum of 2 h.
Blocking buffer was removed by washing WB prior to addition of sample or standard (50
µl or 100 µl depending on kit) diluted in blocking buffer. Samples were covered and
incubated overnight at 4°C. Following overnight incubation, plates were washed 3X WB
and 100 µl of detection antibody diluted in blocking buffer was added and plates
incubated for 90 minutes at room temperature. Plates were then washed 3X WB and 100
µl strep-avidin horse-radish peroxidase (SA-HRP) diluted in blocking buffer was added
to plates. Plates were washed 3X WB and 100 µl TMB Single Solution (Invitrogen,
Rockport, MD) was added to each well, incubated for up to 10 minutes avoiding direct
light, and the reaction was stopped with 50 µl 0.3 M H2SO4 (Sigma). The absorbance
was read at 450 nm using a SpectraMax 190 Microplate Reader (Molecular Devices,
Sunnyvale, CA).

	
  

20	
  

2.0.7.3 Bronchoalveolar Lavage Fluid Th2 Cytokine Quantification Using Meso Scale
Discovery V-PLEX: IL-4, IL-5, IL-13
For the quantification of BALF Th2 cytokines IL-4, IL-5, and IL-13, a 10-Plex
Mouse Proinflammatory Panel 1 (Meso Scale Discovery, Rockville, MD) was used
according to manufacturer kit specifications. Plated BALF samples were analyzed using
a QuickPlex SQ 120 (Meso Scale Discovery).
2.0.8

Immunoglobulin Detection & Quantification

2.0.8.1 ELISA for Quantification of IgG1, IgG2b, IgG2c, IgG3, IgM, IgA
For examining immunoglobulin production in serum, ELISA was performed
using SBA Clonotyping System/HRP (Southern Biotech, Birmingham, AL). Briefly,
capture antibody was diluted to a concentration of 5 µg/ml in PBS and added to 96 well
plates (Greiner Bio-One) stored overnight at 4°C. Following overnight incubation, plates
were washed using Thermo Electron Wellwash 5 MK2 Plate washer with ELISA wash
buffer (WB) (0.05% Tween PBS). 200 µl of blocking buffer (1% bovine serum albumin
(Sigma) in PBS) was added and plates were incubated at room temperature for a
minimum of 2 h. Blocking buffer was removed by 3X WB prior to addition of 100 µl
sample or standard diluted in blocking buffer, and plates were covered and stored
overnight at 4°C. Following overnight storage, plates were washed WB and 100 µl
detection antibody diluted 1:500 in blocking buffer was added to plates for 90 minutes.
Plates were washed with 3X WB and 100 µl TMB Single Solution (Invitrogen) was
added to each well, incubated for up to 10 minutes avoiding direct light, and the reaction
was stopped with 50 µl 0.3 M H2SO4 (Sigma). The absorbance was read at 450 nm using
a SpectraMax 190 Microplate Reader (Molecular Devices, Sunnyvale, CA).
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2.0.8.2 ELISA for Quantification of secretory IgA
For quantification of sIgA in BALF and fecal content, our laboratory had
previously developed an ELISA protocol specifically designed for recognition of IgA
coupled to secretory component (pIgR) (Jaffar, Ferrini et al. 2009). Briefly, 96 well
plates (Greiner Bio-One) were coated with goat anti-pIgR (2 µg/ml; R&D Systems)
overnight at 4°C. Following overnight incubation, plates were washed 3X WB, and
incubated with BALF or fecal content samples diluted 1:50 overnight at 4°C. Following
overnight incubation, plates were washed 3X WB and incubated with 1:500 diluted HRPIgA detection antibody (Southern Biotech) at room temperature for 90 min followed by
addition of 100 µl TMB (BD Biosciences. No mouse sIgA standard is commercially
available; however, results were corrected per microgram BALF or fecal protein and
expressed as fold increase from control values.
2.0.9

Airway Inflammation

2.0.9.1 Eosinophil Peroxidase Assay
This assay was specifically used for the detection of eosinophil peroxidase (EPO)
produced by eosinophils in the BALF as determined by colorimetric assay. 100 µl of
PBS was added to each well of a 96 well flat-bottom plate (Greiner Bio-One). The cells
from BALF collected as described in Chapter 2 Methods section 2.0.4.6 were
resuspended in PBS (pH 7.0) in a final volume of 300 µl. In triplicate, 100 µl of cell
suspension was added to each well and serially diluted 1:2 through the 8th well. The
substrate solution was prepared by crushing one tablet of orthophenylene
diaminedihydrochloride (OPD)(Sigma)(final concentration of 0.1% OPD) in 50 µM TrisHCL (Sigma) containing 0.1% Triton X-100 (Sigma) and 1 mM hydrogen peroxide
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(Sigma). 100 µl of substrate solution was added to each well and plates were incubated at
room temperature for 30 min or until sufficient color development had occurred. 50 µl of
0.3 M H2SO4 (Sigma) was added to stop the reaction, and the absorbance was measured
at 495 nm using a SpectraMax 190 Microplate Reader (Molecular Devices). The
measurements determined using this assay were total EPO, not released EPO, and are
indicative of the number of eosinophils present in the BAL.
2.0.9.2 Airway Hyperreactivity: Respiratory Resistance and Dynamic Compliance
In order to assess pulmonary function and airway hyperreactivity, control and
OVA-challenged (with or without SPL-334 treatments) Balb/c mice were anesthetized
and tracheotomized. Respiratory resistance (RL, cm H2O.s/ml) and dynamic compliance
(CDyn, ml/cm H2O) to increasing concentrations of methacholine inhalation (1.5 – 24
mg/ml) were measured by mechanical ventilation using Buxco Resistance/Compliance
equipment (Buxco Research Systems, Wilmington, NC) by Mary Buford in the
Inhalation Core Facility (University of Montana).
2.0.10 Cell Staining
2.0.10.1 Cell Differential
Cytospin preparations were performed on 5x104 cells followed by staining using a
Wright-Giesma protocol (Hema 3 Staining Kit, Thermo Scientific). Cell differential
percentages were determined by light microscopy evaluation and expressed as absolute
cell numbers.
2.0.10.2 Lung Histology: Hematoxylin and Eosin Stain
The lower lobes of non-lavaged lungs were removed and fixed in 4%
paraformaldehyde and embedded in paraffin using a Shandon Citadel tissue processor
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(Thermo Scientific). Microtome sections were cut at 5-µm thickness and stained with
hematoxylin and eosin (H&E) staining using a Shandon Varistain 24 – 4 (Thermo
Scientific).
2.0.10.3 Lung Histology: Periodic acid-Schiff Stain (PAS)
Schiff reagent was made by heating distilled water to boiling, removing water
from heat and adding 4 g basic fuchsin (Sigma), and heating the solution again to boiling.
The reagent solution was allowed to coil to 50°C and filtered. 80 mL of 1 N hydrochloric
acid was added, the solution allowed to cool completely, and 4 g of sodium metabisulfite
(Sigma) were added. Reagent solution was allowed to stand overnight in the dark,
followed by addition with shaking of 2 g activated charcoal for 1 min. Schiff reagent was
filtered and stored at 4°C for 2 to 4 months as needed.
For PAS staining, tissue sections generated as described in Chapter 2 Methods
section 2.0.10.2 were deparaffinized and hydrated in water. These sections were then
oxidized in 0.5% periodic acid solution (2.5 g periodic acid in 500 ml distilled water) for
5 min followed by rinsing in distilled water. Tissue sections were placed in Schiff
reagent for 15 minutes followed by washing in lukewarm tap water for 5 min. Sections
were counterstained in Mayer’s hematoxylin (10 dips) followed by washing in tap water
for 5 min. Tissue was dehydrated and coverslipped using a synthetic mounting medium.
Slides were then imaged with an iCys CompuCyte Laser Scanning Cytometer (LSC,
Westwood, MA) in order to determine the amount of PAS staining and bronchial wall
thickness between samples.
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2.0.10.4 Immunofluorescent Microscopy
For immunofluorescent staining, lung tissue was frozen in Sakura Tissue-Tek
OCT (Sakura Finetek USA, Torrance, CA). Cryosections were mounted on glass slides,
blocked, and dual stained with 100 µl mAb. Coverslips were mounted with FluorSave
(EMD, Gibbstown, NJ) or Prolong gold (Life Technologies, Gand Island, NY) and
sections were examined using an Olympus FV1000 IX81 inverted laser scanning
confocal microscope (with spectral detection and TIRF Module)(Olympus Corporation of
the America, New Orleans, LA).
2.0.10.5 Flow Cytometry: Surface Receptor Expression
Cells (1x106) isolated from BALF and dissociated tissue as described in Chapter 2
Methods section 2.0.4 were added to 5 ml polystyrene round bottom tubes (BD
Biosciences) and centrifuged at 1350 RPM for 10 min at 4°C. After media was poured
off and the cell pellet broken up, 100 µl FC block (clone 2.4G2; ATCC) was added to
each tube for 5 min. 1- 2 µl of flurochrome-conjugated antibodies (Chapter 2 Methods
section 2.0.10.8) were added to each tube and tubes were placed on ice avoiding direct
light for 20 min. Cells were washed with 1 ml staining buffer and centrifuged at 1350
RPM for 10 min at 4°C, resuspended in 500 µl staining buffer and transferred to filter-top
5 ml polystyrene round bottom tubes (BD Biosciences). Stained cells were analyzed
using a BD FACSAria (BD Biosciences) utilizing FACSDiVa software for performing
multi-parameter analysis of immune cells.
2.0.10.6 Flow Cytometry: Intracellular Staining
For intracellular staining of cytokines and transcription factors, we used a
modified FOXP3 Fix/Perm Buffer Set protocol (Biolegend). Normal surface staining of
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immune cells as described in Chapter 2 Methods section 2.9.10.5 was performed prior to
intracellular staining. 1 ml of 1X Fix/Perm solution (Biolegend) was added to each tube,
followed by incubation for 20 min at room temperature avoiding direct light. Cells were
washed with 1 ml staining buffer by centrifugation for 10 min at 4°C. Cells were
resuspended in 1 ml 1X FOXP3 Perm Buffer (Biolegend), followed by incubation for 15
min at room temperature avoiding direct light. Cells were centrifuged for 10 min at 4°C,
and resuspended in 100 µl of 1X FOXP3 Perm Buffer (Biologend). 1 – 2 µl of
fluorochrome-conjugated antibodies (Chapter 2 Methods section 2.0.10.8) were added to
each tube, followed by incubation for 20 min at room temperature avoiding direct light.
Cells were washed with 1 ml staining buffer by centrifugation for 10 min at 4°C,
resuspended in 500 µl staining buffer and transferred to filter-top 5 ml polystyrene round
bottom tubes (BD Biosciences). Stained cells were analyzed using a BD FACSAria (BD
Biosciences) utilizing FACSDiVa software for performing multi-parameter analysis of
immune cells.
2.0.10.7 Intracellular Staining Using PMA and Ionomycin
For intracellular staining of Granzyme A, Granzyme B, and IFN-γ, immune cells
isolated from lung tissue as described in Chapter 2 Methods section 2.0.4.1 required prior
stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin to initiate
production. Cells were resuspended at a concentration of 2x106 cells/ml and 500 µl of
cells were added to 5 ml polystyrene round bottom tubes (BD Biosciences). 50 ng PMA
(Sigma), 500 ng ionomycin (Sigma), and 1 µl GolgiPlug (Brefeldin A)(BD Biosciences)
were added to each tube and then incubated 4 h (IFN-γ) or 24 h (Granzyme A and
Granzyme B) at 37°C. Following incubation, cells were washed 2X with staining buffer
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by centrifugation for 10 min at 4°C, and the intracellular staining protocol described in
Chapter 2 Methods section 2.0.10.6 was used to complete intracellular staining.
2.0.10.8

Chapter 3

Flow Cytometry Antibodies
Specificity

Clone

Conjugated

Company

Anti-CD4

GK1.5

APC-Cy7

BD
Biosciences

Anti-CD8

53-6.7

PE

Biolegend

KJ1-26

APC

eBioscience

RB6-8C5

APC-Cy7

Biolegend

Anti-CD11b

M1/70

APC

Biolegend

Anti-F4/80

BM8

AF647

Biolegend

Anti-Siglec-F

E50-2440

PE

BD
Biosciences

Anti-IL-4

11B11

APC

Biolegend

Anti-IFN-γ

XMG1.2

FITC

Biolegend

Anti-NK1.1

PK136

Anti-CD3

145-2C11

Anti-CD19

6D5

APC-Cy7

Biolegend

Anti-Dx5 (CD49b)

Dx5

PE

Biolegend

Anti-CD27

LG.3A10

APC

Biolegend

Anti-CD127

A7R34

APC

Biolegend

Anti-Ly49A

YE1/48.10.6

FITC

Biolegend

Anti-Ly49C

14B11

FITC

Biolegend

Anti-CD117 (c-kit)

2B8

APC

Biolegend

Anti-NKp46

29A1.4

PE, APC

Biolegend

Anti-DO11.10
TCR
Anti-Gr-1 (Ly6G/Ly-6C)

Chapter 4
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APC, FITC,
PE
PE, FITC,
APC

Biolegend
Biolegend

Chapter 5

	
  

Anti-NKG2D

CX5

PE

eBioscience

Anti-Granzyme A

GzA-3G8.5

APC

eBioscience

Anti-Granzyme B

GB11

FITC

Biolegend

Anti-IFN-γ

XMG1.2

APC

Biolegend

Anti-CD11b

M1/70

FITC

Biolegend

Anti-F4/80

BM8

APC

Biolegend

Anti-Siglec-F

E50-2440

PE

BD
Biosciences

Anti Gr-1(Ly6G/Ly-6C)

RB6-8C5

APC-Cy7

Biolegend

Anti-CD4

GK1.5

APC-Cy7,
FITC

Biolegend

Anti-CD8

53-6.7

PE

Biolegend

Anti-CD45R/B220

RA3-6B2

APC

Biolegend

Anti-IgA

C10-3

FITC

BD
Biosciences

Anti-IgM

RMM-1

PE

Biolegend

Anti-CD3

145-2C11,
17A2

FITC, APC,
AF647

Biolegend

Anti-CD4

GK1.5

FITC

Biolegend

Anti-CD8

53-6.7

FITC

Biolegend

Anti-NKp46

29A1.4

PE, APC

Biolegend

Anti-RORγt

B2D

APC

eBiosceinces

Anti-IL-23r

O78-1208

PE

BD
Biosciences

Anti-CD127

A7R34

APC

Biolegend
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2.0.11

Statistics
Unless otherwise described, the data presented in this dissertation are summarized

as mean ± SEM. Statistical analysis was performed using GraphPad Prism software
(GraphPad Software, La Jolla, CA) using unpaired student’s t test (Welch’s correction
was utilized where F test revealed unequal variance between groups). Statistical
significance was attributed to data achieving p < 0.05.
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3.0

ABSTRACT
Allergic asthma is characterized by Th2 type inflammation, leading to airway

hyperresponsiveness, mucus hypersecretion, and tissue remodeling.
S-Nitrosoglutathione reductase (GSNOR) is an alchohol dehydrogenase involved in the
regulation of intracellular levels of S-nitrosothiols. GSNOR activity has been shown to
be elevated in human asthmatic lungs, resulting in diminished S-nitrosothiols and thus
contributing to increased airway hyperreactivity. Using a mouse model of allergic airway
inflammation, we report that intranasal administration of a new selective inhibitor of
GSNOR, SPL-334, caused a marked reduction in airway hyperreactivity, allergenspecific T cells and eosinophil accumulation, and mucus production in the lungs in
response to allergen inhalation. Morever, SPL-334 treatment resulted in a significant
decrease in the production of the Th2 cytokines IL-5 and IL-13 and the level of the
chemokine CCL11 (eotaxin-1) in the airways. Collectively, these observations reveal
that GSNOR inhibitors are effective not only in reducing airway hyperresponsiveness but
also in limiting lung inflammatory responses mediated by CD4+ Th2 cells. These
findings suggest that the inhibition of GSNOR may provide a novel therapeutic approach
for the treatment of allergic airway inflammation.
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3.1

Introduction

3.1.1

Biochemical Alterations Identified in Asthma
While the principle effort to delineate processes that drive the pathogenesis of

asthma have rightly centered on the immunological events occurring in the airway, these
immunological events occur in conjunction with specific biochemical processes as well.
These reactions have received intense scrutiny as a consequence of the regulatory
capacity they can exert on immune function. Several key biomarkers that occur
downstream of these potential biochemical alterations have been identified that have the
potential to influence immunological as well as respiratory function.
Superoxide dismutases (SOD) are a family of metalloprotein enzymes responsible
for the scavenging and removal of reactive oxygen species, in particular superoxide
radical following production of nitric oxide (NO), through the conversion of superoxide
radical into hydrogen peroxide and oxygen (McCord and Fridovich 1988). They can be
divided into three types based on the reactive metal ion present in the active site of the
enzyme: (i) Copper/Zinc (Cu/Zn) (ii) Manganese (Mn) (iii) or Iron (Fe) (Mruk,
Silvestrini et al. 2002). Of these types, eukaryotes primarily express the Cu/Zn isoform
of SOD in the cytosol and Mn isoform of SOD in mitochondria. Additionally, an
extracellular Cu/Zn isoform of SOD (SODEX) has been described that resides in the
extracellular matrix of several tissues including the brain, lungs, and extracellular fluid
such as plasma (Marklund 1984). Superoxide radicals can induce widespread and
substantial damage in the airway through direct interaction with cells to create a
‘cascade’ of reactive oxygen species, as well as through interaction with nitric oxide
radicals to form peroxynitrite (Jain, Kannan et al. 1998). Several studies have shown that
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serum activity of SOD is low in patients with severe asthma, suggesting a potential role
of reactive oxygen species such as superoxide radicals in inducing airway obstruction and
hypersensitivity (De Raeve, Thunnissen et al. 1997; Comhair, Ricci et al.
2005). However, attempts to treat asthma utilizing antioxidant therapy have ultimately
proven unsuccessful (Fogarty, Lewis et al. 2003).
Arginase is a metalloprotein enzyme containing Mn in its active site that is
responsible for the final enzymatic reaction of the urea cycle via conversion of L-arginine
into L-ornithine and urea (Wu, Lee et al. 1998). Increased activity of arginase has been
observed in asthmatic patients with decreased lung function, in addition to the
identification of single nucleotide polymorphisms (SNPs) in populations with
asthma (Lara, Khatri et al. 2008; Litonjua, Lasky-Su et al. 2008). The role of arginase in
decreased lung function is not entirely clear, although it has been proposed that
competition with nitric oxide synthases (NOSs) for L-arginine results in decreased
production of NO, a smooth muscle relaxant, in the airway leading to bronchoconstriction
and airway hyperreactivity (Strapkova and Antosova 2011).
Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of
NOS that is released following degradation of methylated proteins (Boger 2004). The
lung has been shown to be a major source of ADMA, and in mice it has been shown that
elevated ADMA levels in the airway are responsible for the inhibition of NOS activity,
resulting in increased bronchoconstriction and airway hyperreactivity (Bulau, Zakrzewicz
et al. 2007; Klein, Weigel et al. 2010).
Eosinophil peroxidase (EPO) is a haloperoxidase critical to the cytolytic function
of eosinophils. In the presence of hydrogen peroxide and either bromide (preferred) or
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chloride, EPO generates hypobromite or hypobromous acid, which is stored in
intracellular granules until needed for the removal of multicellular parasites as well as a
limited repertoire of bacteria (Mayeno, Curran et al. 1989). As one of the hallmark
features of allergic asthma is accumulation of eosinophils in the airway, it should be little
surprise that elevated levels of EPO exist in the airways of asthmatic patients, and urinary
bromotyrosine levels have been used to track increased airway eosinophilia (Wedes, Wu
et al. 2011). As hypobromous acid is highly cytotoxic, an increased level of EPO in the
airway is highly undesirable and likely leads to increased injury of the airway.
3.1.2

Nitric Oxide Signaling
When analyzing the biochemical alterations described in Chapter 3 Section 3.1.1

that have been implicated to exert a role in asthma pathogenesis, a noticeable
characteristic becomes apparent. Specifically, all the biochemical pathways associated
with these biomarkers are dependent to varying degrees on the involvement of the NO
signaling pathway. A deeper understanding of this pathway is helpful in understanding
how alterations in NO signaling can lead to profound affects on the airway.
3.1.2.1 Synthesis of Nitric Oxide
Due to the importance of NO in both cell signaling and as an effector molecule
for immune-regulated defense against pathogens, synthesis of NO occurs widely in a
wide variety of tissues. While several isoforms of nitric oxide synthases (NOSs) exist, all
isoforms utilize the substrate L-arginine in conjunction with co-substrates reduced
nicotinamide-adenine-dinucleotide phostphate (NADPH) and O2 for the production of
NO and L-citrulline utilizing electron transfer via the cofactors flavin adenine
dinucleotide (FAD), flavin mononucleotide (FMN), tetrabydriobiopterin (BH4), and heme
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(Forstermann and Sessa 2012). Additionally, binding of calmodulin to NOS enzymes is a
critical step in the facilitation of electron transport, and intracellular increases in Ca2+ are
therefore critical in controlling NO synthesis (Hemmens and Mayer 1998).

Figure 3.1
Nitric Oxide Synthesis. Metabolism of arginine resulting in NO and citrulline is
mediated by several nitric oxide synthase isoforms in conjunction with co-substrates NADPH and O 2 as
well as co-factors including FAD, FMN, and BH4. Binding of CA2+ to NOS via calmodulin (CaM) is a
critical step in NO synthesis. Inhibition of NO production occurs when compounds such as NG-nitroL-arginine methyl ester (L-NAME) bind to NOS(Freire, Guimaraes et al. 2009).

Neuronal NOS (nNOS; NOS-1) is constitutively expressed in immature and
mature neurons of both the central and peripheral nervous systems, localized to synaptic
spines, as well as being present in skeletal muscle smooth muscle, and cardiac muscle
myoctes (Chen, Tu et al. 2004; Zhou and Zhu 2009). The production of NO via nNOS
has been shown to play an important role in long term potentiation, a form of synaptic
plasticity critical in the process of learning and memory, and inhibition of nNOS leads to
impairment of this process (Bohme, Bon et al. 1993; Bon and Garthwaite 2003). Binding
of NO to proteins that have accessible metal-containing amino acids such as cysteine
residues in muscle, a process termed S-nitrosylation discussed more fully in Chapter 3
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section 3.1.3, can affect muscle contractility (Xu, Eu et al. 1998). Additionally, the
expression of nNOS and subsequent synthesis of NO by nitrergic nerves has been shown
to alter smooth muscle tone (Forstermann and Sessa 2012). However, NO has been
implicated to play a deleterious role in excitotoxicity and ischemia, as overstimulation of
N-methyl-D-aspartate (NMDA) receptors by glutamate results in increased intracellular
Ca2+ levels capable of inducing high levels of NO synthesis which can lead to subsequent
cytotoxicity in surrounding neurons (Eliasson, Huang et al. 1999).
Endothelial NOS (eNOS; NOS-3) is also constitutively expressed, primarily in
endothelial cells, in a membrane-anchored form, but has been shown in cardiac myoctes,
neurons, synctiotrophoblasts, and kidney tubularepithelial cells (Forstermann and Sessa
2012). The association of eNOS and endothelial cells results in several critical functions
in controlling cardiovascular function. NO synthesized from eNOS has been shown to
cause dilation of blood vessels through stimulation of soluble guanylyl cyclase and
increasing cyclic guanosine monophosphate (Forstermann, Mulsch et al.
1986). Originally identified as endothelial-derived growth factor (EDGF), NO plays an
integral role in the proliferation of both vascular smooth muscle and in the stimulation of
angiogenesis (Garg and Hassid 1989; Han and Stewart 2006). eNOS-derived NO has
also been shown to have an effect on the immune system and vascular inflammation by
decreasing the production of chemoattractant protein MCP-1, also known as CCL2, by
endothelial cells in addition to suppressing the expression of adhesion molecules
CD11/CD18 on leukocytes resulting in decreased extravasation of leukocytes into
tissue (Kubes, Suzuki et al. 1991; Zeiher, Fisslthaler et al. 1995).
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The final isoform of NOS is inducible NOS (iNOS; NOS-2). Unlike nNOS and
eNOS, iNOS is not constitutively expressed in cells, and altered amino acid structure at
the calmodulin-binding site results in high affinity binding of calmodulin by iNOS
independently of intracellular Ca2+ concentration (Cho, Xie et al. 1992). Instead, iNOS is
transcriptionally regulated via activation of transcription factors such as NK-κB, AP-1,
signal transducer and activator of transcription (STAT)-1α, interferon-regulatory factor-1
(IRF-1), and nuclear factor interleukin-6 (NF-IL-6) (Kleinert, Euchenhofer et al. 1998;
Dlaska and Weiss 1999; Ganster, Taylor et al. 2001). Activation of these signaling
pathways have been shown following cellular stimulation utilizing bacterial
lipopolysaccharide, IFN-γ, TNF-α, IL-1β, and IL-12, while IL-4, IL-13, and TGF-β has
been implicated to inhibit iNOS expression (Green, Scheller et al. 1994; MacMicking,
Xie et al. 1997; Bogdan 2001). iNOS expression has been identified in a wide variety of
immune cells, especially innate immune cells such as macrophages, dendritic cells,
natural killer cells, neutrophils, and even in non-immune populations such as epithelial
and endothelial cells (Bogdan 2001; Ricciardolo, Timmers et al. 2003). The widespread
adoption of NO by the immune system, and even non-immune cells, as a mechanism for
the initial early-stage clearance of infection should be an indication of the effectiveness
and importance of NO in defense against pathogens.
3.1.2.2 Mechanism of Action of Nitric Oxide
NO is a membrane-permeable, gaseous free radical and the smallest known
signaling molecule. Capable of rapid diffusion following synthesis, NO has the capacity
to interact with intracellular molecular sites in an autocrine or paracrine manner. The
best-characterized site of action involving NO is the iron-containing heme component of
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guanylate cyclase where stimulation of the conversion of guanosine triphosphate to cyclic
guanosine monophosphate (cGMP), a key component in the activation of a protein
kinases involved in cell signaling pathways, occurs (Ignarro and Kadowitz
1985). Additionally, NO has been found to regulate gene transcription of vascular cell
adhesion molecule 1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1), and Eselection (CD62E) by endothelial cells, regulate mRNA translation of ferritin, and induce
post-translational modification in proteins via ADP ribosylation (Pozdnyakov, Lloyd et
al. 1993; Pantopoulos and Hentze 1995; Khan, Harrison et al. 1996).
The concentration of NO that is synthesized has a direct impact on the mechanism
of action of NO. For example, high concentrations produced by iNOS in activated
macrophages have potent cytotoxic capabilities including the killing of tumor cells and
elimination of various viral, bacterial, fungal, and parasitic pathogens (Denis 1991;
Karupiah, Xie et al. 1993). The ability of NO and its reactive nitrogen intermediates to
induce mutation of DNA, inhibit DNA repair and protein synthesis, alter protein function
via S-nitrosylation, inactive enzymes through binding and disruption of metal-containing
active sites, or induce lipid peroxidation can lead to highly effective control of pathogens
by the innate immune system. However, high concentrations of NO can have deleterious
effects on the host tissue as well, as the mechanisms utilized to destroy pathogens are not
pathogen-specific. As a free radical, NO has the capacity to induce cell and tissue
damage itself, or the interaction of NO with superoxide radical can result in the formation
of peroxynitrite, a highly cytotoxic molecule (Radi, Beckman et al. 1991). NO has been
implicated to be the initial factor involved in the initiation of septic shock following
bacterial endotoxin exposure, leading to massive vasodilation, hypotension, and capillary
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damage (MacMicking, Nathan et al. 1995). Therefore, when attempting to understand
the role that NO is exerting during a pathological event, it is critical to consider that small
changes in NO synthesis and signaling could lead to vastly differing outcomes.
3.1.2.3 Role of Nitric Oxide in the Airway
The capability of NO to induce vasodilation and smooth muscle relaxation, in
addition to its potent antimicrobial effects, lead to extensive investigation of the role of
NO in a location where all three facets are in close proximity, namely the airway. The
capacity of NO-containing compounds to induce bronchodilation through activation of
guanylate cyclase and increased cGMP was identified in 1989 and raised further interest
in the airway regulatory abilities of NO (Gruetter, Childers et al. 1989). In addition to the
activation of guanylate cyclase, modification of proteins through addition of NO to
metal-containing amino acids, discussed more fully in section 3.1.3, has been identified
as an additional mechanism via which NO can regulate bronchodilation that is
independent of cGMP (Gaston, Drazen et al. 1994). The use of NOS inhibitors such as
Nω-nitro-L-arginine methyl ester (L-NAME) or N9-monomethyl-L-arginine (L-NMMA)
have been shown in guinea pigs to result in significant increases in airway resistance
following bronchoconstriction-inducing stimuli, including allergens (Nijkamp, van der
Linde et al. 1993; Persson, Friberg et al. 1993; Ricciardolo, Nadel et al. 1994). Utilizing
NOS knockout-mice, recent work by Bratt et al revealed that the production of NO by
iNOS during allergen-induced airway inflammation is essential for the reduction of lung
inflammation, and that upregulation of iNOS during inflammation required eNOS, but
not nNOS, activation (Bratt, Williams et al. 2010). The role of eNOS in controlling
bronchoconstriction through iNOS-synthesized NO is interesting when considering that
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eNOS-derived NO has been shown to play a critical role in regulating pulmonary
vasoconstriction and vascular permeability in patients with pulmonary hypertension,
chronic obstructive pulmonary disease, and cystic fibrosis (Dinh-Xuan, Higenbottam et
al. 1991). While the source of NO in the airway appears to be of little consequence to
overall affect on the lungs, it is clear that the presence of NO in the airway is capable of
having a dramatic influence on airway function.
3.1.2.4 Regulation of Nitric Oxide in the Airway
Due to the importance of NO as a key cell signaling molecule, a critical
consideration when considering the biological efficacy of NO lies not only in its rate of
synthesis following stimulation, but also in the rate of decomposition. While the rate of
decomposition is reliant on factors such as initial concentration, systemic location, or
presence of other reactive gasses, the half-life of NO in blood has been estimated to range
between 0.05 – 1.8 ms (Liu, Miller et al. 1998). In order to facilitate long-term signaling
in tissue, storage of NO is therefore necessitated.
3.1.2.4.1

Nitrosylation

As a free radical, NO can be rapidly oxidized into NO-derived intermediates.
Early work by Stamler et al described the stabilization of NO via binding to proteins
containing sulfhydryl-groups such as thiols (Stamler, Jaraki et al. 1992). This redox
reaction, known as S-nitrosylation, falls under the broader category of nitrosylation
reactions, which also includes the binding of NO to transition metals as well as tyrosine,
known as metal nitrosylation and tyrosine nitration, respectively (Mengel, Chaki et al.
2013). Over 100 protein substrates have been identified to undergo nitrosylation,
primarily through S-nitrosylation, indicating the critical importance of nitrosylation in
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controlling signal transduction (Stamler, Lamas et al. 2001). A critical early example of
the role of S-nitrosylation in controlling receptor signaling was the discovery that the Nmethyl-D-aspartate (NMDA) receptor was regulated via S-nitrosylation (Lipton, Choi et
al. 1993). While nitrosylation can occur spontaneously, enzymatic control of the reaction
has been recognized to play a critical role in maintain the levels of nitrosylated proteins
in tissue. Enzymes such as ceruloplasmin, superoxide dismutase, and even NOS have
been identified to induce nitrosylation, while enzymes such as thioredoxin and S-nitrosoglutathione reductase have been identified to lead to the removal of NO from nitrosylated
proteins, or denitrosylation (Hess, Matsumoto et al. 2005). It is critical to recognize that
S-nitrosylation of proteins does not remove the biological activity of NO, as Snitrosylated proteins have been shown to induce vasodilation via activation of guanylate
cyclase in a more controlled manner than pure NO (Stamler, Jaraki et al. 1992). This
enhanced activity of NO in tissue means that regulation of nitrosylated proteins in tissue
takes on critical importance.
3.1.2.4.2

S-Nitrosoglutathione & S-nitrosoglutahione Reductase

Proteins that have undergone S-nitrosylation are referred to as S-nitrothiols
(SNOs). In the airway, the reaction of NO with the sulfhydryl group present on
glutathione results in the formation of S-nitrosoglutathione (GSNO). In humans, GSNO
has been identified to be the most abundant SNO present in both cells as well as
extracellular spaces, such as the airways, and addition of exogenous NO into the airway
was shown to lead to increased formation of GSNO (Gaston, Reilly et al. 1993). Liu et al
described a glutathione-dependent fomaldehyde dehydrogenase that has been highly
evolutionarily conserved termed S-nitrosoglutathione reductase (GSNOR) capable of
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regulating GSNO levels on both a tissue and intracellular level (Liu, Hausladen et al.
2001).

NO

NO

S-nitrosoglutathione
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Figure 3.2
Regulation of Nitric Oxide Signaling. Nitric oxide has the capacity to bind to thiol
containing proteins such as glutathione (GSH), via S-nitrosylation, resulting in stabilization of NO
signaling in both cells and tissues. The release of protein-bound NO in the airways is regulated by Snitrosoglutathione reductase (GSNOR), and this down-regulation in NO signaling via destabilization
has been implicated to have dramatic effects on airway responses. It has been suggested that inhibition
of GSNOR could be an effective poteintial therapeutic option for airway disorders such as asthma.

GSNO has been shown to have potent and long-lasting biological activity similar
to that of native NO, including bronchodilatory capabilities (Gaston, Reilly et al. 1993).
Treatment of tracheal smooth muscle cells in vitro utilizing GSNO revealed that
exogenous GSNO has a 100-fold greater potency in inducing bronchodilatory activity
than theophylline, a drug commonly used for the treatment of respiratory diseases
including asthma (Gaston, Drazen et al. 1994). This has led to recognition of its role in
potentially regulating the development and severity of diseases characterized by
bronchoconstriction and airway hyperreactivity such as asthma. Examination of airway
GSNO levels in asthmatic children revealed that severe asthma is associated with
decreased levels of airway GSNO (Gaston, Sears et al. 1998). Examination of GSNO in
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animal models of allergic asthma has revealed that degradation of GSNO occurs resulting
in bronchoconstriction of the airways (Fang, Johns et al. 2000). In an attempt to
understand how degradation of GSNO is occurring in asthmatic airways, researchers have
focused on whether GSNOR dysregulation could be a potential underlying cause.
GSNOR-/- mice exhibit increased levels of SNOs in the airways, leading to protection
from the development of methacholine-induced airway hyperreactivity following OVAsensitization (Que, Yang et al. 2009). Additionally, supplementation of the airway with
GSNO of OVA-sensitized and –challenged mice resulted in amelioration of airway
hyperreactivity, but did not alter the infiltration of the airway by inflammatory immune
cells (Que, Yang et al. 2009). These studies suggest that pharmacological intervention
with the goal of controlling levels of GSNO in the airway could provide a unique and
powerful therapeutic approach to combat respiratory diseases such as asthma.
3.2

RESULTS

3.2.1 Characterization of Allergic Pulmonary Responses in Mice Treated with Snitrosoglutathione Reductase Inhibitor SPL-334
The GSNO/GSNOR system exerts significant influence on airway responsiveness
and asthma pathogenesis (see Chapter 3 Background section 3.1.2.4.2). In this study, we
utilized the specific GSNOR inhibitor SPL-334 to establish whether therapeutic
inhibition of GSNOR could lead to alteration in the development of allergic asthma.
Sanghani et al identified SPL-334 (C3) as a potent and selective inhibitor of GSNOR
activity capable of inducing increased intracellular SNO levels in RAW 264.7 cells
following treatment (Sanghani, Davis et al. 2009). Additionally, SPL-334 was
demonstrated to result in suppression of NF-κB activation due to the inability to reverse
nitrosylation of IKKβ (Sanghani, Davis et al. 2009). These characteristics strongly
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suggested that inhibition of GSNOR utilizing SPL-334 could be a potential therapeutic
approach to the treatment of allergic asthma.
3.2.1.1

Reduced Infiltration of Airways by Inflammatory Immune Cell
Populations
Infiltration of the airway by inflammatory immune cell populations, specifically

eosinophils and CD4+ Th2 cells, is considered one of the defining characterizations of
allergic asthma. Following adoptive transfer of OVA-specific Th2 cells and subsequent
exposure to aerosolized OVA (detailed in Chapter 2 Methods), Th2 recipient mice, but
not control animals (no Th2 adoptive transfer), developed a pronounced influx of
lymphocytes and eosinophils (Figure 3.3) as determined by total cell number and
measurement of EPO levels in the BALF. Intranasal SPL-334 treatment resulted in a
significant reduction in both infiltrating lymphocytes and eosinophils into the airway
(Figure 3.3).

Figure 3.3
Treatment with the GSNOR inhibitor SPL33-4 Caused a Reduction in Allergic Lung
Inflammation. DO11.10 CD4+ Th2 cells were adoptively transferred into Balb/c recipient mice that were then
exposed to aerosolized OVA for 7 consecutive days. Mice were treated intranasally with either the GSNOR
inhibitor SPL-334 (Th2 + SPL-334, 0.1 or 1 mg/kg daily) or vehicle (Th2). Control mice did not receive Th2 cells
but did receive inhaled OVA aerosols. (A) Cell differential counts in the BALF were determined by light
microscopic evaluation of stained cytospin preparations. Results are expressed as absolute numbers (per mouse) of
lymphocytes (Lym), macrophages (Mac), eosinophils (Eos), and neutrophils (Neu). (B) EPO levels in the BALF
from Th2 recipient or control mice were assessed by colorimetric analysis. Results are mean ± SEM (n= 4 – 6) in
triplicate and are representative of four independent experiments. *p < 0.05, compared with Th2 group.
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Consistent with the reduction in inflammation, FACS analysis showed a reduction
in the proportion of CD4+KJ-126+ T cells as well as CD11b+Siglec-F+ eosinophils present
in the BALF of mice receiving GSNOR inhibitor as compared to the Th2 untreated group
(Figure 3.4). There was no alteration observed in the number or proportion of
CD11b+GR-1+ neutrophils or CD11c+F4/80+ alveolar macrophages in the airway (Figure
3.4).
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Figure 3.4
GSNOR Inhibitor SPL-334 Reduced the Number of OVA-specific T cells and
Eosinophils During Allergic Airway Inflammation. DO11.10 CD4+ Th2 cells were transferred into
Balb/c mice that were then challenged with aerosolized OVA for 7 consecutive days. Mice were treated
with either SPL-334 (Th2 + SPL-334) or vehicle (Th2). Control mice did not receive Th2 cells but did
receive inhaled OVA aerosols. (A) The number of CD4+ KJ-126+ T cells in the BALF following OVA
inhalation as determined using flow cytometry. (B) The number of CD11b+Siglec-F+ eosinophils or
CD11b+Gr-1+ neutrophils in the BALF following OVA inhalation as determined using flow cytometry.
Data are representative of two independent experiments.
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3.2.1.2

Reduced Peribronchial Inflammation, Mucus Production, & Airway
Hyperreactivity
Analysis of lung histology utilizing H&E staining revealed that Th2 recipient

mice had markedly increased peribronchial and perivascular inflammation compared to
control mice (Figure 3.5). In addition, a substantial increase in mucus production was
observed and characterized utilizing %PAS staining per bronchiole (Figure 3.5)
following OVA exposure. Treatment with SPL-334 resulted in a significant reduction in
both mucus secretion and bronchial inflammation when compared to Th2 recipient mice
(Figure 3.5). Control mice did not develop any pulmonary inflammation or mucus
secretion following aerosolized OVA exposure.
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Figure 3.5
GSNOR Inhibitor SPL-334 Caused a Reduction in Peribronchial Inflammation
and Mucus Secretion During Airway Inflammation. DO11.10 CD4+ Th2 cells were transferred into
Balb/c mice that were then challenged with aerosolized OVA for 7 consecutive days. Mice were treated
with either SPL-334 (Th2 + SPL-334) or vehicle (Th2). Control mice did not receive Th2 cells but did
receive inhaled OVA aerosols. (A) Peribronchial inflammation determined by histological analysis by
staining lung tissue section with H&E (20X). (B) Mucus production determined by histological
analysis by staining lung tissue sections with PAS (20X). PAS staining was expressed as % PAS+ area
per bronchiole, and bronchial wall thickness expressed in µm. Data are representative of two
independent experiments. *p < 0.05, compared with Th2 group.
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The pulmonary inflammation observed following histological analysis was
associated with an increase in airway hyperreactivity, as measured by airway resistance
(RL) and dynamic compliance (CDym), in Th2 recipient mice when compared to control
mice (Figure 3.6). Treatment with SPL-334 resulted in reduced airway resistance and
improved dynamic compliance when compared to Th2 recipient mice (Figure 3.6).

Figure 3.6
Treatment with the GSNOR Inhibitor SPL334 Caused a Reduction in AHR.
DO11.10 CD4+ Th2 cells were transferred into Balb/c mice that were then challenged with aerosolized
OVA for 7 consecutive days. Mice were treated with either SPL-334 (Th2 + SPL-334) or vehicle
(Th2). Control mice did not receive Th2 cells but did receive inhaled OVA aerosols. Lung Resistance
(RL) and dynamic compliance (CDyn) was assessed in anesthetized and tracheotomized mice that were
mechanically ventilated in response to increasing concentrations of methacholine inhalation. Data are
mean ± SEM (n=10) *p < 0.05, compared with Th2 group.

3.2.1.3 Reduced Production of Th2-associated Cytokines
Following observation that the GSNOR inhibitor SPL-334 affected the severity of
lung inflammation following aerosolized OVA exposure, we characterized the effect of
SPL-334 on Th2-associated cytokine production during OVA-induced airway
inflammation. Stimulation of isolated lung mononuclear cells from Th2 recipient mice
using OVA323-339 peptide or anti-CD3 showed production of high levels of IL-4, IL-5, and
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IL-13 (Figure 3.7). Control mice displayed low production of all three cytokines
following similar stimulation (Figure 3.7). However, a significant reduction when
compared to Th2 recipient mice in the levels of IL-5 and IL13, though not IL-4, was
observed following SPL-334 treatment (Figure 3.7).

Figure 3.7
Treatment with the GSNOR Inhibitor SPL334 Reduced Th2 Cytokine
Production During Allergic Airway Inflammation. DO11.10 CD4+ Th2 cells were transferred into
Balb/c mice that were then challenged with aerosolized OVA for 7 consecutive days. Mice were treated
with either SPL-334 (Th2 + SPL-334) or vehicle (Th2). Control mice did not receive Th2 cells but did
receive inhaled OVA aerosols. LMCs were obtained from control mice and Th2 recipient mice that
were treated with either SPL-334 or vehicle. LMCs were stimulated with anti-CD3 (2 µg/ml) or
OVA323-339 peptide (1 µg/ml) for 24 h and supernatant analyzed for IL-4, IL-5, or IL-13 production by
ELISA. Data are mean ± SEM (n=4) in triplicate and are representative of two independent
experiments. *p < 0.05, compared with Th2 group.

3.2.1.4 Reduced Production of Asthma-associated Chemokine CCL11
CCL11, also known as eotaxin-1, plays a critical role in the chemotaxis of
eosinophils into the airway during allergic asthma. Therefore, we examined whether
treatment with GSNOR inhibitor had an effect on airway CCL11 production. Similar to
the increased production of Th2-associated cytokines described above, Th2 recipient
mice exposed to aerosolized OVA displayed an increased production of CCL11 in both
BALF and following in vitro stimulation of lung mononuclear cells (Figure 3.8).
However, increased in vitro CCL11 production was only observed following stimulation
with OVA323-339 peptide, not anti-CD3 (Figure 3.8). Treatment with SPL-334 resulted in
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a significant reduction in CCL11 production in both BALF and following in vitro
stimulation of lung mononuclear cells when compared to Th2 recipient mice (Figure 3.8).
The decrease in in vitro CCL11 production was observed in both OVA323-339 peptide and
anti-CD3 stimulated lung mononuclear cells (Figure 3.8).

Figure 3.8
Treatment with the GSNOR Inhibitor SPL334 Reduced CCL11 Production
During Allergic Airway Inflammation. DO11.10 CD4+ Th2 cells were transferred into Balb/c mice
that were then challenged with aerosolized OVA for 7 consecutive days. Mice were treated with either
SPL-334 (Th2 + SPL-334) or vehicle (Th2). Control mice did not receive Th2 cells but did receive
inhaled OVA aerosols. LMCs were obtained from control mice and Th2 recipient mice that were
treated with either SPL-334 or vehicle. LMCs were stimulated with anti-CD3 (2 µg/ml) or OVA323-339
peptide (1 µg/ml) for 24 h and supernatant analyzed for CCL11 (eotaxin) by ELISA. Data are mean ±
SEM (n=4 – 6) in triplicate and are representative of two independent experiments. *p < 0.05,
compared with Th2 group.

3.3

DISCUSSION
Work performed by Que et al utilizing transgenic mouse models deficient in

expression of GSNOR have suggested it plays a critical role in the pathogenesis of
asthma (Que, Liu et al. 2005). Examination of the airways revealed that airway epithelial
cells were the primary GSNOR-expressing cell population, but was expression was also
observed in macrophages and infiltrating leukocytes (Que, Liu et al. 2005). Exposure of
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WT mice to ovalbumin resulted in increased GSNOR activity in the airway lining fluid,
possibly as a consequence of epithelial or inflammatory cell lysis (Que, Liu et al. 2005).
This elevation in GSNOR activity following allergen challenge has been suggested to
result in increased breakdown of endogenous airway SNOs in human asthmatic airway
lining fluid (Gaston, Reilly et al. 1993; Que, Liu et al. 2005). GSNOR-/- transgenic mice
displayed attenuated development of bronchoconstriction in response to metacholine
challenge that was concurrent with elevated levels of airway SNOs, suggesting strongly
that GSNOR-mediated regulation of endogenous airway SNOs plays a critical role in
protection from AHR (Que, Liu et al. 2005). The accumulating evidence for the role of
GSNOR in asthma pathogenesis makes the investigation of potential inhibitors of
GSNOR a tantalizing target for the treatment of asthma (Henderson and Gaston 2005;
Wu, Romieu et al. 2007; Que, Yang et al. 2009).
In this study, we elucidated the effects SPL-334, a selective inhibitor of GSNOR,
on allergic airway inflammation. SPL-334 was identified by Sanghani et al as compound
C3, and shown to exclude GSNO from its binding site and preferentially inhibit GSNOR
when compared to other alcohol dehydrogenase isoforms (Sanghani, Davis et al. 2009).
The regulation of GSNOR activity led to increased protein S-nitrosylation in C3-treated
RAW 264.7 cells and the subsequent accumulation of intracellular SNOs, indicating a
role for GSNOR in the active regulation of SNO turnover and metabolism within the cells
(Sanghani, Davis et al. 2009). Our study was the first to demonstrate that intranasal
administration of SPL-334 results in significantly reduced Th2-mediated airway
inflammation, mucus production, and AHR in a mouse model of asthma. Specifically,
SPL-334 treatment led to a marked decrease in the number of OVA-specific T cells and
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eosinophils present in the BALF of mice that received adoptive transfer of DO11.10 Th2
cells and subsequent inhalation exposure to aerosolized OVA. Consistent with the
observed decrease in BALF Th2 cells, there was a significant reduction in the production
of the Th2 cytokines IL-5 and IL-13 by LMCs of SPL-334-treated mice following
stimulation with OVA323-339 peptide or KJ-126 mAb, consistent with the decrease in the
infiltration of OVA-specific Th2 cells into the airways observed in this group. It is likely
this phenomena was responsible for the reduced level of inflammatory cell infiltrate
evident in H&E stained tissues and mucus secretion observed in the airway.
Additionally, a significant decrease in CCL11 (eotaxin) production by stimulated LMCs,
as well as in CCL11 levels in the BALF, were observed in SPL-334-treated mice
compared to vehicle-treated animals. Administration of SPL-334 during allergeninduced inflammation also led to a reduction in spontaneous production of CCL11 by
cultured LMCs, suggesting that lung stromal cells may by a source of CCL11 in the
airway sensitive to GSNOR inhibition.
As CCL11 is a potent chemokine for recruitment of eosinophils into the airway
during allergic inflammation, the observed reduction of airway infiltration by eosinophils
in this study are likely to be a result of GSNOR-mediated reduction in the production of
CCL11. It is possible the inhibition of GSNOR by SPL-334 led to the suppression of
NF-κB activation by airway epithelial and stromal cells, which have been shown to
express CCL11 by a NF-κB- & STAT6-dependent mechanism following stimulation with
TNF-α and IL-4 (Matsukura, Stellato et al. 1999). As NF-κB is thought to have a pivotal
role in inflammatory responses through transcriptional regulation of genes encoding
proinflammatory cytokines, adhesion molecules, chemokines, growth factors, and
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inducible enzymes such as iNOS and cyclooxygenase 2. Consequently, its regulation has
the potential to affect many aspects of the allergic response (Li and Verma 2002). In the
present study, intranasal treatment with SPL-334 resulted in a reduction in the number of
Th2 cells accumulating in the lungs, in addition to reduced levels of IL-5, IL-13, and
CCL11 present in the airways, suggesting that inhibition of GSNOR induced suppression
of NF-κB activation. Consistent with this hypothesis, SPL-334 treatment has been shown
to cause smooth muscle relaxation and suppression of NF-κB activation (Sanghani, Davis
et al. 2009). Concordant with our findings, Sun et al have also generated a novel
GSNOR inhibitor that has proven effective at reducing airway eosinophilic inflammation
as well as improved metacholine-induced bronchoconstriction (AHR) in OVA-exposed
mice (Sun, Qiu et al. 2012). Taken together, these studies suggest that GSNOR inhibition
could have enticing potential as a therapeutic option for the treatment of asthma.
In summary, this study demonstrated that intranasal administration of SPL-334, a
selective inhibitor of GSNOR, limits eosinophilic and Th2 cell inflammation, mucus
production, and airway hyperreactivity in a mouse model of allergic asthma. Although
further studies are needed, continued investigation of the effects of GSNOR inhibition in
experimental asthma are needed, and this study suggest that increasing airway GSNO
levels through the selective inhibition of GSNOR may provide a novel therapeutic option
for the treatment of allergic airway inflammation in asthma and related lung diseases.
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4.0

ABSTRACT
The increasing prevalence of asthma represents a clear public health concern.

The heterogeneous nature of asthma requires continuous improvement in our
understanding of the mechanisms regulating asthma pathogenesis. In particular, the role
of the innate immune system and the inflammatory mediators regulating their activation,
represent a novel area for developing new therapeutic approaches. In this study, we
developed a mouse model of house dust mite-induced allergic asthma, and utilized
transgenic knockout mice deficient in the prostacyclin (PGI2) receptor (IP) to understand
the role of PGI2 in the regulation of innate immunity during the development of allergic
airway inflammation. Our results revealed that loss of PGI2 signaling caused significant
alteration in naïve pulmonary NK cell phenotype, specifically up-regulation in activating
receptor NKp46 expression. In vitro stimulation with either α-NK1.1 or α-NKp46 mAb
resulted in significantly increased production of IFN-γ compared to WT mice.
Interestingly, evaluation of allergic airway inflammation in IP-/- mice following HDM
exposure revealed an attenuated allergic response, characterized by decreased infiltration
of the airway by inflammatory immune cells, decreased peribronchial inflammation and
goblet cell mucus production, and reduced production of Th2-associated cytokines. In
vivo depletion of NK cells using α-NK1.1 mAb PK136 in IP-/- mice prior to HDM
sensitization resulted in restoration of allergic airway inflammation. These results
suggest a previously unrecognized role for PGI2 signaling in the regulation of NK cell
function, as well as indicating a critical role for NK cells in the pathogenesis of asthma
following HDM exposure.
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4.1

Background

4.1.1

Prostaglandins
While protein-based signaling molecules such as cytokines and chemokines are

the primary focus in immunological cell signaling, other cell-derived signaling molecules
have an equally critical role in the regulation of immune cells. Lipid-based signaling
molecules are capable of exerting both activating, as well as inhibitory,
immunoregulatory effects on a wide variety of immune cell types. Eicosanoids are
endogenous lipid-based signaling molecules derived from arachidonic acid that have
varied and potent effects under physiological and pathophysiological conditions (Funk
2001). Eicosanoids encompass a broad array of compounds that includes prostaglandins,
leukotrienes, and lipoxins (Hirata and Narumiya 2012). While the role of prostaglandins
in regulating immune responses has been recognized for 40 years, recent advances have
resulted in renewed interest on their immunoregulatory role (Plescia, Smith et al. 1975;
Goodwin, Bankhurst et al. 1977).
4.1.1.1 Prostaglandin Synthesis
Following cellular activation, increases in intracellular Ca2+ result in
phospholipase A2-mediated release of arachidonic acid from membrane phospholipids
into the cytoplasm (Gijon and Leslie 1999). The production of prostaglandins is initiated
by the action of two cyclooxygenase (COX) isoforms, the constitutively expressed COX1 and the inducible COX-2, both of which catalyze the conversion of free arachidonic
acid into prostaglandin H2 (PGH2) in a two-step reaction (Smith and Langenbach 2001).
Further conversion of PGH2 into the five primary bioactive prostaglandins is catalyzed by
cell-specific prostaglandin synthases, responsible for the production of prostaglandin D2
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(PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), prostaglandin I2 (PGI2), and
thromboxane A2 (TXA2) (Hirata and Narumiya 2012). COX-1 expression occurs in
almost all cell types, particularly at high levels in cells of the gastrointestinal tract,
kidneys, and platelets, while COX-2 is expressed under inflammatory conditions by
macrophages, neutrophils, dendritic cells, and activated mesenchymal cells (Davies,
Bailey et al. 1984; Vane, Bakhle et al. 1998; Garavito and DeWitt 1999). Of particular
importance, non-steroidal anti-inflammatory drugs (NSAIDs) are typically capable of
nonspecifically inhibiting COX-1 and COX-2. This inhibition plays a critical role in the
beneficial anti-inflammatory and analgesic effects of NSAIDs, as well as in deleterious
NSAID-associated gastrointestinal toxicity (Vane 1976; Rao and Knaus 2008).

Figure 4.1
Prostanoid Biosynthesis. Membrane phospholipids are metabolized to arachidonic
acid via PLA2. Cyclooxygenase isoforms further metabolize the formation of prostaglandin H2 (PGH 2)
which is converted into prostaglandins by prostaglandin-specific synthases. Prostaglandin synthesis can
be disrupted through the inhibition of COX isoforms such as NSAIDs (Sirois, Sayasith et al. 2004).
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4.1.1.2 Prostaglandin Signaling
Prostaglandin signaling is mediated by several specific receptors. The first
prostaglandin receptor identified, TXA2 receptor (TP), was revealed to be a G-protein
coupled receptor expressed by platelets (Hirata, Hayashi et al. 1991). Subsequent
analysis led to the identification of eight additional prostaglandin receptors with a high
degree of homology, that include two isoforms of prostaglandin D2 receptor (DP1 &
DP2), four isoforms of prostaglandin E2 receptor (EP1 – 4), as well as single receptors of
prostaglandin I2 (IP) and prostaglandin F2α (FP) (Sugimoto, Namba et al. 1992; Honda,
Sugimoto et al. 1993; Watabe, Sugimoto et al. 1993; Hirata, Kakizuka et al. 1994;
Namba, Oida et al. 1994). The nine prostaglandin receptors are phylogenetically
classified into three subfamilies based on structural and functional similarities based on
signal transduction pathways (Toh, Ichikawa et al. 1995). The DP1-EP2-EP4-IP
subfamily couple to GS resulting in increased cAMP production, and subsequent cellular
activation, the EP1-FP-TP subfamily couple to Gq resulting in increased cytosolic Ca2+
mobilization, while the EP3-DP2 subfamily couples to Gi resulting in decreased cAMP
production and Ca2+ mobilization (Katoh, Watabe et al. 1995; Hirai, Tanaka et al. 2001;
Sands and Palmer 2008). While prostaglandin receptors display preferentially high
affinity for their respective prostaglandins, it has been observed that some cross-reactivity
exists in certain receptors (Kiriyama, Ushikubi et al. 1997).
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Figure 4.2
Prostanoid Signaling. Prostaglandins bind to prostanoid-specific G-protein coupled
receptors. Signaling through these receptors leads to the activation of several diverse signal
transduction pathways capable of regulating activation and inhibition of cellular function (Hirata and
Narumiya 2012).
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4.1.2

Prostaglandin-associated Regulation of Respiratory Immune Responses
While prostaglandins play a crucial role in the regulation of responses in a diverse

array of tissues such as the gastrointestinal tract, cardiovascular system, respiratory tract,
and uterine tissue, the role of prostaglandins in regulating innate and adaptive immune
responses has received the most recent attention. In the respiratory tract, alteration in
prostaglandin signaling has been associated with both beneficial and deleterious effects
on the pathogenesis of asthma. It is critical to consider the inflammatory environment
where prostaglandin signaling occurs in order to fully understand the regulatory role of
prostaglandins in controlling immune cell function.
4.1.2.1 Adaptive Immune Cells
Recognition of bacterial lipopolysaccharide (LPS) and IL1-β results in potent NFκB-induced COX-2 expression in macrophages and dendritic cells that is followed by
subsequent production of prostaglandins capable of regulating immune cell function in an
autocrine or paracrine manner (Rocca and FitzGerald 2002). Binding of PGE2 has been
implicated to inhibit MHC class II expression and TNF-α production in macrophages and
dendritic cells, while leading to increased production of IL-10 in dendritic cells (Nataraj,
Thomas et al. 2001; Vassiliou, Jing et al. 2003). PGI2 and PGD2 have been shown to
inhibit the activation and maturation of monocyte-derived dendritic cells, resulting in
reduced capacity to induce T cell-associated responses (Gosset, Bureau et al. 2003; Zhou,
Hashimoto et al. 2007). PGD2-mediated inhibition of migration to draining lymph nodes
by pathogen-activated peripheral dendritic cells plays a critical role in the inhibition of T
cell activation (Hammad, de Heer et al. 2003; Angeli, Staumont et al. 2004). In addition
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to these indirect methods of inhibiting T cell activation, TXA2 has been shown to inhibit
direct DC-T cell interaction (Kabashima, Murata et al. 2003).
In mice and humans, PGE2 has been shown to enhance both Th1 and Th17
differentiation in vitro, while in vivo administration of EP inhibitors resulted in decreased
accumulation of both Th1 and Th17 cell migration into draining lymph nodes (Yao,
Sakata et al. 2009; Esaki, Li et al. 2010). In particular, PGE2 regulation of IL-23
production by dendritic cells results in increased expansion and activation of Th17 cells
that have been implicated to increase the progression and severity of several diseases,
including asthma (Chizzolini, Chicheportiche et al. 2008; Boniface, Bak-Jensen et al.
2009). Treatment of T cells in vitro utilizing an IP agonist revealed that PGI2 signaling
drives Th1 differentiation and subsequent decreases in contact hypersensitivity responses
(Nakajima, Honda et al. 2010). However, PGI2 has also been shown to inhibit the
production of cytokines by both Th1 and Th2 cells following activation, indicating that IP
signaling contributes to both pro- and anti-inflammatory regulation of cellular function
(Zhou, Blackwell et al. 2007). The role of prostaglandin signaling in B cells has
remained more complicated than that of T cells. While PGE2 has been shown to inhibit B
cell proliferation, it has been observed that it also has the capacity to induce IgG and IgE
class switching (Fedyk and Phipps 1996; Roper, Graf et al. 2002). Additionally, in
germinal centers, dendritic cell-derived IL-21 in conjunction with PGE2 readily induced
costimulatory B cell apoptosis (Magari, Nishikawa et al. 2011).
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Figure 4.3
Regulation of Adaptive Immunity by Prostaglandins. Autocrine and paracrine
signaling by prostanoids has the capacity to lead to the activation and inhibition of dendritic cells The
resulting changes in dendritic cell populations results in alterations in Th cell maturation and
differentiation (Hirata and Narumiya 2012).

4.1.2.2 Innate Immune Cells
PGE2 signaling in neutrophils has been associated with reduced inflammatory
responses, while autocrine signaling of PGD2 by eosinophils results in eosinophil
activation (Wright, Moots et al. 2010; Luna-Gomes, Magalhaes et al. 2011). PGE2 has
been shown to result in suppression of NK cell effector function directly, while
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production of PGE2 by dendritic cells leads to decreased NK cell production of IFN-γ as
well as suppression of cytotoxicity (Van Elssen, Vanderlocht et al. 2011; Holt, Ma et al.
2012). NK cell-derived PGD2 has also been shown to inhibit NK cell cytotoxicity,
migration, and cytokine production in an autocrine manner (Chen, Perussia et al. 2007).
Alteration of epithelial cell function in the airway and subsequent skewing of the T cell
response has been associated with prostaglandin signaling, as PGD2 signaling has been
shown to induce the secretion of Th2-associated chemokines, while PGE2 has been
shown to inhibit this secretion resulting in decreased airway inflammation (Matsuoka,
Hirata et al. 2000; Kunikata, Yamane et al. 2005). Prostaglandins exhibit duality in
controlling innate γδ T cells responses as well, as PGE2 has been demonstrated to reduce
γδ T cell cytotoxicity, while work we have previously performed has indicated that PGI2
promotes the development of IL-17-producing γδ T cells that exacerbate allergic airway
inflammation in mice (Martinet, Jean et al. 2010; Jaffar, Ferrini et al. 2011).
4.1.3

Natural Killer Cell Effector Functions
A key component of the innate immune system, natural killer (NK) cells were

originally described as large, granular cells of the lymphoid lineage with natural affinity
(i.e. no priming required) towards tumor-specific cytotoxicity both through direct
interaction as well as through the production of cytokines (Trinchieri 1989). In addition
to their well-documented targeting of tumor cells, NK cells are also capable of
recognizing and killing virus-infected cells (Biron, Byron et al. 1989). While most
studies have focused on the cytotoxicity mediated by NK cells, recent advances have
begun to spur interest in the regulatory role of NK and NK-related immune cells (Spits
and Di Santo 2011; Bernink, Peters et al. 2013). The increased focus on the regulatory
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capabilities of NK cells offers new opportunities to explore the role that NK cells have in
the regulation of disease pathogenesis, especially in capacities not related to direct
defense against invading pathogens or tumors.
4.1.3.1 Regulation of Natural Killer Cell Function
While NK cell-mediated regulation of the immune system has become the most
recent focus of NK cell-related research, cytotoxicity still plays a vital role in
understanding how NK cells interact with their environment, including other immune
cells. One of the hallmark features of NK cells is their innate capacity to mediate
cytotoxicity without any apparent need to be primed via MHC-presented antigen, and
thus providing a mechanism to rapidly respond to encountered pathogens or virusinfected cells. With no regulation, this constitutive state of cytotoxicity would have
devastating consequences from autoreactivity to unchecked inflammatory responses.
Fortunately, an elaborate system of activating and inhibiting receptors has evolved in
order to highly regulate the destructive capabilities of NK cells.
4.1.3.1.1

Inhibitory Receptors

In 1986, Karre et al published a seminal study that would influence all further
understanding of NK cell effector function (Karre, Ljunggren et al. 1986). In this study,
Karre et al described that NK cells have the capability of targeting lymphoma variants
that were deficient in MHC Class I while ignoring lymphoma variants that maintained
MHC class I expression. In essence, this allowed the NK cells to recognize the
difference between self and non-self cells within tissue, allowing NK cells to target cells
that down-regulate MHC class I expression in order to avoid the attention of cytotoxic
CD8+ T cells. This initial look at the regulation of NK cell-mediated cytotoxicity
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revealed the existence of inhibitory receptors controlling NK cell effector function.
Further studies have identified a vast array of inhibitory receptors in both mice and
humans, including killer cell immunoglobulin-like receptors (KIRs), leukocyte
immunoglobulin-like receptors (LILRs), and C-type lectin type II glycoproteins (Ravetch
and Lanier 2000). Some of these inhibitory receptors, such as Ly49a & Ly49c in mice
and various KIR (CD158) istotypes in humans, are capable of recognizing specific
classical MHC class I ligands (Lanier 2008). The inhibitory receptor CD94/NKG2A is
conserved in both rodents and primates, and binds to the widely expressed nonclassical
MHC class I molecule Qa-1b leading to inhibition of NK-mediated effector functions
(Colmenero, Zhang et al. 2007).

Figure 4.4
Natural Killer Cell Receptor Expression. NK cells express a wide variety of surface
receptors. Binding of ligands to activating and inhibitory receptors leads to regulation of NK cell
cytotoxicity (Vivier, Raulet et al. 2011).
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4.1.3.1.2

Activating Receptors

While inhibitory receptors play a crucial role in the regulation of NK cell effector
function, inhibitory signals alone are not the sole arbiter of NK-cell mediated
cytotoxicity. In addition to the loss of inhibitory signaling, recognition of ligands via
activating receptors on the surface of NK cells are necessary, in most cases, to fully
engage NK cell effector function. These activating receptors thus allow for the targeting
of tumor or virus-infected cells that do not down-regulate expression of MHC class I
(Correa, Corral et al. 1994). The prototypical NK cell activating receptor is NKG2D, a
C-type lectin surface receptor expressed by NK cells, γδ T cells, CD8+ T cells, and
activated macrophages (Jamieson, Diefenbach et al. 2002). While serving as a costimulatory receptor for T cells, NK cells and activated macrophages respond directly to
NKG2D cross-linking following association with the adaptor proteins DAP10 and
DAP12 (Diefenbach, Tomasello et al. 2002; Jamieson, Diefenbach et al. 2002). Similarly
to NKG2D, the lectin-like type II membrane proteins Ly49H have also been shown to
induce activation of NK cells in conjunction with DAP12 to induce cytotoxicity in
addition to cytokine production (Lanier 1998). In addition to these lectin receptors,
identification of immunoglobulin-like type I membrane proteins termed natural
cytotoxicity receptors (NCRs) which include NKp30, NKp44, and NKp46 has greatly
expanded the repertoire of activating receptors responsible for regulating NK cell
function (Koch, Steinle et al. 2013). NKp46 (CD335; NCR-1) has been identified on
both murine and human NK cells as a highly specific marker of NK cells, and it has been
suggested that it represents an evolutionally conserved method for the removal of tumors
and viral pathogens as blocking of NKp46 with monoclonal antibody resulted in
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significantly reduced cytotoxicity of certain tumors (Pessino, Sivori et al. 1998; Moretta,
Bottino et al. 2001). This removal has been shown to be mediated via recognition of
several different ligands, including virally-associated ligands like Hemagglutinin as well
as endogenous ligands such vimentin or tumor-specific antigens (Harris, Kapur et al.
1992; Mandelboim, Lieberman et al. 2001; Garg, Barnes et al. 2006; Halfteck, Elboim et
al. 2009).
4.1.3.2 Natural Killer Cell-Mediated Cytotoxicity
Activation of NK cells following tumor or pathogen recognition results in the
prototypical NK cell effector response of cytotoxicity. NK cell-mediated cytotoxicity
requires direct contact between NK cells and target cells, and occurs via three possible
mechanisms.
The primary mechanism of NK cell-mediated cytotoxicity utilizes cytoplasmic
granule toxins that lead to apoptosis of target cells via exocytosis, similarly to cytotoxic T
lymphocytes. Within these cytoplasmic granules, NK cells package a potent combination
of perforin, a membrane-disrupting protein, and a family of structurally related serine
proteases known as granzymes (Grz) (Smyth, O'Connor et al. 1996). The use of perforindeficient knockout mice has clearly demonstrated the critical role that perforin has in NK
cell-mediated cytotoxicity, but this role extends beyond allowing Grz access to target cell
cytoplasm, as it has been demonstrated that Grz uptake into target cells can occur
efficiently and rapidly following receptor-mediated endocytosis (Kagi, Ledermann et al.
1994; Smyth, Browne et al. 1995; Motyka, Korbutt et al. 2000). It has been suggested
that the role of perforin in NK-cell mediated cytotoxicity leads to disruption of
endosomal trafficking following Grz uptake in target cells (Browne, Blink et al. 1999).
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There are eleven different Grz that have been described to date, but granzyme A (GrzA)
and granzyme B (GrzB), which are conserved between mice and humans, have received
the most focus in attempts to understand the mechanism of NK-cell mediated cytotoxicity
(Smyth, O'Connor et al. 1996). In combination with perforin, GrzB induces apoptosis of
target cells via caspase-dependent oligonucleosomal fragmentation of DNA, while GrzA
has been demonstrated to generate single-stranded DNA nicks that induce apoptosis in
target cells via a caspase-independent mechanism (Heusel, Wesselschmidt et al. 1994;
Beresford, Xia et al. 1999). Mouse models deficient in GrzA/GrzB have provided
interesting insights into the role of Grz in NK cell-mediated cytotoxicity. Specifically,
while the role of Grz in NK-mediated cytotoxicity cannot be denied, functional
redundancy in individual Grz leads to only moderate decreases in Grz-induced apoptosis,
suggesting that individual Grz may have distinct cell signaling effects beyond inducing
cytotoxicity (Heusel, Wesselschmidt et al. 1994; Ebnet, Hausmann et al. 1995).
The secondary mechanism utilized during NK-cell mediated cytotoxicity relies on
the activation of tumor necrosis family (TNF)-related death receptor pathways on target
cells. The two most highly characterized TNF death receptor pathways involved in NK
cell-mediated cytotoxicity utilize NK expression of the TNF-related apoptosis-inducing
ligand (TRAIL) or Apo2 ligand, or the Fas ligand (FasL). While TRAIL is constitutively
expressed by a small subset of liver NK cells, TRAIL expression is typically induced in
peripheral NK cells following stimulation of NK cells with IL-2, IL-12-induced IFN-γ, or
IL-15 (Smyth, Cretney et al. 2001; Takeda, Hayakawa et al. 2001; Takeda, Smyth et al.
2001). TRAIL receptors such as TRAIL-R2 (DR5) are widely expressed by both murine
and human cells, and activation following TRAIL binding results in the activation of
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caspase 8-dependent apoptosis pathway (Wiley, Schooley et al. 1995; Chaudhary, Eby et
al. 1997). In addition to TRAIL, NK cells have also been shown to express the
homologous FasL protein. The most intensely studied death receptor, Fas (CD95)
binding of FasL ultimately results in caspase-8 activation and subsequent cellular
apoptosis. While several tumor lineages down-regulate Fas expression, it has been
observed that NK cell production of IFN-γ induces Fas expression on tumor cells
resulting in Fas-dependent apoptosis (Screpanti, Wallin et al. 2001).

Figure 4.5
Mechanisms of Natural Killer Cell Cytotoxicity. Activation of NK cells results in
NK-mediated cytotoxicity by two distinct mechanisms. (1) The release of reactive granule products
such as granzymes and perforin from NK cells results in caspase-dependent and caspase-independent
target cell apoptosis. (2) IFN-γ signaling induces death receptor ligand expression such as FasL or
TRAIL on the surface of NK cells which upon binding to the appropriate TNF-family death receptor
induces caspase-dependent target cell apoptosis (Smyth, Cretney et al. 2005).

Antibody-dependent cell-mediated cytotoxicity (ADCC) is the final mechanism of
NK cell-mediated cytotoxicity. NK cells have been shown to express multiple isoforms
of Fc receptor, including FcγRIIIa/ FcγRIIc (CD16/CD32), FcµR, and FcαR that bind the
Fc regions of IgG, IgM, and IgA, respectively (Pricop, Rabinowich et al. 1993; Trinchieri
and Valiante 1993; Mota, Manciulea et al. 2003). Activation of NK cells by CD16 cross-
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linking results in potent activating signals capable of overriding inhibitory KIR signals
and subsequent lysis of target cells utilizing cytokine production and granule-mediated
cytotoxicity (Chan, Kung Sutherland et al. 2012).
4.1.3.3 Natural Killer Cell-Derived Cytokines: IFN-γ
While cytotoxicity has long been recognized as the primary method by which NK
cells interact with pathogens and non-pathogens, the production of cytokines by NK cells
results in extensive regulation of both innate and adaptive immunity. NK cells have been
observed to produce several cytokines following activation, none are as critical as IFN-γ
in NK cell effector function.
IFN-γ is the canonical Th1-associated cytokine, involved in removal of
intracellular bacterial and viral pathogens as well as tumors (Kaplan, Shankaran et al.
1998; Jouanguy, Doffinger et al. 1999; Ikeda, Old et al. 2002; Filipe-Santos, Bustamante
et al. 2006). Signaling via IFN-γ can lead to increased expression of MHC class I and
class II on mononuclear cells such as macrophages as well as epithelial cells (Basham
and Merigan 1983; King and Jones 1983). Activation of macrophages by IFN-γ results in
increased phagocytosis and production of antimicrobials such as superoxide radicals,
nitric oxide, and hydrogen peroxide (Boehm, Klamp et al. 1997). IFN-γ plays a critical
role in the determination of T helper cell lineage, as IFN-γ has been observed to lead to
permanent commitment to the Th1 lineage in addition to suppressing Th2 proliferation
and cytokine production (Grogan and Locksley 2002; Ho and Glimcher 2002; Murphy
and Reiner 2002). NK cell-derived IFN-γ in particular has been shown to enhance CD4+
Th1 cell polarization in secondary lymphoid tissues as well as promote dendritic cell
maturation (Gerosa, Baldani-Guerra et al. 2002; Morandi, Bougras et al. 2006). Similarly

	
  

71	
  

to their ability to rapidly induce cytotoxicity following activation, NK cells are capable of
rapid and prolific production of IFN-γ immediately following activation. Stimulation of
NK cells with IL-12, IL-18, IL-15, IL-2, or type I Interferons (IFN-α/β) results in
significant production of IFN-γ (Lieberman and Hunter 2002; Walzer, Dalod et al. 2005).
In particular, IL-12, originally identified as NK cell stimulatory factor, synergistically
increases production of IFN-γ by NK cells following co-stimulation with IL-18
(D'Andrea, Rengaraju et al. 1992). In contrast, TGF-β has been identified as a potent
negative regulator of NK cell IFN-γ production, and is an important component in
preventing uncontrolled NK cell-mediated inflammation (Li, Wan et al. 2006).
4.2

RESULTS

4.2.1

Characterization of Pulmonary Natural Killer Cells in the Airways of Naïve

IP-/- Mice
Previous work done in our laboratory by Jaffar et al displayed how alterations in
prostacyclin signaling had a critical role on the development of asthma through the action
of innate γδ T cells (Jaffar, Ferrini et al. 2011). The biological effects of prostacyclin
action in vivo were examined using mice lacking the prostacyclin receptor (IP). Results
from this study suggested that prostacyclin signaling could be involved in the regulation
of other innate immune cell populations as well. Examination of the lung tissue of naïve
IP-/- mice revealed that there was a significantly increased number of NK1.1+ cells
present in the airway compared to wild-type C57BL/6 (WT) mice (Figure 4.6). NK1.1,
also known as CD161 or Nkrp1c, is a C-type lectin receptor expressed on the cell surface
of NK cells as well as NKT cells and Th17 cells (Bartel, Bauer et al. 2013). Further
characterization of this NK1.1+ population revealed a lack of CD3 expression, identifying
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the population as NK cells (Figure 4.6). Little is known of the characteristics of NK cells
that reside in the lung tissue. Consequently, we found the doubling in the number of
pulmonary NK cells resulting from lack of prostacyclin signaling in the IP-/- mouse
intriguing. The ability of prostacyclin to inhibit NK cell cytotoxicity has been previously
described in purified, pharmaceutically treated NK cells (Lanefelt, Ullberg et al. 1983),
but the role that prostacyclin signaling exerts on in vivo NK cell development and
function has been poorly examined. Utilizing the IP-/- mouse allows us a unique
opportunity to examine the modulatory role of prostacyclin signaling on NK cell function
in vivo.

0.57%

5.27%

IP-/-

0.65%

NK1.1

2.79%

Wild-Type

16.5%

14.7%

CD3
Figure 4.6
Naïve IP-/- Mice Display Increased Numbers of Pulmonary Natural Killer Cells.
Lung mononuclear cells were obtained from dissociated lung tissue from naïve IP-/- and WT mice.
LMCs were stained with anti-CD3 (FITC) and anti-NK1.1 (APC) and analyzed for receptor expression
using a BD FACSAria Flow Cytometer. Natural killer cells were classified as CD3- NK1.1+.
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4.2.1.1 Increased Expression of the Activating Receptor NKp46 By Natural Killer Cells
in IP-/- Mice
The term ‘NK cell’ actually encompasses a broad array of specific subtypes based
on factors such as tissue residency, stage of maturity, and effector function.
Classification of these specific subtypes is generally based on surface expression of
several distinct markers.
Recently, differences in marker expression between ‘conventional’ (cNK) and
‘tissue resident’ (trNK) NK cells have been described based on expression of CD49b,
also known as Dx5, and CD49a (Yokoyama, Sojka et al. 2013), respectively. cNKs are
found in the spleen and periphery, whereas trNKs have been described primarily in the
liver, although in the skin and uterine lining as well (Sojka, Plougastel-Douglas et al.
2014). In addition to differences in surface receptor expression, differences in effector
function reveal that cNKs and trNKs have distinct immunological roles (Sojka,
Plougastel-Douglas et al. 2014). Initial characterization of NK cells present in the
airways revealed that NK cells (defined as CD3-CD19-NK1.1+) exclusively expressed
CD49b in both IP-/- and WT mice (Figure 4.7).
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Figure 4.7
Naïve IP-/- and WT Pulmonary Natural Killer Cells Express Dx5 (CD49b). Lung
mononuclear cells were obtained from dissociated lung tissue from naïve IP-/- and WT mice. LMCs
were stained with anti-CD3 (FITC), anti-CD19 (APCCy7), anti-NK1.1 (APC), and anti-Dx5
(CD49b)(PE) and analyzed for receptor expression using a BD FACSAria Flow Cytometer. Natural
killer cells were classified as CD3-CD19-NK1.1+.

NK cell development can be divided into several stages of maturity characterized
by expression of specific surface receptors (Di Santo 2006). We compared IP-/- and WT
mouse pulmonary NK cells for a selection of these receptors and found minimal
differences in expression profiles. Flow cytometry analysis revealed that both IP-/- and
WT mouse pulmonary NK cells had essentially identical phenotypic profiles of CD27,
Ly49a, Ly49c, CD117, and CD127 expression (Figure 4.8). Expression of CD27,
LY49a, and Ly49c was observed on approximately 20% (20% to 23%, 17% to 18%, &
15% to 21%, respectively) of NK1.1+ cells in both IP-/- and WT mice, while no
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expression of CD127 (IL-7r) or CD117 (c-kit) was observed on NK1.1+ cells of either
strain (Figure 4.8).
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Figure 4.8
Naïve IP-/- and WT Pulmonary Natural Killer Cell Phenotyping. Lung
mononuclear cells were obtained from dissociated lung tissue from naïve IP-/- and WT mice. LMCs
were stained with anti-CD3 (FITC, PE, APC), anti-CD19 (APCCy7), anti-NK1.1 (APC, FITC), antiCD27 (APC), anti-CD127 (APC), anti-Ly49A (FITC), anti-Ly49C (FITC), and anti-CD117 (ckit)(APC) and analyzed for receptor expression using a BD FACSAria Flow Cytometer. Natural killer
cells were classified as CD3-CD19-NK1.1 +.
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The effector functions of NK cells are controlled by a complex system of
activating and inhibitory receptors expressed on the NK cellular surface (Vivier, Raulet et
al. 2011). Although less recognized than classic NK activation receptors such as
NKG2D and aKIRs, natural cytotoxicity receptors (NCRs) are a family of activating
receptors that upon direct binding to both exogenous and endogenous ligands lead to NK
cell activation (Hudspeth, Silva-Santos et al. 2013). NCR1, more commonly referred to
as NKp46, is expressed by several species, including humans and mice, and is considered
the primary NCR involved in pathogen and tumor recognition due to evolutionary
conservation (Koch, Steinle et al. 2013). Expression of NKp46 on the cellular surface of
NK cells is one of the key markers of NK cell maturity in mice, as well as providing an
indication of the activation state of NK cells (Di Santo 2006). Therefore, we examined
the expression of NKp46 on pulmonary NK cells in IP-/- mice. We found that NK cells
present in the airway of IP-/- mice had significantly increased expression of activating
receptor NKp46 when compared to WT mice (Figure 4.9). Approximately 82% of the
IP-/- mouse pulmonary NK cells expressed NKp46, as opposed to 35% of WT mouse
pulmonary NK cells. Further comparison of NKp46 expression by IP-/- mouse NK cells
at several other key immunological sites, including the spleen (93% compared to 50%),
brachial (82% to 37%) & mesenteric lymph nodes (77% to 36%), Peyer’s patches (59%
to 36%), and bone marrow (54% to 23%), revealed that NK cells present in all of those
sites had significantly increased expression of NKp46 in IP-/- mice when compared to WT
mice, suggesting a systemic shift in IP-/- mouse NK cell expression of NKp46 (Figure
4.9).
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Figure 4.9
Naïve IP-/- Natural Killer Cells Display Increased Systemic Expression of
Activating Receptor NKp46. Mononuclear cells were obtained from dissociated lung tissue, spleen,
mesenteric and brachial lymph nodes, peyer’s patches, and bone marrow from native IP-/- and WT mice.
Mononuclear cells were stained with anti-CD3 (FITC), anti-CD19 (APCCy7), anti-NK1.1 (PE), and
anti-NKp46 (APC) and analyzed for receptor expression using a BD FACSAria Flow Cytometer.
Natural killer cells classified as CD3-CD19-NK1.1+.
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NKG2D is recognized as one of the primary activating receptors responsible for
initiation of NK cell effector functions. Although we attempted to examine NKG2D
expression by splenic NK cells in both IP-/- and WT mice, flow cytometry analysis was
unable to detect any level of NKG2D expression on splenic NK cells of either strain
(Figure 4.10).
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Figure 4.10
Naïve IP-/- and WT Splenic Natural Killer Cells Lack Expression of NKG2D.
Splenic mononuclear cells were obtained from dissociated spleen tissue from naïve IP -/- and WT mice.
Mononuclear cells were stained with anti-NK1.1 (APC) and anti-NKG2D (PE) and analyzed for
receptor expression using a BD FACSAria Flow Cytometer.

4.2.1.2 Increased Intracellular Expression of Granzyme A by Natural Killer Cells in
IP-/- Mice
The significant increase in systemic expression of activating receptor NKp46 by
IP-/- mouse NK cells described in section 4.2.1.1 could lead to potential ramifications for
IP-/- mouse NK cell cytotoxicity. As described more fully in Chapter 4 Background
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section 4.1.3.2, excretory lysosomal exocytosis is a primary method of NK cell-mediated
cytotoxicity, specifically through the release of cytotoxic proteins such as perforin and
granzymes. Granzymes A & B are the most abundant granzymes, and recognition of the
cytotoxic capabilities of these molecules has been known since the early 1990s (Hayes,
Berrebi et al. 1989) (Shi, Kam et al. 1992). Induction of granzyme production in NK
cells was accomplished by 24-hour in vitro treatment utilizing PMA/ionomycin as
described in Chapter 2 Methods Section 2.0.10.7. Following treatment, FACS analysis
utilizing intracellular staining revealed that IP-/- mouse NK cells displayed markedly
increased intracellular (IC) levels of granzyme A when compared to WT mice (Figure
4.11). Approximately 78% of IP-/- pulmonary NK cells displayed production of IC
granzyme A following PMA/ionomycin treatment, as opposed to 65% of WT pulmonary
NK cells. Flow cytomety analysis of IC granzyme B revealed that there were minimal
differences in production in IP-/- pulmonary NK cells compared to WT pulmonary NK
cells, with approximately 16% of IP-/- pulmonary NK cells compared to 20% of WT
pulmonary NK cells expressing production of IC granzyme B following PMA/ionomycin
treatment (Figure 4.11). This increase in intracellular granzyme A was only observed in
pulmonary NK cells, with no difference observed between IP-/- and WT splenic NK cells
(Figure 4.11). Consequently, the majority of pulmonary NK cells present in the IP-/mouse are granzyme A+ and likely to exhibit increased cytotoxicity.
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Figure 4.11
Naïve IP-/- Pulmonary Natural Killer Cells Display Increased Production of
Granzyme A. Mononuclear cells were obtained from dissociated spleen and lung tissue of naïve IP-/and WT mice. Mononuclear cells were treated with PMA/ionomycin for 24 hours prior to intracellular
staining. Mononuclear cells were stained with anti-CD3 (PE), anti-CD19 (APCCy7), anti-NK1.1
(FITC, APC), anti-Granzyme A (APC), and anti-Granzyme B (FITC) and analyzed for receptor and
intracellular cytokine expression using a BD FACSAria Flow Cytometer. Natural killer cells were
classified as CD3-CD19-NK1.1+.
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4.2.1.3 Increased Intracellular and in vitro Production of IFN-γ by Natural Killer Cells
in IP-/- Mice
In addition to production of cytotoxic lysosomal proteins such as perforin and
granzymes, NK cells are recognized to produce several pro-inflammatory cytokines in
response to activation, particularly IFN-γ and TNF-α (Perussia 1996). The increased
expression of activating receptor NKp46 as well as increased production of cytotoxic
protein granzyme A, described in section 4.2.1.1 and 4.2.1.2 respectively, seen in naïve
IP-/- mouse pulmonary NK cells could also be associated with the increased production of
pro-inflammatory cytokines. Induction of pro-inflammatory cytokine production in NK
cells was accomplished by 24-hour in vitro treatment utilizing PMA/ionomycin as
described in Chapter 2 Methods Section 2.0.10.7. Flow cytometry analysis utilizing IC
staining revealed that IP-/- pulmonary NK cells had slightly decreased production of IC
IFN-γ when compared to WT pulmonary NK cells (Figure 4.12). Approximately 61% of
IP-/- pulmonary NK cells produced IC IFN-γ following PMA/ionomycin treatment, as
opposed to 70% of WT pulmonary NK cells.
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Figure 4.12
Naïve IP-/- Pulmonary Natural Killer Cells Display Reduced Intracellular IFN-γ
Production. Lung mononuclear cells were obtained from dissociated lung tissue from naïve IP-/- and
WT mice. LMCs were treated with PMA/ionomycin for 24 hours prior to intracellular staining. LMCs
were stained with anti-CD3 (FITC), anti-CD19 (APCCy7), anti-NK1.1 (PE), and anti-IFN-γ (APC) and
analyzed for receptor and intracellular cytokine expression using a BD FACSAria Flow Cytometer.
Natural killer cells were classified as CD3-CD19-NK1.1+.

As mentioned in section 4.2.1, NK1.1 is a primary surface marker for recognizing
NK cells, and it has also been shown to be a signaling molecule involved in the activation
of NK cells (Arase, Arase et al. 1996). Specifically, Arase et al. described that NK1.1
receptor cross-linking with co-stimulation utilizing IL-2 led to significant production of
IFN-γ in both NK cells and NK1.1+ iNKT cells. Unexpectedly, IP-/- pulmonary NK cells
had slightly decreased production of pro-inflammatory cytokine IFN-γ as determined by
intracellular (IC) flow cytometry (Figure 4.12). To examine these results further, we
performed in vitro stimulation of isolated lung mononuclear cells utilizing anti-NK1.1
mAb PK136 in the presence or absence of IL-2 as described in Chapter 2 Methods
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Section 2.0.7.1. Stimulation of NK1.1 in the presence of IL-2 resulted in significantly
increased production of IFN-γ by IP-/- lung mononuclear cells compared to IFN-γ
produced by WT lung mononuclear cells (930 pg/ml compared to 414 pg/ml), while
stimulation of NK1.1 alone was not sufficient to induce significant cytokine production
in either strain (Figure 4.13). Although IFN-γ production was induced in both strains
following in vitro NK1.1 stimulation, we observed consistently low levels of less than 50
pg/ml TNF-α production by pulmonary NK cells in either strain following in vitro NK1.1
stimulation in the presence or absence of IL-2 (Figure 4.13).

Figure 4.13
Naïve IP-/- Pulmonary Natural Killer Cells Display Significantly Increased in
vitro IFN-γ Production Following NK1.1 Stimulation. Lung mononuclear cells were obtained from
dissociated lung tissue from naïve IP-/- and WT mice. LMCs were stimulated in vitro with anti-NK1.1
mAb (20 µg/ml) ± IL-2 (10 ng/ml) for 24 h at 37°C. Supernatants were analyzed for IFN-γ and TNF-α
production by ELISA. Data are mean ± SEM (n = 3 – 6) in triplicate and are representative of three
independent experiments. **p < 0.01 compared to WT mice

Since NK-like cell populations such as iNKT and Th17 cells have been found to
both express NK1.1 (Bartel, Bauer et al. 2013) and respond to NK1.1 stimulation (Arase,
Arase et al. 1996), it is possible that the increase in IFN-γ levels by stimulated IP-/- lung
mononuclear cells described in Figure 4.13 could be attributed to these alternative
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populations. Therefore, a more specific NK cell activation is necessary to truly establish
pulmonary NK cell involvement. Walzer et al. described that 98% of NKp46 expression
occurs on mouse NK cells, while the remaining 2% is expressed on a minute fraction of
non-invariant NKT cells, making it a highly selective marker for recognition of NK cell
populations (Walzer, Blery et al. 2007). In addition, they also demonstrated that
stimulation utilizing anti-NKp46 mAb resulted in IC IFN-γ production by stimulated
splenic NK cells (Walzer, Blery et al. 2007). To clearly establish pulmonary NK cell
IFN-γ production, we performed in vitro stimulation of isolated lung mononuclear cells
utilizing anti-NKp46 mAb in the presence or absence of IL-2 as described in Chapter 2
Methods Section 2.0.7.1. Stimulation of lung mononuclear cells utilizing NKp46 in the
presence of IL-2 resulted in the production of IFN-γ that was significantly elevated in IP/-

lung mononuclear cells when compared to IFN-γ produced by WT lung mononuclear

cells (753 pg/ml compared to 177 pg/ml)(Figure 4.14). In comparison to anti-NK1.1 +
IL-2 stimulation, IP-/- lung mononuclear cells stimulated with anti-NKp46 + IL-2
produced slightly lower levels of IFN-γ compared to IFN-γ produced in anti-NK1.1
stimulated IP-/- lung mononuclear cells (753 pg/ml compared to 930 pg/ml), a difference
which was found to be non-significant. We believe that this similarity in IFN-γ
production following both NK1.1 and NKp46 stimulation provides strong evidence that
pulmonary NK cells are specifically responsible for the observed increase in IFN-γ levels
observed in stimulated IP-/- mouse lung mononuclear cells.
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Figure 4.14
Naïve IP-/- Pulmonary Natural Killer Cells Display Significantly Increased in
vitro IFN-γ Production Following NKp46 Stimulation. Lung mononuclear cells were obtained from
dissociated lung tissue from naïve IP-/- and WT mice. LMCs were stimulated in vitro with anti-NKp46
mAb (20 µg/ml) ± IL-2 (10 ng/ml) for 24 h at 37°C. Supernatants were analyzed for IFN-γ production
by ELISA. Data are mean ± SEM (n = 3) in triplicate and are representative of two independent
experiments. **p < 0.01 compared to WT mice

4.2.2

IP-/- Mice Display an Attenuated Development of Allergic Lung

Inflammation Elicited Following House Dust Mite Exposure
Given the marked increase in pulmonary NK cells present in lung tissue of IP-/mice that was coincident with elevated expression of activating receptor NKp46 as
described in Chapter 4 Methods section 4.2.1, it was important to determine if lung
inflammatory responses had been affected by this increased NK cell population.
Although it has been recognized for almost two decades that one of the defining
features of the asthmatic phenotype in humans is elevated serum levels of house dust mite
(HDM)-specific IgE (Shibasaki, Noguchi et al. 1997) (Ohshima, Yamada et al. 2002)
(Kimura, Tsuruta et al. 2000), animal models of allergic asthma have been slow to adapt.
The earliest study we were able to identify suggesting the efficacy of an HDM-induced
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animal model of allergic asthma was submitted by Cates et al. back in 2004 (Cates,
Fattouh et al. 2004). Despite the attempts of this and other studies that demonstrate the
viability of HDM as a more clinically relevant animal model as compared to the
traditional ovalbumin (OVA)-induced animal models, it is only in the last few years that
a dramatic shift has seemed to occur in preference of the HDM model when seeking
asthma-related funding opportunities. In part, this reflects recently available HDM
preparations that are endotoxin-free from commercially available sources.
In order to maintain pace with advancements in the field, our laboratory adopted
and developed a protocol for the HDM-induced mouse model of allergic asthma (see
Chapter 2 Methods Section 2.0.3.3). One of the key advantages of the HDM-induced
model lies in the direct sensitization of the airway to the allergen via intranasal delivery.
Although new advancements in the field have led to the development of commercially
available purified recombinant HDM-associated proteins, the use of whole dust mite
extract has been predominantly used due to lack of more sophisticated reagents.
However, contamination of whole dust mite extract with other potential antigens, in
particular LPS which is a potent activator of the immune system, are a concern when
analyzing the capacity of whole dust mite extract to induce an immune response.
Therefore, we were careful to utilize batches of whole dust mite extract with undetectable
levels of LPS in order to remove a potential confounding factor in subsequent exposurerelated immune responses.
Although previous work in our laboratory has shown that prostacyclin signaling
exerts a crucial role in the development of ovalbumin-induced allergic lung
inflammation, the role of prostacyclin signaling in HDM-induced allergic lung
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inflammation remains relatively unknown, although an increase in prostacyclin present in
the airway has been observed in mice following HDM exposure (Herrerias, Torres et al.
2009). In this study, we performed a short-term sensitization of the murine airway via
intranasal exposure to whole dust mite extract obtained from Greer followed by two
further challenges one week apart (see Chapter 2 Methods Section 2.0.3.3 for specific
details). Following allergen sensitization and challenge, analysis of HDM-induced
pulmonary inflammation in IP-/- and WT mice was determined.
4.2.2.1 Reduced Infiltration of the Airway by Inflammatory Cells in IP-/- Mice
As mentioned in Chapter 3, infiltration of the airway by inflammatory immune
cells including Th2 lymphocytes, mast cells, alveolar macrophages, and eosinophils is a
defining characteristic of allergic asthma. The observation of increased tissue and
circulatory eosinophilia has been noted since the earliest characterization of the disease,
although the exact role in driving the asthmatic phenotype was contested between the
1970s and 1980s (Wardlaw, Brightling et al. 2000). Continued demonstration that
eosinophil-derived proteins are capable of causing substantial injury to the airway
cemented the role of the eosinophil as the principal effector cell of asthma (Frigas,
Motojima et al. 1991). This focus on the eosinophil has meant that any relevant animal
model of asthma has been primarily characterized by the induction of eosinophilia in the
airway. Thus, several techniques have been utilized to quantify the presence of
eosinophils in the airway to study the development and treatment of allergic asthma. The
use of cell differential counts and flow cytometry analysis has been universally used to
visualize and quantify increases in eosinophilia. Additionally, the release of eosinophilderived proteins such as eosinophil peroxidase (EPO) into the airway has been
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recognized since the mid-1990s as biomarkers of increased airway eosinophilia (Cheng,
Pillar et al. 1993) (Bjornsson, Janson et al. 1996).
Inflammatory cell infiltration into the bronchoalveolar lavage fluid (BALF) is an
effective indicator of the inflammatory process in the lung. Therefore, following the
short-term intranasal HDM exposure described in Chapter 2 Methods Section 2.0.3.3,
examination of the BALF was performed in order to determine the effects of HDM
exposure on infiltration by inflammatory immune cells into the airway of IP-/- mice. We
revealed that HDM-exposed IP-/- mice displayed significantly reduced numbers of both
infiltrating eosinophils and lymphocytes present in the BALF when compared to HDMexposed WT mice as determined by both total cell number as well as measurement of
BALF EPO levels (Figure 4.15). Although both eosinophil and lymphocyte infiltration
into the airway was affected by intranasal HDM exposure, we observed no significant
differences in the number of neutrophils or macrophages present in the BALF of HDMexposed IP-/- mice when compared to HDM-exposed WT mice as determined by total cell
number, although there was a non-significant reduction in the numbers of macrophages
present in BALF of both control and HDM-exposed IP-/- mice compared to control and
HDM-exposed WT mice (Figure 4.15). Control mice that had not been exposed to
intranasal HDM had essentially undetectable numbers of eosinophils, lymphocytes, and
neutrophils in both IP-/- and WT BALF as determined by total cell number, while
macrophage numbers remained essentially identical when comparing HDM-exposed and
control animals of their respective strains (Figure 4.15).
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Figure 4.15
IP-/- Mice Display Attenuated Infiltration of the Airway by Inflammatory Cells
Following Intranasal Exposure to HDM. IP-/- and WT mice were intranasally sensitized with 30 µl
HDM (100 µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3 d
following final HDM challenge, BALF was collected to determine development of allergic lung
inflammation. Control mice received intranasal PBS. (A) Cell differential counts in the BALF were
determined by light microscopic evaluation of stained cytospin preparations. Results are expressed as
absolute numbers (per mouse) of lymphocytes (Lym), macrophages (Mac), eosinophils (Eos), and
neutrophils (Neu). (B) EPO levels in the BALF of HDM-sensitized or control mice were assessed by
colorimetric analysis. Results are ± SEM mean (n = 3) and are representative of two independent
experiments. *p < 0.05, compared to WT HDM mice **p < 0.01, compared to WT HDM mice

The identification of granulocyte populations in the BALF using FACS analysis is
a multi-step process. All granulocytes, including eosinophils, neutrophils, and basophils,
can be differentiated from other immune cells based on the light scatter properties of the
cell. These scatter properties, which include forward scatter and side scatter, are a
relative analysis of the size and the cytoplasmic contents of a cell, respectively. Plotting
these scatter property values against each other leads to specific grouping of granulocytes
due to their large size and dense granule content in the cytoplasm. However, to
differentiate granulocyte populations, specific surface receptor expression must be
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analyzed. Although all granulocytes express particular markers in common, such as
CD11b and F4/80, eosinophils and neutrophils can be individually identified by the
expression of Siglec-F and Gr-1, also known as Ly-6G, respectively (Zhang, Angata et al.
2007) (Noffz, Qin et al. 1998). Consistent with the reduction in infiltrating immune cell
populations observed by cell differential in the BALF, flow cytometry analysis of the
airway revealed that HDM-exposed IP-/- mice displayed a reduction in the proportion of
CD11b+Siglec-F+ eosinophils as well as CD4+ T lymphocytes present in the airway when
compared to HDM-exposed WT mice (Figure 4.16). There was no alteration observed in
the number or proportion of CD11b+Gr-1+ neutrophils in the airway of HDM-exposed IP/-

mice compared to HDM-exposed WT mice (Figure 4.16). Control mice that received

no exposure to HDM displayed low numbers of CD11b+Siglec-F+ eosinophils, CD4+
lymphocytes, and CD11b+Gr-1+ neutrophils present in the airway with no noticeable
differences between strains (Figure 4.16).
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Figure 4.16
Flow Cytometry Analysis of Infiltrating Inflammatory Immune Cells into the
Airway of IP-/- and WT Mice Following Intranasal Exposure to HDM. IP-/- and WT mice were
intranasally sensitized with 30 µl HDM (100 µg) on d 0 with subsequent intranasal challenge with
HDM (50 µg) on d 7 and d 14. 3 d following final HDM challenge, BALF was collected to determine
development of allergic lung inflammation. Control mice received intranasal PBS. BALF cells were
stained with anti-CD3 (APC), anti-CD4 (APCCy7), anti-CD8 (PE), anti-CD11b (FITC), anti-F4/80
(APC), anti-Siglec-F (PE), and anti-Gr-1 (Ly-6G/Ly-6C) and analyzed for receptor expression using a
BD FACSAria Flow Cytometer.
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4.2.2.2 Histologic Examination of Lung Tissue
In addition to infiltration of the airway by inflammatory immune cells, one
of the primary clinical pathologies of allergic asthma is airway obstruction and
remodeling due to increased peribronchial inflammation, mucus secretion, and airway
hyperreactivity (Shifren, Witt et al. 2012). We therefore utilized H&E staining to
characterize the effects of HDM exposure on peribronchial inflammation in the airway of
mice following exposure to HDM. We found that HDM-exposed IP-/- mice had markedly
decreased peribronchial inflammation when compared to HDM-exposed WT mice
(Figure 4.17). Examination of control mice that received no exposure to HDM revealed
that HDM-exposed WT mice had substantially increased peribronchial inflammation
when compared to control WT mice, while HDM-exposed IP-/- mice had a slight increase
in peribronchial inflammation compared to control IP-/- mice (Figure 4.17).
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Figure 4.17
IP-/- Mice Display Decreased Peribronchial Inflammation Following Intransal
Exposure to HDM . IP-/- and WT mice were intranasally sensitized with 30 µl HDM (100 µg) on d 0
with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3 d following final HDM
challenge, peribronchial inflammation was determined by histological analysis by staining lung sections
with H&E (20X).

Additionally, analysis of mucus secretion was performed utilizing % Periodic
acid-Schiff (PAS) staining per bronchiole. We found that HDM-exposed IP-/- mice had
significantly decreased mucus secretion in the airway when compared to HDM-exposed
WT mice (Figure 4.18). Similarly to the H&E analysis of peribronchial inflammation,
we found that HDM-exposed WT mice had substantially increased airway mucus
production when compared to control WT mice, while HDM-exposed IP-/- mice had a
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slight increase in airway mucus production when compared to control IP-/- mice (Figure
4.18).

WT HDM

IP -/- HDM

WT PBS

IP -/- PBS

Figure 4.18
IP-/- Mice Display Decreased Airway Mucus Production Following Intransal
Exposure to HDM . IP-/- and WT mice were intranasally sensitized with 30 µl HDM (100 µg) on d 0
with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3 d following final HDM
challenge, mucus production was determined by histological analysis by staining lung sections with
PAS (20X).

4.2.2.3 Reduced Production of Th2-associated Cytokines in IP-/- Mice
The role of Th2-associated cytokine as an initiating factor during allergic asthma
has been widely accepted for over two decades (Robinson, Hamid et al. 1992). The
initiation of a Th2 response and subsequent role of Th2-associated cytokines IL-4, IL-5,
and IL-13 in the recruitment and activation of B cells, mast cells, and eosinophils has
been studied extensively and described in more detail in Chapter 1 Introduction. As
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demonstrated in Chapter 4 section 4.2.2.1 and 4.2.2.2, loss of prostacyclin signaling
results in a reduction in infiltration of the airway by inflammatory effector cells as well as
peribronchial inflammation and mucus secretion associated with HDM-induced allergic
lung inflammation. Due to the regulation of both these outcomes by Th2-associated
cytokines, we examined whether loss of prostacyclin signaling altered the levels of Th2associated cytokines in the airway.
In order to characterize Th2 cytokine levels in the airway, we analyzed BALF of
IP-/- and WT mice following intranasal HDM exposure. We found that HDM-exposed
IP-/- mice had reduced levels of IL-4 (< 5 pg/ml to ~30 pg/ml), IL-5 (< 2 pg/ml to ~5
pg/ml), and IL-13 (< 50 pg/ml to ~300 pg/ml) when compared to HDM-exposed WT
mice (Figure 4.14). HDM-exposed WT mice had increased levels of IL4, IL-5, and IL-13
when compared to control WT mice, while the levels of these cytokines were not
significantly increased in HDM-exposed IP-/- mice when compared to control IP-/- mice
(Figure 4.19). Both control IP-/- and WT mice displayed levels of these cytokines in the
BALF below the threshold of detection (Figure 4.19).
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Figure 4.19
IP-/- Mice Display Attenuated Th2 Cytokine Production Following Intranasal
Exposure to HDM. IP-/- and WT mice were intranasally sensitized with 30 µl HDM (100 µg) on d 0
with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3 d following final HDM
challenge, BALF was collected to determine development of allergic lung inflammation. Control mice
received intranasal PBS. BALF was assessed using Meso Scale Discovery V-PLEX Mouse
Proinflammatory Panel to determine IL-4, IL-5, or IL-13 production. Results are ± SEM mean (n = 3)
and are representative of two independent experiments.
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4.2.2.4 Altered Production of GM-CSF, CX3CL1, and CCL2 in the Airways of IP-/Mice
Once immune cells responsible for airway surveillance have recognized an
allergen capable of eliciting an immune response, recruitment of effector cells to the site
of allergen challenge typically follows. Although dendritic cells and alveolar
macrophages are often regarded as the principal immune cells responsible for airway
surveillance, it has been well documented that bronchoepithelial cells have a critical role
in the innate recognition of airway antigens. Upon antigen recognition by a wide variety
of pathogen recognition receptors (PRRs), bronchoepithelial cells release a wide variety
of cytokines and chemokines responsible for the activation and recruitment of
inflammatory immune cells (Salazar and Ghaemmaghami 2013). These signaling
proteins capable of recruitment and activation of inflammatory immune cells produced by
bronchoepithelial cells, as well as dendritic cells and macrophages, are critical to
understanding the underlying mechanisms responsible for the development of allergic
asthma.
One of these signaling proteins, CX3CL1, also known as fractalkine, is a novel
chemokine recognized to exist as a membrane-bound adhesion protein in addition to
being cleaved to function as a soluble chemotactic signaling protein (Bazan, Bacon et al.
1997). Expression of CX3CR1, the receptor for CX3CL1, had been shown to occur on
monocytes, NK cells, and CD4+ & CD8+ T cells, and treatment of those immune cells
with soluble CX3CL1 was capable of inducing recruitment and adhesion of NK cells and
T cells, but not monocytes (Imai, Hieshima et al. 1997). The ability of CX3CL1 to
recruit CD4+ T cells led to subsequent studies on the role of CX3CL1 in allergic asthma,
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and it was shown that atopic asthma patients displayed significantly increased production
of CX3CL1 in the BALF following allergen challenge in addition to increased plasma
concentrations before allergen challenge compared to non-asthmatic controls (Rimaniol,
Till et al. 2003).
Another signaling protein, CCL2, also known as monocyte chemotactic protein-1
(MCP-1), was the first CC chemokine identified in humans (Yoshimura, Yuhki et al.
1989). The receptor for CCL2 is separated into two isoforms, CCR2A and CCR2B,
which are restrictively expressed on specific cell types, with CCR2B being expressed by
monocytes and activated NK cells (Deshmane, Kremlev et al. 2009). Elevated levels of
MCP-1 present in the BALF of patients suffering from atopic asthma compared to
healthy controls has been observed (Jahnz-Rozyk, Kuna et al. 1997), and more recently it
was reported that primary airway smooth muscle cultures from biopsies of asthmatic
patients displayed increased secretion of CCL2 when compared to healthy controls
(Singh, Sutcliffe et al. 2014).
Finally, granulocyte-macrophage colony-stimulating factor (GM-CSF), a member
of the cytokine family that also includes IL-3 and IL-5, has been recognized to control the
recruitment and activation, as well as be produced by, monocytes, macrophages, dendritic
cells, and T lymphocytes (Yamashita, Tashimo et al. 2002). In particular, GM-CSF has
been shown to be essential for eosinophil survival, chemotaxis, and activation in regard
to degranulation as well cytokine production (Owen, Rothenberg et al. 1987). With the
capacity to widely affect many immune cells attributed to the pathogenesis of asthma, the
role of GM-CSF in allergic asthma has received much research attention. An increase in
GM-CSF levels in the BALF of atopic asthma patients compared to healthy controls has
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been observed (Robinson, Hamid et al. 1992), and airway epithelial cells of asthmatics
patients have also been shown to produce more GM-CSF than those of healthy controls
(Sousa, Poston et al. 1993). Treatment of mice with neutralizing anti-GM-CSF
antibodies resulted in decreased AHR in addition to airway inflammation (Yamashita,
Tashimo et al. 2002). More recently, the facilitation of allergic airway inflammation
following sub-threshold HDM exposure has been attributed to a GM-CSF/IL-33
controlled pathway (Llop-Guevara, Chu et al. 2014).
The lack of infiltration of the airway by inflammatory immune cells in the IP-/mouse following HDM exposure described in section 4.2.2.1 could be attributed to the
alterations in chemokines such as CX3CL1, CCL2, or GM-CSF. Therefore, we
examined the airway of control and HDM-exposed IP-/- mice to determine whether the
levels of these chemokines in the airway were significantly altered. We found that nonHDM-exposed control IP-/- mice had 1387 pg/ml CX3CL1 present in BALF, which was
significantly elevated compared to the 808 pg/ml CX3CL1 observed in control WT mice
(Figure 4.20). Since CX3CL1 has been demonstrated to be a potent chemokine for the
recruitment of NK cells, this raises the possibility that the observed increase in CX3CL1
level is responsible for the elevated number of pulmonary NK cells in naïve IP-/- mice.
Exposure to HDM resulted in a significant decrease in CX3CL1 levels to 616 pg/ml
present in the BALF of IP-/- mice compared to 1387 pg/ml in control IP-/- mice, as well as
a significant reduction to 450 pg/ml in HDM-exposed WT mice compared to 808 pg/ml
CX3CL1 in control WT mice (Figure 4.20). Comparison of CXCL1 levels between
HDM-exposed IP-/- and HDM-exposed WT mice revealed no significant differences
(Figure 4.20).
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Figure 4.20
Naïve IP-/- Mice Display Increased Levels of CX3CL1 in the Airway. IP-/- and
WT mice were intranasally sensitized with 30 µl HDM (100 µg) on d 0 with subsequent intranasal
challenge with HDM (50 µg) on d 7 and d 14. 3 d following final HDM challenge, BALF was collected
to determine CX3CL1 (fractalkine) levels by ELISA. Control mice received intranasal PBS. Results
are ± SEM mean (n = 3) and are representative of three independent experiments. *p < 0.05

Examination of CCL2 levels in the airway revealed that production of CCL2 in
control IP-/- and WT mouse BALF was very low, with less than 10 pg/ml CCL2 present
in the BALF of either strain (Figure 4.21). Following exposure to HDM, IP-/- mice
displayed a non-significant elevation in BALF CCL2 production to 21 pg/ml compared to
< 10 pg/ml present in the BALF of control IP-/- mice (Figure 4.21). This was directly
contrasted by the results observed in WT mice, as HDM-exposed WT mice displayed a
significant increase in CCL2 production to 154 pg/ml CCL2 present in the BALF
compared to < 10 pg/ml CCL2 found in control WT mice (Figure 4.21). Comparison of
BALF CCL2 levels between HDM-exposed IP-/- and WT mice revealed that the 21 pg/ml
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CCL2 present in the BALF of HDM-exposed IP-/- mice was significantly reduced
compared to the 154 pg/ml CCL2 observed in the BALF of HDM-exposed WT mice
(Figure 4.21). These results suggest that following HDM exposure, production of CCL2
in the airways of IP-/- mice is markedly decreased. As CCL2 is a critical component for
the recruitment of inflammatory monocytes that mature to dendritic cell and macrophage
populations that have been associated with driving allergic lung inflammation (Chen, Liu
et al. 2013) (Lee, Jeong et al. 2014), the inability of IP-/- mice to induce CCL2 production
following HDM exposure could be a possible mechanism in the attenuated development
of allergic lung inflammation.

Figure 4.21
IP-/- Mice Display Attenuated Production of CCL2 in the Airway Following
Intranasal Exposure to HDM. IP-/- and WT mice were intranasally sensitized with 30 µl HDM (100
µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3 d following final
HDM challenge, BALF was collected to assess CCL2 (MCP-1) production by ELISA. Control mice
received intranasal PBS. Results are ± SEM mean (n = 3) and are representative of three independent
experiments. *p < 0.05
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Finally, we examined the levels of GM-CSF present in the airway of control and
HDM-exposed IP-/- and WT mice. We attempted to measure levels of GM-CSF present
in the BALF, but we found that they were below the level of detection for the ELISA kit
used in this study. This is in agreement with previous publications suggesting that this
cytokine has an affinity for the extracellular matrix and is not freely released into the
airway. Therefore, we plated dissociated LMCs from naïve and HDM-exposed IP-/- and
WT mice in vitro as described in Chapter 2 Methods Section 2.0.7.1. We found that
control IP-/- mice had similar levels of production of GM-CSF when compared to GMCSF produced by control WT mice (161 pg/ml compared to 121 pg/ml)(Figure 4.22).
However, following HDM exposure, LMCs from both IP-/- and WT mice displayed
significant increases in GM-CSF production when compared to control mice. HDMexposed IP-/- LMCs displayed significantly increased production of GM-CSF compared
to non-exposed control IP-/- LMCs (291 pg/ml compared to 161 pg/ml) (Figure 4.22).
HDM-exposed WT LMCs displayed significantly increased production of GM-CSF
compared to non-exposed control WT LMCs (981 pg/ml compared to 121 pg/ml)(Figure
4.22). Despite the significantly increased production of GM-CSF by HDM-exposed IP-/LMCs compared to control IP-/- LMCs, comparison of IP-/- and WT LMC production of
GM-CSF revealed that HDM-exposed IP-/- LMCs had significantly reduced production of
GM-CSF compared to HDM-exposed WT LMCs (291 pg/ml compared to 981 pg/ml)
(Figure 4.22). Although the source of the GM-CSF in the lungs was not determined,
these results suggest that IP-/- mice have a deficiency in GM-CSF production in the lungs
following HDM exposure compared to WT mice. As GM-CSF is critical for the survival
of eosinophils in tissue following release from the bone marrow (Park and Bochner
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2010), as well as in the development and activation of monocyte-derived dendritic cells
necessary to drive the Th2 response (van de Laar, Coffer et al. 2012), the reduction in
GM-CSF production observed in HDM-exposed IP-/- mice could be a critical component
in the attenuated development of allergic lung inflammation.

Figure 4.22
IP-/- Mice Display Attenuated Production of GM-CSF in the Airway Following
Intranasal Exposure to HDM. IP-/- and WT mice were intranasally sensitized with 30 µl HDM (100
µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3 d following final
HDM challenge. 3 d following final HDM challenge, lung mononuclear cells were isolated and
incubated for 24 hours at 37°C. Supernatants were subsequently harvested to assess GM-CSF
production by ELISA.. Results are ± SEM mean (n = 3) and are representative of two independent
experiments. *p < 0.05

4.2.2.5 Increased Production of IFN-γ and TNF-α by Pulmonary NK Cells Stimulated
in vitro
As described in Chapter 4 section 4.2.1, naïve IP-/- mice display significantly
increased numbers of pulmonary NK cells (identified as CD3-CD19-NK1.1+). These
pulmonary NK cells appear to be associated with a highly cytotoxic phenotype with
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increased expression of activating receptor NKp46, increased intracellular production of
granzyme A, and significantly increased production of IFN-γ, but not TNF-α, following
in vitro stimulation with either NK1.1 or NKp46. In order to determine the effect of
HDM exposure on this altered pulmonary NK cell population, we isolated LMCs from
HDM-exposed IP-/- and WT mice and stimulated them in vitro utilizing anti-NK1.1 mAb
PK136 in the presence or absence of IL-2 as described in Chapter 2 Methods Section
2.0.7.1. Following exposure to HDM, IP-/- mouse NK cells had significantly increased
production of IFN-γ compared to HDM-exposed WT mice (1210 pg/ml compared to 241
pg/ml)(Figure 4.23). However, comparison of HDM-exposed IP-/- mice to unexposed
control IP-/- mice revealed that exposure to HDM did not appear to have any effect on
production of IFN-γ, as levels were nearly identical (1210 pg/ml compared to 1086
pg/ml)(Figure 4.23). Similarly, comparison of HDM-exposed WT mice to unexposed
control WT mice revealed that exposure to HDM did not appear to have any effect on
production of IFN-γ (241 pg/ml compared to 261 pg/ml)(Figure 4.23). However, we
found that exposure to HDM resulted in significantly increased production of TNF-α
from HDM-exposed IP-/- mouse pulmonary NK cells compared to HDM-exposed WT
mouse pulmonary NK cells (544 pg/ml compared to 129 pg/ml), while TNF-α production
was consistently low (<100 pg/ml) from both control IP-/- and WT mouse pulmonary NK
cells (Figure 4.23). In marked contrast, attempts to analyze IFN-γ and TNF-α levels in the
BALF were unsuccessful as levels were found to be below the threshold of detection.
The ability of HDM to induce TNF-α, but not IFN-γ, production in IP-/- mouse pulmonary
NK cells is an intriguing development that will require further investigation.
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Figure 4.23
IP-/- Pulmonary Natural Killer Cells Display Significantly Increased in vitro IFNγ and TNF-α Production Following NK1.1 Stimulation. IP-/- and WT mice were intranasally
sensitized with 30 µl HDM (100 µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on
d 7 and d 14. 3 d following final HDM challenge, lung mononuclear cells were obtained from
dissociated lung tissue from IP-/- and WT mice. LMCs were stimulated in vitro with anti-NK1.1 mAb
(20 µg/ml) ± IL-2 (10 ng/ml) for 24 h at 37°C. Supernatants were analyzed for IFN-γ and TNF-α
production by ELISA. Data are mean ± SEM (n = 3) in triplicate and are representative of three
independent experiments. **p < 0.01 *p < 0.05

4.2.3

Depletion of Natural Killer Cells Restores Allergic Lung Inflammation in

IP-/- Mice
Although NK cells have a critical role in the modulation of infection and
inflammation in the airway in a variety of different diseases understanding the regulation
of pulmonary NK cells during pathogenesis of asthma is still severely lacking (Culley
2009). The question of whether NK cells exert a beneficial or deleterious role in the
development of asthma has been confused by conflicting reports. Marcenaro et al
demonstrated that NK cells activated with IL-4 were incapable of driving immature DC
maturation responsible for Th1 cell priming, resulting in an environment favorable to the
development of a Th2-associated response (Marcenaro, Della Chiesa et al. 2005).
Korsgren et al had demonstrated almost five years earlier that depletion of NK cells prior
to allergic sensitization resulted in significantly reduced development of eosinophilia and
Th2-associated cytokines production in the airway, indicating that NK cells were critical
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for the development of allergic lung inflammation (Korsgren, Persson et al. 1999).
However, recent work has also demonstrated that resolution of allergic lung inflammation
by resolvin E1 is accomplished through NK cell-mediated clearance of eosinophils and T
lymphocytes (Haworth, Cernadas et al. 2011). Understanding the mediators that regulate
the function of pulmonary NK cells offer us a unique and vital insight into finally
resolving the role of pulmonary NK cells in the development of allergic lung
inflammation.
The attenuated development of allergic asthma observed in IP-/- mice following
HDM exposure described in section 4.2.2 was very unexpected based on our previous
experience with the ovalbumin-induced mouse model of allergic asthma. Understanding
the underlying mechanism responsible for this attenuated response could be of great
interest in developing future therapeutic targets for allergic lung inflammation. The
results presented in Chapter 4 section 4.2.1 demonstrated that loss of prostacyclin
signaling leads to an alteration in the phenotype of the naïve pulmonary NK cells found
in IP-/- mice. Specifically, pulmonary NK cells of IP-/- mice appear to exhibit
characteristics indicative of increased cytotoxicity, including increased expression of
activating receptor NKp46, increased baseline production of granzyme A & IFN-γ, and
increased production of TNF-α following HDM exposure. The question then arises, does
this altered NK cell population in IP-/- mice exert influence in the attenuated development
of allergic lung inflammation following HDM exposure as described in Chapter 4 section
4.2.2? To answer that question, a critical aspect was the depletion of NK cells prior to
exposure to HDM. Therefore, we performed in vivo depletion of NK cells utilizing anti-
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NK1.1 mAb PK136 prior to HDM exposure with subsequent analysis of the development
of allergic lung inflammation.
4.2.3.1 Depletion of Natural Killer Cells Utilizing anti-NK1.1 Monoclonal Antibody
PK136
In order to determine the physiologic role of NKp46+ pulmonary NK cells in the
attenuation of HDM-induced allergic lung inflammation, it is first necessary to devise a
method for their removal from the tissue. One of the most commonly used
immunological techniques for removal of a cell population of interest is in vivo treatment
utilizing a monoclonal antibody (mAb) recognizing a cell-specific receptor. In the case
of NK cells, markers such as NK1.1 (Bartel, Bauer et al. 2013) have been used very
successfully as a method of in vivo NK cell depletion since the development of PK136, a
mAb specific to NK1.1, in 1984 (Koo and Peppard 1984). Since the development of
PK136, it has been shown to induce the depletion of NK cells in vivo in a highly specific
and selective manner (Seaman, Sleisenger et al. 1987) (Kulesza, Hoser et al. 2006)
(Miller, Andres et al. 2003). The strong supporting background for the use of PK136 as
an excellent method for the in vivo depletion of NK cells led us to utilize PK136 for our
own depletion strategy.
Following in vivo treatment of IP-/- and WT mice with PK136 as outlined in
Chapter 2 Methods Section 2.0.5.1, flow cytometry analysis was performed in order to
determine whether treatment utilizing anti-NK1.1 mAb PK136 in WT and IP-/- mice
resulted in depletion of natural killer cell populations in the airway. As described in
Chapter 4 section 4.2.2.1, NK cells were defined as a CD3-CD19-NK1.1+ cell population.
Treatment of both IP-/- and WT mice utilizing PK136 resulted in complete depletion of
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NK1.1+ mononuclear cells in the airway when compared to untreated controls of either
strain (Figure 4.24). In order to verify specificity of PK136 in removing NK cells, in vivo
depletion utilizing control rat IgG was performed as described in Chapter 2 Methods
Section 2.0.5.1. No alteration in NK1.1+ mononuclear cells (NK cells) was observed in
the airway when compared to untreated controls of either strain (Figure 4.24). This data
indicates that the in vivo depletion strategy for NK cells described in Chapter 2 Methods
Section 2.0.5.1 used in this study leads to highly selective and successful in vivo
depletion of NK cells in the airway.
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Figure 4.24
In Vivo Depletion of Pulmonary NK Cells Utilizing anti-NK1.1 mAB PK136.
Naïve IP-/- and WT mice received intraperitoneal (i.p.) injection of PK136 (250 µg) or rat IgG (control
Ig) on day 0, followed by subsequent i.p. injection on day 3, 6, 10, and 13. Lung mononuclear cells
were collected on day 14 to determine depletion of pulmonary NK1.1+ cells. LMCs were stained with
anti-CD3 (PE), anti-CD19 (APCCy7), anti-NK1.1 (FITC), and anti-NKp46 (APC) and analyzed for
receptor expression using a BD FACSAria Flow Cytometer. Natural killer cells were classified as CD3CD19-NK1.1+.
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4.2.3.2 Increased Infiltration by Inflammatory Immune Cell Populations Following
NK Cell Depletion in IP-/- Mice
As described in more detail in section 4.2.2.1, infiltration of the airway by
inflammatory immune cell such as eosinophils and T lymphocytes is critical in the
development of allergic lung inflammation. Following depletion of NK cells with PK136
and subsequent exposure to HDM as described in Chapter 2 Methods Section 2.0.5.1,
examination of the BALF was performed in order to determine the role of NK cells in
modulating infiltration of the airway by inflammatory immune cells following HDM
exposure. We observed that PK136-treated IP-/- mice displayed increased infiltration by
eosinophils into the BALF when compared to untreated IP-/- mice as determined by total
cell number in addition to measurement of EPO levels in the BALF (Figure 4.25).
Interestingly, we also observed increased infiltration by eosinophils into the airway of
PK136-treated WT mice when compared to untreated, HDM-exposed WT mice (Figure
4.25). Treatment of IP-/- and WT mice utilizing control rat IgG did not significantly
impact eosinophilic infiltration of the airway (Figure 4.25) as determined by total cell
number in addition to measurement of EPO levels in the BALF. Although a slight
increase in airway infiltration was observed in PK136-treated IP-/- mice, this infiltration
was not significantly different from that of untreated, HDM-exposed WT mice (Figure
4.25). These results suggest that the NKp46+ NK cell population observed in naïve IP-/mice has the capacity to suppress infiltration of the airway by inflammatory immune cells
such as eosinophils following exposure to HDM.
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Figure 4.25
Depletion of Pulmonary NK Cells in IP-/- Mice Leads to Increased Eosinophilic
Infiltration of the Airway Following Exposure to HDM.
Naïve IP-/- and WT mice received
intraperitoneal (i.p.) injection of PK136 (250 µg) or rat IgG (control Ig) on day -1, followed by
subsequent i.p. injection on day 3, 6, 10, and 13. IP-/- and WT mice were intranasally sensitized with
30 µl HDM (100 µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14.
3 d following final HDM challenge, BALF was collected to determine development of allergic lung
inflammation. (A) Cell differential counts in the BALF were determined by light microscopic
evaluation of stained cytospin preparations. Results are expressed as absolute numbers (per mouse) of
eosinophils (CD11b+F4/80 -SigF+Gr-1-) (B) EPO levels in the BALF of HDM-sensitized mice receiving
i.p. injection of PK136, control Ig, or PBS were assessed by colorimetric analysis. Results are ± SEM
mean (n = 3) and are representative of two independent experiments. **p < 0.01

4.2.3.3 Increased Production of IL-13 Following NK Cell Depletion in IP-/- Mice
Decreased infiltration of inflammatory immune cells into the airway and
decreased peribronchial inflammation & mucus secretion was evident in IP-/- mice
following HDM exposure. In addition, decreased production of the Th2-associated
cytokines IL-4, IL-5, and IL-13 characterized the attenuated allergic lung inflammation in
IP-/- mice following HDM exposure described in section 4.2. In order to characterize the
effects of pulmonary NK cells on Th2-associated cytokine production in the airway, we
analyzed BALF of IP-/- and WT mice following depletion of NK cells. We observed that
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PK136-treated IP-/- mice had significantly increased levels of IL-13 (122 pg/ml to 28
pg/ml) when compared to untreated, HDM-exposed IP-/- mice (Figure 4.26). While
PK136 treatment was effective in increasing production of IL-13 following HDM
exposure, we observed no significant changes in IL-13 production in the BALF following
treatment of IP-/- mice with control rat IgG (Figure 4.26). Comparison of the levels of IL13 present in the BALF of HDM-exposed IP-/- mice following PK136 treatment and
untreated HDM-exposed WT mice revealed that depletion of NK cells prior to HDM
exposure led to restoration IL-13 (~100 pg/ml) production in the airway (Figure 4.26).
The levels of IL-13 in the BALF were not significantly altered following PK136 or
control rat IgG treatment in WT mice, as the level of IL-13 (~100 pg/ml) remained
constant between all three groups (Figure 4.26). This data is consistent with the increased
infiltration of T lymphocytes in the airway following NK depletion and subsequent HDM
exposure described in Chapter 4 section 4.2.3.2, and suggests that the altered NKp46+
NK cells found in IP-/- mice suppress the development of a Th2 response in the airway,
and this effect contributes to the attenuated allergic lung inflammation observed in HDMexposed IP-/- mice.
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Figure 4.26
Depletion of Pulmonary NK Cells in IP-/- Mice Restores IL-13 Production in the
Airway Following Intranasal Exposure to HDM. Naïve IP-/- and WT mice received intraperitoneal
(i.p.) injection of PK136 (250 µg) or rat IgG (control Ig) on day -1, followed by subsequent i.p.
injection on day 3, 6, 10, and 13. IP-/- and WT mice were intranasally sensitized with 30 µl HDM (100
µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3 d following
final HDM challenge, BALF was collected to determine production of IL-13 by ELISA. Results are ±
SEM mean (n = 3) and are representative of two independent experiments. *p < 0.05

4.2.3.4 Altered Production of GM-CSF, CX3CL1, and CCL2 in the Airway Following
NK Cell Depletion in IP-/- Mice
As described more fully in Chapter 4 section 4.2.2.4, we examined the airway for
alterations in the production of several asthma-associated chemotactic and maturation
factors, including GM-CSF, CX3CL1, and CCL2. We observed that IP-/- mice had
significantly reduced production of GM-CSF and CCL2 following HDM exposure
compared to WT mice, while naïve IP-/- mice displayed significantly increased CX3CL1
levels in the airway compared to naïve WT mice (Figure 4.20 – 4.22). While the
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increased CX3CL1 levels likely contribute to the increased numbers of pulmonary NK
cells present in the lungs of naïve IP-/- mice the reduction in GM-CSF and CCL2
production could contribute to the attenuated allergic lung inflammation observed in IP-/mice. Therefore, we examined whether restoration in GM-CSF or CCL2 production
occurred following depletion of NK cells in HDM-exposed IP-/- mice.
Examination of CCL2 revealed that depletion of NK cells utilizing PK136 in
HDM-exposed IP-/- mice resulted in a non-significant increase in CCL2 production (63
pg/ml CCL2) in the BALF compared to CCL2 production (21 pg/ml) in the BALF of
untreated HDM-exposed IP-/- mice (Figure 4.27). In WT mice, depletion of NK cells
resulted in a non-significant decrease in CCL2 production in the BALF of untreated
HDM-exposed WT mice when compared to PK136-treated HDM-exposed WT mice (154
pg/ml compared to 54 pg/ml)(Figure 4.27). Although CCL2 production in BALF of
HDM-exposed IP-/- mice (63 pg/ml) treated with PK136 was reduced compared to
untreated HDM-exposed WT mice (154 pg/ml), this difference was found to be nonsignificant (Figure 4.27). These results suggest that depletion of NK cells in IP-/- mice
does result in partial restoration of CCL2 production in the airways following HDM
exposure.
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Figure 4.27
Depletion of NK Cells in IP-/- Mice Leads to a Non-significant Increase in CCL2
Production in the Airway. IP-/- and WT mice were given intraperitoneal injection of anti-NK1.1 mAb
(PK136)(250 µg) 1 d prior to intranasal HDM exposure, and received twice weekly i.p. injection of
PK136 (250 µg) for the duration of the experiment. IP-/- and WT mice were intranasally sensitized with
30 µl HDM (100 µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3
d following final HDM challenge, BALF was collected to assess CCL2 (MCP-1) production by ELISA.
Control mice received intranasal PBS. Results are ± SEM mean (n = 4) and are representative of two
independent experiments. *p < 0.05 compared to WT HDM mice

Depletion of NK cells utilizing PK136 in HDM-exposed IP-/- mice resulted in a
significant increase in GM-CSF production by LMCs (1035 pg/ml) when compared to
GM-CSF produced by LMCs of untreated HDM-exposed IP-/- mice (291 pg/ml) as well
as untreated control IP-/- mice (161 pg/ml) (Figure 4.28). In WT mice, depletion of NK
cells also resulted in a significant increase in GM-CSF production by LMCs compared to
LMCs from control WT mice (611 pg/ml compared to 121 pg/ml)(Figure 4.28).
Interestingly, depletion of NK cells in HDM-exposed WT mice resulted in a significant
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decrease in GM-CSF production when compared to untreated HDM-exposed WT mice
(611 pg/ml compared to 981 pg/ml)(Figure 4.28). This decrease in GM-CSF production
following NK cell depletion in WT mice could be explained by the loss of NK cells in the
airway, which produce GM-CSF upon activation and contribute to overall airway GMCSF production. Comparison of the GM-CSF produced by LMCs of PK136-treated IP-/mice (1035 pg/ml) to the GM-CSF produced by LMCs of untreated HDM-exposed WT
mice (981 pg/ml), no significant differences were observed (Figure 4.28). These results
suggest that the NKp46+ NK cells present in the lungs of naïve IP-/- mice are capable of
suppressing GM-CSF production in the lung following exposure to HDM, and depletion
of this NK cell population results in complete restoration of GM-CSF production in the
lung in response to HDM exposure.
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Figure 4.28
Depletion of NK Cells in IP-/- Mice Results in Significantly Increased GM-CSF
Production in the Airway Following Intranasal Exposure to HDM. IP-/- and WT mice were given
intraperitoneal injection of anti-NK1.1 mAb (PK136)(250 µg) 1 d prior to intranasal HDM exposure,
and received twice weekly i.p. injection of PK136 (250 µg) for the duration of the experiment. IP-/- and
WT mice were intranasally sensitized with 30 µl HDM (100 µg) on d 0 with subsequent intranasal
challenge with HDM (50 µg) on d 7 and d 14. 3 d following final HDM challenge, lung mononuclear
cells were isolated and incubated for 24 hours at 37°C. Supernatants were subsequently harvested to
assess GM-CSF production by ELISA. Control mice received intranasal PBS. Results are ± SEM
mean (n = 4) and are representative of two independent experiments. *p < 0.05

Finally, examination of CX3CL1 revealed that depletion of NK cells in IP-/- and
WT mice had almost no effect on CX3CL1 production in the airway following HDM
exposure, as non-significant difference were observed when comparing PK136-treated
and untreated BALF of both strains (Figure 4.29). We found that PK136 treatment and
subsequent HDM exposure in IP-/- and WT mice resulted in a non-significant decrease in
CX3CL1 levels in the BALF compared to unexposed IP-/- and WT control mice (765
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pg/ml to 1387 pg/ml and 615 pg/ml to 809 pg/ml CX3CL, respectively)(Figure 4.29).
These results lend support to the concept that, while CX3CL1 would seem to exert a
critical role in the recruitment of NK cells to the lungs of naïve IP-/- mice, the role of
CX3CL1 in direct response to HDM exposure in the attenuation of allergic lung
inflammation observed in IP-/- mice is likely minimal.

Figure 4.29
Depletion of NK Cells in IP-/- Mice Does Not Alter CX3CL1 Production in the
-/Airway. IP and WT mice were given intraperitoneal injection of anti-NK1.1 mAb (PK136)(250 µg)
1 d prior to intranasal HDM exposure, and received twice weekly i.p. injection of PK136 (250 µg) for
the duration of the experiment. IP-/- and WT mice were intranasally sensitized with 30 µl HDM (100
µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on d 7 and d 14. 3 d following final
HDM challenge, BALF was collected to assess CX3CL1 (fractalkine) production by ELISA. Control
mice received intranasal PBS. Results are ± SEM mean (n = 4) and are representative of two
independent experiments. *p < 0.05
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4.2.4

Adoptive Transfer of IP-/- Mouse Natural Killer Cells Results in Attenuated

Response in Wild-type Mice
As described in Chapter 4 section 4.2.3, the use of anti-NK1.1 mAb PK136 to
deplete NK cells in the lungs strongly implies that NK1.1+ cells are responsible for the
attenuated development of allergic lung inflammation following exposure to HDM
observed in IP-/- mice. However, treatment with PK136 does have an important
limitation when determining the specific role of NK cells, as most invariant NKT cells
express NK1.1 and have been shown to be depleted following treatment with PK136
(Teige, Bockermann et al. 2010). Thus, in order to definitively state that NK cells are
responsible for the attenuated development of allergic lung inflammation observed in IP-/mice, we needed to find a solution that clearly established NK cell, not iNKT cell,
involvement. A confounding factor in resolving this issue is that, while examination of
responses in Rag-1-/- mice would facilitate analysis of NK cell involvement in isolation,
the eosinophilic infiltration associated with allergic lung inflammation would be largely
lost in the absence of adaptive immunity. Therefore, given these limitations, we
examined whether adoptive transfer of purified NK cells directly into the airway of WT
mice was sufficient to inhibit the development of allergic inflammation elicited following
exposure to HDM as described in Chapter 2 Methods Section 2.0.5.2. The decision to
utilize oral-pharyngeal administration as the route of adoptive transfer was based on the
possibility that the pulmonary NK cells from IP-/- mice regulate antigen-presenting
immune cells such as alveolar macrophages involved in the recognition of HDM.
Following adoptive transfer of WT and IP-/- mouse splenic NK cells and
subsequent exposure to HDM as described in Chapter 2 Methods Section 2.0.5.2, we
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examined the infiltration of eosinophils into the airway of WT mice. Adoptive transfer of
both IP-/- and WT splenic NK cells resulted in significantly reduced eosinophilic
infiltration into the airway when compared to HDM-exposed control WT mice as
determined by measurement of BALF EPO levels (Figure 4.30). However, the
suppression of eosinophil infiltration into the airway was most effective following
adoptive transfer of IP-/- splenic NK cells (Figure 4.30). These results suggest that NK
cells, and not other NK1.1-expressing immune cells such as iNKTs, are specifically
responsible for the attenuated development of allergic lung inflammation observed in IP-/mice, and that it is possible to induce in WT mice the attenuated response observed in the
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Figure 4.30
Adoptive Transfer of Splenic WT and IP-/- NK Cells Leads to Significantly
Reduced EPO Production in the Airway Following Intranasal Exposure to HDM. IP-/- and WT
mice were intranasally sensitized with 30 µl HDM (100 µg) on d 0 with subsequent intranasal challenge
with HDM (50 µg) on d 7 and d 14. Splenic NK cells were purified from IP-/- and WT mice using
MagCellect magnetic cell sorting. Purified NK cells were resuspended (5x105 cells/ml) in RPMI
supplemented with 10 ng/ml IL-2 (no FBS), and 30 µl was instilled by oral-pharyngeal administration
24 hours following initial HDM sensitization. Control mice received oral-pharyngeal PBS. BALF was
collected and assessed by colorimetric analysis. Results are ± SEM mean (n = 4) and are representative
of two independent experiments. *p < 0.05
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Understanding that IP-/- and WT mice exhibit significant differences in airway
chemokine levels while naïve as well as following HDM exposure (see Figure 4.20 –
4.22 & Figure 4.27 – 4.29), we attempted to examine airway chemokine levels in WT
mice exposed to HDM following oral-pharyngeal adoptive transfer of IP-/- splenic NK
cells. WT mice receiving IP-/- splenic NK cells displayed significantly increased
production of CX3CL1 (525 pg/ml) compared to WT mice receiving no adoptively
transferred cells (254 pg/ml)(Figure 4.31). However, no significant differences were
observed in CCL2 levels (Figure 4.31). These results suggest that adoptive transfer of
NK cells into the airway initiates either the induction or release of CX3CL1 into the
airway, and could play a vital role in the regulation of airway responsiveness to allergens
such as HDM.
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Figure 4.31
Adoptive Transfer of Splenic IP-/- NK Cells Leads to Significantly Levels of
CX3CL1 in the Airway Following Intranasal Exposure to HDM. WT mice were intranasally
sensitized with 30 µl HDM (100 µg) on d 0 with subsequent intranasal challenge with HDM (50 µg) on
d 7 and d 14. Splenic NK cells were purified from IP-/- mice using MagCellect magnetic cell sorting.
Purified NK cells were resuspended (5x105 cells/ml) in RPMI supplemented with 10 ng/ml IL-2 (no
FBS), and 30 µl was instilled by oral-pharyngeal administration 24 hours following initial HDM
sensitization. Control mice received oral-pharyngeal PBS. BALF was collected and assessed ELISA.
Results are ± SEM mean (n = 4) and are representative of two independent experiments. *p < 0.01
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4.2.5

Naïve IP-/- Mice Display Reduced Numbers of Vimentin+ Alveolar

Macrophages in the Airway
While alterations in airway production of chemokines, particularly CX3CL1,
offer a putative mechanism for the attenuated development of allergic airway
inflammation in IP-/- mice following HDM exposure, the direct role of NK cells remained
unresolved. The observed increase in NKp46 expression by pulmonary NK cells offered
another potential direction for understanding the underlying mechanism. In addition to
recognizing exogenous bacterial and viral ligands, NKp46 also has the capacity to
recognize endogenous ligands. The most well-described of these ligands is vimentin, a
universally expressed structural protein that has been shown to activate NK cells resulting
in cytotoxicity (Harris, Kapur et al. 1992; Garg, Barnes et al. 2006; Chong, Zhou et al.
2010). A wide variety of cell types have been shown to express surface vimentin,
including macrophages, dendritic cells, monocytes, and T cells (Benes, Maceckova et al.
2006; Chen, Tseng et al. 2009; Chong, Zhou et al. 2010). It is possible that NK-mediated
targeting of vimentin-expressing pulmonary immune cells could result in the attenuated
development of allergic airway inflammation. Examination of BALF in naïve IP-/- mice
revealed a significant decrease in vimentin+ alveolar macrophages present in the airway
when compared to WT mice (Figure 4.32). Recent studies have identified a pathogen
recognition receptor, dectin-2, that is critical for promoting the HDM-induced immune
response (Clarke, Davis et al. 2014; Norimoto, Hirose et al. 2014; Parsons, Li et al.
2014). Examination of dectin-2 expression in conjunction with vimentin expression in
naïve IP-/- mice revealed that dectin-2+vimentin+ alveolar macrophages are markedly
decreased when compared to WT mice. It is possible that NK-mediated targeting of
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vimentin-expressing alveolar macrophages in the airways results in loss of the immune
cells responsible for the initial recognition and presentation of HDM antigen, and could
be a possible mechanism for the attenuated development of allergic airway inflammation
observed in IP-/- mice.

Figure 4.32
Airways of Naïve IP-/- Mice Display Reduced Numbers of Vimentin+ Alveolar
Macrophages. BALF was collected from naïve IP-/- and WT mice and stained with anti-CD11c, antiDectin-2, and anti-vimentin, and analyzed for receptor expression using a BD FACSAria Flow
Cytometer.

4.3

DISCUSSION
Asthma is classically considered a disease in which the adaptive immune system,

specifically Th2 lymphocytes, plays a central role. However, the innate immune system
likely contributes to the pathogenesis of asthma and its role should not be overlooked. As
front-line sentinels in virtually every tissue, innate immune cells have the capacity for
recognition and responsiveness to environmental allergen long before the adaptive
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immune system develops the capacity to respond. Innate immune cells such as NK cells
have been implicated to exert a role in asthma pathogenesis, as they have been
demonstrated to regulate the development of T cell-mediated allergic inflammation of the
airway (Korsgren, Persson et al. 1999; Wingett and Nielson 2003; Ple, Barrier et al.
2010). Surprisingly, it has been shown that IgE stimulation can activate murine NK cells
via FcγR resulting in the production of a variety of cytokines including IFN-γ, TNF-α,
and GM-CSF as well as direct cytotoxicity targeting IgE-coated cells (Arase, Arase et al.
2003). Clinical observations of asthmatic patients have revealed enhanced NK activity in
peripheral blood, and suggested that NK cells migrate into the airways following antigen
exposure (Timonen and Stenius-Aarniala 1985; Jira, Antosova et al. 1988). Previous
reports have investigated the effect of NK cells on allergic lung inflammation with
contradictory findings, in some instances NK cells inhibited allergic lung inflammation
and in others they promoted eosinophilic inflammation (Walker, Checkel et al. 1998;
Han, Fan et al. 2008; Haworth, Cernadas et al. 2011; Farhadi, Lambert et al. 2014).
However, none of these reports investigated the properties of tissue NK cells in the
absence of specific eicosanoids. This is particularly relevant given that NK cells are
responsive to a range of endogenously produced eicosanoids which include resolvin-E1,
lipoxin-A4, PGD2, PGE2, and leukotrienes (Zielinski, Gisinger et al. 1984; Bray and
Brahmi 1986; Chen, Perussia et al. 2007; Barnig, Cernadas et al. 2013). Nevertheless,
attempts to understand the underlying regulatory signals responsible for controlling NK
cell function during allergic inflammation remain unresolved, and represent a highly
viable avenue of research for understanding asthma pathogenesis.
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In this study, we attempted to expand our understanding of the role that
prostaglandins, specifically PGI2, exert on NK cell function during allergic lung
inflammation in a model using mice lacking expression of the PGI2 receptor (IP). A
previous study published from our laboratory has demonstrated the potent
immunoregulatory role of PGI2 on innate immune cells in the airway and the subsequent
impact on the regulation of asthma pathogenesis (Jaffar, Ferrini et al. 2011). Previous
studies have demonstrated that NK cell effector function is effectively down-regulated
via direct and indirect signaling via PGE2 and PGD2 (Linnemeyer and Pollack 1993;
Yakar, Melamed et al. 2003; Chen, Perussia et al. 2007). However, relatively few studies
have looked at PGI2-mediated regulation of NK cell effector function, although stable
analogues of PGI2 have been suggested to regulate the activation and inhibition of NK
cells (Constantini, Kornowski et al. 1991).
4.3.1

Loss of PGI2 Signaling Causes Significant Phenotypic and Functional

Alterations in Pulmonary Natural Killer Cells
Understanding the role of PGI2 signaling on pulmonary NK cell effector function
began with characterization of these immune cells in the airway of naïve IP-/- mice.
Interestingly, examination of the lungs revealed significantly increased numbers of
pulmonary NK cells (identified as CD3-CD19-NK1.1+ cells) in naïve IP-/- compared to
C57BL/6 (WT) mice. NK1.1 is an activating receptor universally expressed by NK cells,
and stimulation of this receptor in conjunction with IL-2 has been shown to result in
active proliferation and cytokine production by NK cells (Karlhofer and Yokoyama 1991;
Reichlin and Yokoyama 1998). In addition to increased numbers of CD3-CD19- cells
expressing NK1.1, IP-/- pulmonary NK cells exhibited markedly increased expression of
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another activating receptor, NKp46 (CD335). While this increased expression of NKp46
was observed most strongly in the airways, evaluation of systemic NKp46 expression
revealed a virtually universal up-regulation of this receptor in IP-/- mouse NK cells
indicating that prostacyclin signaling may play a critical role in the regulation of NKp46
expression. NKp46 is universally and specifically expressed by NK cells, and the
evolutionary conservation of NKp46 across species has led to the suggestion that
identification of NK cells based on NKp46 expression may be the most highly accurate
method to identify NK cells classification, rather than NK1.1 (Narni-Mancinelli, Chaix et
al. 2011). NKp46 is a critically important activating receptor for NK cells, responsible
for the recognition of a wide variety of exogenous ligands, including viral ligands such as
hemagglutinin (Mandelboim, Lieberman et al. 2001). Activation of NK cells via NKp46
has been shown to result in potent cytotoxicity and cytokine production in order to
resolve infections, particularly following viral recognition (Vankayalapati, Wizel et al.
2002; Bozzano, Picciotto et al. 2011; Pembroke, Christian et al. 2014).
Increased expression of NKp46 by IP-/- pulmonary NK cells could potentially
result in NK cells programmed for increased pro-inflammatory responses and increased
NK-cell mediated cytotoxicity. Indeed, our analysis of naïve IP-/- pulmonary NK cells
revealed increased numbers of cells producing Granzmye A when compared to WT mice.
Granzyme B staining was found to be typically weak. Curiously, analysis of intracellular
IFN-γ seemed to suggest that naïve IP-/- pulmonary NK cells similar capability for
cytokine production. However, in vitro stimulation of naïve IP-/- pulmonary NK cells
utilizing either NK1.1 and IL-2 or NKp46 and IL-2 costimulation resulted in significantly
increased production of IFN-γ, but not TNF-α, presumably reflecting the elevated number
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of NK cells present in the lungs of IP-/- mice. As these results are suggestive of increased
NK cell cytotoxicity, we attempted to determine whether IP-/- pulmonary cells were
capable of increased lysis of tumor cell lines. However, the results of these initial studies
were inconclusive (data not shown), and further analysis of IP-/- pulmonary NK cells in
order to characterize alterations in cytotoxicity will be required to definitively address
this question. However, these results still indicate that following ligand binding by
NK1.1 or NKp46, IP-/- pulmonary NK cells have the capacity for significantly increased
effector function when compared to WT pulmonary NK cells.
Our results suggest that the expression of NKp46 by pulmonary and systemic NK
cells may be regulated by prostacyclin signaling, and that PGI2 potentially inhibits NK
cell effector function in WT mice through the regulation of NK-derived cytotoxic
mediators and activating receptor expression. This regulation of NK cell effector
function by PGI2 has the capacity to dramatically alter the role of NK cells in the
pathogenesis of a wide variety of potential diseases, including asthma.
4.3.2

Attenuation of House Dust Mite-Induced Allergic Airway Inflammation

Following the Loss of PGI2 Signaling
Almost a decade ago, Cates et al described a novel HDM-induced animal model
for the study of allergic asthma (Cates, Fattouh et al. 2004). While exposure to OVA has
been widely accepted as the standard animal model in the study of allergic asthma, the
advantages of HDM as a biologically relevant animal model of allergic asthma have
recently led to wide spread adoption of HDM-induced models. HDM-specific allergy is
the most prevalent cause of sensitization associated with asthma, and almost 85% of
asthmatics in highly populated area of North and South America are HDM allergic
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(Pollart, Chapman et al. 1989; Thomas, Hales et al. 2010). Although previous work done
in our lab has focused on understanding the role of PGI2 in the regulation of OVAinduced allergic airway inflammation, maintaining consistency with advancements in the
field required the development and adoption of a model of allergic asthma involving
HDM-induced short-term intranasal sensitization of murine airways. Unexpectedly,
while WT mice developed the predicted levels of allergic airway inflammation following
HDM exposure, IP-/- mice exhibited an attenuated immune response characterized by lack
of infiltrating inflammatory immune cells, reduced peribronchial inflammation and goblet
cell mucous secretion, and reduced production of Th2-associated cytokines in the airway.
While an increase in airway levels of PGI2 following HDM exposure has been described,
understanding whether airway PGI2 production in response to HDM exposure exerts proor anti-inflammatory effects has so far remained unclear (Herrerias, Torres et al. 2009).
These results suggest that PGI2 signaling is a critical requirement for the promotion of
HDM-induced allergic airway inflammation. However, the mechanism underlying this
observed decrease in infiltrating immune cells and subsequent reduction in allergic
airway inflammation remained unclear.
In an attempt to elucidate a mechanism, we examined the airway for alterations in
the production of chemotactic factors involved in the recruitment of asthma-associated
immune cells. Specifically, airway levels of CX3CL1 (fractalkine), CCL2 (MCP-1), and
GM-CSF were chosen based on their well-studied capacity for inducing recruitment of
adaptive and innate immune cells into the airway as well as their association with asthma
(Owen, Rothenberg et al. 1987; Imai, Hieshima et al. 1997; Deshmane, Kremlev et al.
2009; Singh, Sutcliffe et al. 2014). Analysis of these chemokines revealed substantial
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alterations in all 3 chemokines, both pre- and post-HDM exposure when comparing IP-/and WT mice. Naïve IP-/- mice displayed significantly increased production of airway
CX3CL1, although treatment of both IP-/- and WT mice with HDM resulted in significant
reduction in CX3CL1 production when compared to naïve mice. This increase in
CX3CL1 observed in IP-/- mice is particularly interesting when considering the marked
increase in pulmonary NK cells present in the airway. NK cells have been well-described
to express the receptor for CX3CL1 (CX3CR1), and treatment of NK cells with CX3CL1
has been shown to induce their recruitment (Sechler, Barlic et al. 2004; Huang, Shi et al.
2006; Hamann, Unterwalder et al. 2011; El-Shazly, Doloriert et al. 2013). It is possible
that this constitutive increase in airway CX3CL1 observed in naïve IP-/- mice results in
the recruitment and increased tissue residence described earlier in this dissertation.
However, the source of CX3CL1 production remains unclear, and further studies will be
needed to definitively resolve the potential sources. Unlike CX3CL1, examination of
CCL2 and GM-CSF revealed that naïve IP-/- and WT mice did not display constitutive
production of either cytokine. However, unlike WT mice, HDM-exposure failed to
induce production of CCL2, and only minor, though significant, increases in GM-CSF
were observed in the airways of IP-/- mice following HDM exposure. As CCL2 and GMCSF are critical in recruiting inflammatory monocytes capable of maturing into antigenpresenting dendritic cells, the loss of these signaling molecules could result in an inability
to initiate the differentiation and activation of the adaptive immune system responsible
for allergic airway inflammation (van de Laar, Coffer et al. 2012; Chen, Liu et al. 2013;
Lee, Jeong et al. 2014). Alterations in any of these chemokines could be a putative
mechanism underlying the attenuated development of allergic asthma observed in IP-/-
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mice, and further analysis will be required to determine the respective contributions of
each of these chemokines.
Our results demonstrate that loss of PGI2 signaling results in attenuation in the
development of allergic airway inflammation, suggesting that production of PGI2 in the
airway following HDM exposure promotes the development of allergic airway
inflammation. Understanding the mechanism responsible for the attenuated inflammation
observed in this study could potentially lead to novel therapeutic approaches responsible
for inhibiting asthma pathogenesis through the regulation of PGI2 signaling in the airway.
4.3.3

Natural Killer Cells Are Responsible For The Attenuated Development of

House Dust Mite-Induced Allergic Airway Inflammation
While our results clearly indicated a role for PGI2 signaling in the development of
HDM-induced allergic airway inflammation, the mechanism responsible for attenuation
remained unclear. While alterations in the production of chemokines including CX3CL1,
CCL2, and GM-CSF in the airway of IP-/- mice were observed, the underlying cause of
these alterations remained in question. Fortunately, the substantial changes in the NK
cell populations we observed in IP-/- mice presented a clear target as a potential mediator
of the attenuated response to HDM. This potential was further strengthened by the
examination of pulmonary NK cells following HDM exposure, as IP-/- pulmonary NK
cells displayed significantly increased production of IFN-γ and TNF- α compared to WT
mice. While we had observed increased IFN-γ in naïve IP-/- pulmonary NK cells, TNF-α
production had previously remained unaltered. The changes in TNF-α production we
observed following HDM exposure suggested further alterations in the IP-/- pulmonary
NK cells.
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In this study, we utilized an in vivo depletion method using anti-NK1.1 mAb
PK136 in order to systemically deplete NK cells prior to HDM exposure in IP-/- and WT
mice. Depletion of NK cells in IP-/- mice and subsequent intranasal HDM exposure
resulted in restoration of allergic airway inflammation as characterized by increased
eosinophilic airway infiltration and significantly increased production of Th2-associated
cytokines, specifically IL-13. As in vivo depletion of NK1.1 has the potential to lead to
depletion of NKT cells, we also utilized oral-pharyngeal adoptive transfer of purified NK
cells to definitively show that NK cells are responsible for the attenuated allergic airway
inflammation observed in IP-/- mice. Adoptive transfer of IP-/- splenic NK cells resulted
in significant inhibition of eosinophilic infiltration of WT mouse airways. These results
suggest a previously unrecognized role of NK cell-mediated suppression of airway
inflammation that appears to be regulated by PGI2 signaling. However, the specific
mechanism utilized by NK cells that could suppress allergic airway inflammation
remains unresolved. The observed phenotype of IP-/- pulmonary NK cells suggests
increased cytotoxicity, and it’s possible that these NK cells are responsible for the
removal of immature antigen-presenting cells, as NK-mediated cytotoxicity of immature
dendritic cells has been well described (Carbone, Terrazzano et al. 1999; Della Chiesa,
Vitale et al. 2003; Walzer, Dalod et al. 2005; Poggi and Zocchi 2007). Alternatively, NK
cells could conceivably modulate the vascular endothelium, resulting in reduced
leukocyte recruitment into the airway in response to HDM as CX3CL1-mediated NK
cytotoxicity against endothelial cells has been observed previously (Yoneda, Imai et al.
2000). Finally, NKp46 has been shown to recognize endogenous ligands such as
vimentin, and binding of vimentin by NKp46 results in up-regulation of NKp46
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expression and NK-mediated cytotoxicity (Chong, Zhou et al. 2010). Examination of
vimentin-expression in the airway of IP-/- mice revealed markedly reduced expression of
vimentin compared to WT mice, and its expression was mainly associated with alveolar
macrophages. Although further studies are needed to determine whether cells expressing
increased vimentin interact with NK cells in the airways of IP-/- mice.
In addition to the restoration of allergic airway inflammation in IP-/- mice
following depletion, we also examined whether depletion of NK cells resulted in any
alteration in the levels of the chemokines CX3CL1, CCL2, and GM-CSF in the airway.
While we did not observe any changes in the production of CCL2 or CX3CL1, we
detected significant changes in airway production of GM-CSF. Depletion of NK cells in
IP-/- mice resulted in a significant increase in GM-CSF production in the airway resulting
in levels similar to WT mice following HDM exposure. However, further studies will be
needed to determine whether the increased production of GM-CSF is a consequence of
increased airway infiltration by inflammatory immune cells, or a mediator of recruitment
into the airway. Interestingly, although we observed no change in CX3CL1 levels in the
airway of NK-depleted IP-/- and WT mice following HDM exposure, adoptive transfer of
IP-/- splenic NK cells into the airway of WT mice resulted in a significant increase in
airway CX3CL1 levels. While it remains to be seen whether these NK cells are
responsible for the induction or release of CX3CL1 into the airway, the results are
suggestive that CX3CL1 plays a critical role in the regulation of NK cells responsible for
the attenuated development of allergic lung inflammation observed in IP-/- mice.
Our results suggest that PGI2 signaling is responsible for the regulation of NK cell
effector functions that have the capacity to control the development of allergic airway
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inflammation. While we have attempted to identify a putative mechanism for how this
NK-mediated control is accomplished, further studies will be required to expand our
understanding of the role of NK cells in the development of allergic lung inflammation.
4.3.4

Summary
Collectively, the results of this study represent a previously unrecognized role for

the regulation of allergic airway inflammation involving PGI2 signaling. PGI2 appears to
have an inhibitory effect on pulmonary NK cells, and removal of this inhibition through
loss of prostacyclin signaling results in significant alterations in systemic NK phenotype.
These altered NK cells are capable of mediating the attenuated development of allergic
airway inflammation in response to HDM exposure. Although we have not yet identified
a definitive mechanism behind this regulation, this study suggests that the inhibition of
PGI2 signaling in the airways could be a potentially new target for the development of
novel therapeutic approaches that could eventually lead to inhibition the development of
allergic asthma.

	
  

134	
  

Chapter 5
Loss of Prostacyclin Signaling in the Regulation of Intestinal Immunity

Bryan J Simons, Maria E Ferrini, Zeina Jaffar, Kevan Roberts
Center for Environmental Health Sciences, Biomedical and Pharmaceutical
Sciences, College of Health Professions and Biomedical Sciences, The University of
Montana, 285B Skaggs Building, Missoula, MT 59812
Corresponding Author: Kevan Roberts
Telephone:
FAX:
E-mail:

(406) 243-4034
(406) 243-2807
kevan.roberts@umontana.edu

Working Title: Role of PGI2 in the Regulation of Natural Antibody Production
Acknowledgements: This study was supported in part by Centers of Biomedical
Research Excellence (COBRE, NIH, P20RRO17670) and the National Institutes of
Health (NIH, RO1-HL079189-01A1). The authors would like to thank Pam Shaw (Flow
Cytometry Facility Core) and Lou Herritt (Molecular Histology and Fluorescence
Imaging Core) for expert technical assistance during this study.

	
  

135	
  

5.0

ABSTRACT
The intestinal mucosa represents a critical staging point for the initiation of

humoral immune responses capable of defending against a wide array of potential
pathogens. The regulation of adaptive and innate immune responses by endogenous cellderived lipid mediators known as prostaglandins has long been acknowledged. While
prostaglandins such as PGE2 and PGD2 have an extensive history of study involved in the
activation and inhibition of a diverse assortment of immune responses in many tissues,
the role of prostacyclin (PGI2) as an immunoregulatory molecule has received far less
focus. Utilizing a transgenic mouse model deficient in expression of the PGI2 receptor
(IP-/-), we report that naïve IP-/- mice display attenuated production of natural
immunoglobulins IgG1, IgG2b, and IgA in serum, as well as secretory IgA in the
bronchoalveolar lavage fluid and intestinal fecal contents. Examination of the intenstinal
mucosa of naïve IP-/- mice revealed marked reduction in IgA+ B cells present in both the
lamina propria and Peyer’s patches when compared to C57BL/6 (WT) mice, although no
alterations in Peyer’s patch formation or germinal center structure were observed.
Interestingly, stimulation of Peyer’s patch lymphocytes using recombinant IL-23 resulted
in significantly reduced production of IL-22. While further studies are needed to
understand the mechanism underlying the attenuated production of natural antibodies in
naïve IP-/- mice, the results of this study suggest a previously unrecognized critical role
for PGI2 signaling in the regulation of humoral immune responses.
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5.1

Background

5.1.1

Intestinal Immunity

5.1.1.1 Mucosal Immunobiology
When considering routes of potential environmental exposure that could lead to
activation of the immune system, the mucous membrane comprising the lining of the
digestive, respiratory, and urogenital tract should be of primary focus. With a combined
surface area of approximately 400 m2, no other site in the body offers more potential for
successful entry of toxic elements and infectious pathogens (Peterson and Artis
2014). The physical mucosal barrier is comprised of a layer of columnar epithelial cells
sealed by tight junctions with an underlying lamina propria and musculature which
provides a physical separation between the interior of the body and the external
environment (Turner 2009). In order to halt invasion by environmental pathogens, an
intricate and extensive network of innate and adaptive immune cells has developed to
successfully repel and resolve potential invaders. Immune cells, including macrophages,
dendritic cells, plasma cells, and lymphocytes, reside beneath the epithelial barrier in the
lamina propria.
Far from being a disorganized accumulation of cells spread haphazardly
throughout the lamina propria, defense of the mucosal barrier by these immune cells is
orchestrated by carefully organized lymphoid tissues known as mucosal-associated
lymphoid tissues (MALTs) (Croitoru, Bienenstock et al. 1994). MALTs can be further
subdivided into organ-specific MALTs and include gastrointestinal-lymphoid tissue
(GALT), bronchial-associated lymphoid tissue (BALT), nasopharyngeal-associated
lymphoid tissue (NALT), and several other minor MALTs (Croitoru, Bienenstock et al.
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1994). Functionally, MALT can be divided into two primary sites: (i) inductive sites (ii)
and effector sites (Cesta 2006). Inductive sites are areas where presentation of antigen by
antigen-presenting cells to T lymphocytes occurs in order to drive primary T cell
responses. Activated T cells, mainly CD4+, are responsible for initiating immunoglobulin
class switching and clonal expansion of IgA+ B cells that provide protection against
invading pathogens. Once an immune response has been initiated at an inductive site,
migration and relocalization of both antigen-specific T and B cells to effector sites occurs
(Cesta 2006). This migration is driven by expression of a variety of chemokine receptors
and adhesion molecules including CXCR4, α4β1, P-selectin ligands, CD22, CCR10, and
CCR9 that control site-specific migration throughout the mucosa, for example CCR9 is
required for the homing of activated B cells to the small intestine (Pabst, Ohl et al. 2004;
Mora and von Andrian 2008). While anatomically separated, MALT sites can be
considered functionally connected, as induction of activated IgA+ B cells at an initial site
of antigenic recognition can lead to IgA secretion at effector sites in different organs, and
has been shown to occur independently of systemic immunity. Due to this critical
capacity in the induction of mucosal immune responses, alterations in MALT function
can have dramatic consequences for immune function, and evaluation of MALT remains
a crucial aspect in studying the response of the immune system following antigenic insult.
5.1.1.2 Structure of the Gastrointestinal Tract: Gut - associated lymphoid tissue
The gastrointestinal (GI) tract is critical for the digestion and absorption of
nutrients, in addition to serving as a primary barrier to harmful external pathogens as well
as beneficial microorganisms of the GI microbiome. These two crucial roles result in
essentially constant exposure to dietary, bacterial, fungal, and viral components. The
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importance of robust and diligent immune surveillance in the GI tract cannot be
understated. However, uninhibited, constant activation of immune cells would
potentially lead to a rampant, continuous inflammatory state that would be highly
detrimental to proper GI tract function. In order to maintain levels of activation that are
effective, but not deleterious, the GI tract is stratified into several distinct layers that
serve to maintain a state of homeostasis in the GI tract. As mentioned in Chapter 5
Section 5.1.1.1, these areas of the GI tract are known as gut-associated lymphoid tissue
(GALT). GALT can be broken down into three layers: (i) an epithelial layer comprised
of intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) (ii) lamina
propria containing lamina propria lymphocytes (LPLs) (iii) and a submucosal layer
comprised of organized lymphoid aggregates known as Peyer’s patches (PP), as well as
minor aggregates such as colonic patches (CP) and isolated lymphoid follicles
(ILFs). Each layer plays an important role in maintaining GALT functionality, and will
be described in greater detail.
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Figure 5.1
Organization of Gut-associated Lymphoid Tissue (GALT). The lymphoid tissue
responsible for the initiation of gut-associated immune responses is a highly organized system capable
of producing robust responses to antigens derived from both pathogens as well as commensal bacteria
present in the intestinal lumen (Mowat 2003).

5.1.1.2.1

Intestinal Epithelial Cells & Intraepithelial Lymphocytes

The intestinal epithelium is a single cell layer comprised mainly of absorptive
enterocytes. However, specialized lineages of intestinal epithelial cells (IECs) are also
present throughout the epithelial layer. These IECs are poorly phagocytic, but are
capable of producing large quantities of secretory molecules such as mucin 2 (MUC2)
and antimicrobial proteins such as C-type lectins that establish and maintain a
biochemical barrier to complement the physical barrier (Johansson, Phillipson et al. 2008;
Gallo and Hooper 2012). In addition to direct production of secretory components, IECs
are capable of directly transporting secretory IgA, a process more fully detailed in
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Chapter 5 Section 5.1.2. In addition to secreting luminal products, IECs are responsible
for maintenance of GALT function through regulation of immune cells as
well. Production of cytokines such as thymic stromal lymphoietin (TSLP), transforming
growth-factor β (TGF-β), and IL-25 as well as B cell-regulating factors such as B-cell
activating factor (BAFF) and proliferation-inducing ligand (APRIL) has been shown to
occur in IECs following signaling through a variety of pathogen-recognition receptors
(Zaph, Troy et al. 2007; Zaph, Du et al. 2008; Zeuthen, Fink et al. 2008. These factors
promote the development of tolerogenic dendritic cells and macrophages that in
combination with BAFF and APRIL have been shown to drive T cell-independent IgA
class-switching in naive B cells {Xu, 2007 #280).
In addition to IECs, the epithelial layer of the GALT is comprised of large
numbers of intraepithelial lymphocytes (IELs). This highly heterogenous population is
located at the basolateral surface of the epithelial layer of the GI tract as well as in the
intercellular space between epithelial cells (Cheroutre, Lambolez et al. 2011). Murine
IELs are CD3+ and express either the γδ (45-65%) or αβ (35-45%) T cell receptor with
80% of all IELs expressing CD8 (Lefrancois 1991; Maloy, Mowat et al. 1991). The αβ T
cell receptor of CD8+ IELs is predominantly found to be expressed as a CD8αα+
homodimer (Kunisawa, Takahashi et al. 2007). Upon activation, IELs display potent
cytolytic capacity, and both αβ and γδ IELs are capable of producing IL-2, IL-6, IFN-γ,
TNF-α, or TGF-β (James, Kwan et al. 1990; Taguchi, McGhee et al. 1990). The
activation of γδ IELs can result in expression of Fas ligand that been shown to have the
capacity to induce lysis in target cells during in vitro assays, suggesting the possibility
that IELs are capable of removing damaged IECs present in the epithelial layer (Sakai,
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Kimura et al. 1997). It’s important to note that the cytolytic capabilities of IELs can exert
both a protective role through removal of pathogens and maintenance of epithelial barrier
function, as well as a deleterious role through inflammation leading to epithelial barrier
disruption, and that further investigation into the role of IELs in mucosal immunity
remains a potentially lucrative research direction (Cheroutre, Lambolez et al. 2011).
5.1.1.2.2

Lamina Propria Lymphocytes

The lamina propria (LP) is a loose layer of connective tissue found beneath the GI
epithelial layer. This tissue has a high population of immune cells including
lymphocytes, plasma cells, and macrophages. Unlike IELs, LP T cells almost exclusively
express the αβ T cell receptor (approximately 95%), and maintain a CD4+ to CD8+ ratio
that shares greater similarities with peripheral T cells than IELs (James, Fiocchi et al.
1986; Fujihashi, Yamamoto et al. 1994). However, unlike peripheral T cells, LP T cells
express a greater frequency of surface markers recognized to indicate activation or
memory phenotypes, such as MHC Class II, αEβ7, IL-2R, and CD45RO (Schieferdecker,
Ullrich et al. 1992). While antigenic stimulation results in minimal proliferative capacity
from LP T cells, production of high levels of IL-2, IFN-γ, IL-4, and IL-5 have been
observed, suggesting that LP T cells are uniquely suited for enhancing B cell function in
order to maintain mucosal immunity (Qiao, Schurmann et al. 1991). Indeed, the majority
of LP B cells are plasma cells predisposed toward the production of IgA rather than IgM
or IgG.
5.1.1.2.3

Peyer’s patches

The final layer of GALT is located in the submucosa beneath the lamina propria. This
layer is comprised of organized lymphoid aggregates known as Peyer’s patches
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(PP). Unlike the intestinal epithelium and lamina propria which are primarily effector
sites, PP are the primary inductive site for mucosal immune responses. The unique
nature of PP as an inductive site leads to a complex organized structure comprised of
three regions, (i) follicle-associated epithelium (ii) the interfollicular region as denoted by
subepithelial dome (iii) and the germinal center.
In order to induce mucosal immune responses, antigen processing and
presentation must occur. In order to bypass the tight junctions sealing the epithelial layer
against the intestinal lumen, specialized epithelial cells, known as M cells, are found
periodically throughout the epithelial layer, and are found exclusively in epithelia
localized at MALT sites identified as follicle-associated epithelium (FAE) (Neutra
1999). The apical surface of the M cell has been identified to lack surface microvilli
while the basolateral surface is deeply invaginated to create a large extracellular space,
often containing leukocytes, and thought to be involved in the formation of germinal
centers. M cell differentiation has been observed to occur under the influence of
membrane bound LTα1β2 present primarily on B cells and lymphoid tissue-inducer
cells (Debard, Sierro et al. 2001; Schmutz, Bosco et al. 2009). M cells utilize
transepithelial transport in order to sample antigens from the intestinal lumen and
transport them to lymphocytes on the basolateral membrane of the FAE, consisting of the
interfollicular region or subepithelial dome. The interfollicular region of PP consists of
heterogenous population of cells including B cells, T cells, dendritic cells, and
macrophages where antigen presentation by dendritic cells and macrophages can take
place.
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Once antigen-presenting cells have processed antigen, presentation of antigen to T
and B cells can occur. PP are connected to the systemic immune system by high
endothelial venules, which allow for continuous migration of naive lymphocytes into the
PP. Once recognition of the processed antigen occurs, the formation of germinal centers
takes place underneath the subepithelial dome. In mice, these germinal centers are
comprised of approximately 60% B cells, 25% T cells (45% CD4+, 35% CD8+, 20%
CD4-CD8-), 10% dendritic cells, and 5% macrophages or neutrophils (Jung, Hugot et al.
2010). Several distinct dendritic cell subsets, including CD11c+CD8α+CD11b- lymphoid
dendritic cells, CD11c+CD8α-CD11b+ myeloid dendritic cells, and CD11c+CD8α-CD11b‘double negative’ dendritic cells can be found throughout the FAE, subepithelial dome,
and germinal center (Iwasaki and Kelsall 2000). Dendritic cells from PP exhibit
significantly altered functional differences when compared to splenic dendritic cells,
including increased potency in stimulation of allogeneic T cell proliferation, production
of IL-4 and IL-10, and priming of T cells for lower production of Th1-associated
cytokine IFN-γ (Iwasaki and Kelsall 1999). The skew in Th2-associated phenotype
within the germinal center allows for expansive production of immunoglobulin (Ig) by B
cells, predominantly IgA (approximately 70%) as opposed to the majority IgG observed
in peripheral lymph nodes (Butcher, Rouse et al. 1982). Once activated in the PP, IgA+ B
cells are capable of homing to a wide variety of effector MALT sites, contributing largely
to the systemic IgA response from an initial intestinal pathogen or commensal exposure
(Mora and von Andrian 2008).
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Figure 5.2
Induction of Intestinal Immune Responses in Peyer’s Patches. Peyer’s patches are the
primary inductive site of intestinal immune responses. M cells sample intestinal lumen for antigens,
which are then presented by dendritic cells to T and B cells present in germinal centers beneath the
subepithelial dome (SED). Once activated, effector B cells migrate to inductive sites such as the lamina
propria, where large amounts of IgA are produced (Cerutti 2008).

5.1.2

Immunoglobulins
In order to protect against the diverse array of pathogens that are encountered

every day, lymphocytes of the adaptive immune system must have the capacity to
recognize and respond in a highly specific and efficient manner. Immunoglobulins (Ig)
are heterodimeric proteins that contain a variable binding region that is capable of
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recognizing and binding antigens that can differ by single amino acids, allowing for
highly specific responses to an antigen. Ig are produced by both naïve and activated
mature B cells, and are found as both soluble, secreted proteins in addition to acting as B
cell receptors when bound to the B cell membrane (Klein, Rajewsky et al. 1998).
Secreted Ig are capable of binding to specific antigens or toxic products, induce
recruitment and activation of other immune cells to remove recognized pathogens, and
neutralize viral pathogens and mark them for destruction via phagocytosis. Antigen that
is recognized and bound by membrane-bound Ig results in several distinct changes in the
B cell as activation occurs that allows for a robust and antigen-specific response.
Several distinct isotypes of Ig exist, and exert different roles in signaling and
effector response to antigens. The initial Ig produced by mature, naïve B cells are IgM
and IgD. IgM is a low specificity Ig that is found in both secreted and membrane-bound
forms. IgD is found primarily as a membrane-bound Ig, and is found alongside surface
IgM and is capable of transducing activating and inhibitory signals in B cells (Lutz,
Ledermann et al. 1998). Following antigen recognition by surface IgM or IgD and
concurrent stimulation by signaling via accessory cells such as dendritic cells or T cells,
the naïve B cell undergoes a process known as isotype class switching where
chromosomal alterations result in the production of the more highly specific Ig including
IgG, IgA, and IgE (Stavnezer, Guikema et al. 2008). IgG is the predominant isotype in
the blood (approximately 70 – 75%), and four subclasses have been identified IgG1,
IgG2 (IgG2a and IgG2b in mice), IgG3, and IgG4 (humans only). Considered the
hallmark of immunological memory for humoral immune responses, IgG is capable of
activating the complement system, and has been shown to induce activation of immune
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cells via binding to FcR-expressing cells such as macrophages, natural killers cells, B
cells, neutrophils, dendritic cells, and eosinophils (Bruhns 2012; Karsten and Kohl 2012).
IgE is found at the lowest concentration of any Ig isotype in the blood, but has been the
focus of intense scrutiny due to the close association of IgE with hypersensitivity
reactions, in addition to host defense against parasitic infections.
IgA is the final Ig isotype, and while it is found to contribute only 10 – 15% of the
total Ig in blood, IgA is the predominant and primary antibody present at mucosal sites.
Mucosal IgA is primarily found as a secreted dimer, and this dimerization occurs via a
polypeptide known as the J chain, which is highly expressed by B cells present in
mucosal sites and is critical for IgA function. B cells on the basolateral surface of the
epithelial layer of mucosal surfaces are sequestered from environmental pathogens. In
order for IgA from activated B cells to reach pathogens for neutralization, transport
across the epithelial barrier must occur. When IECs recognize pathogen in the intestinal
lumen via toll-like receptor 4, signaling mediated by the intracellular adaptor protein
MyD88 occurs leading to increased production of the polymeric Ig receptor (pIgR) on the
basolateral surface of the IEC (Bruno, Rogier et al. 2010). While epithelial cells
constitutively express pIgR, use of targeted deletion of Myd88 in transgenic mice has
demonstrated that loss of MyD88 severely impacts expression of pIgR on the basolateral
surface of IECs, leading to subsequently reduced IgA transcytosis (Frantz, Rogier et al.
2012). Binding of J chain present on dimeric IgA to pIgR results in a calcium-dependent
transcytosis of the IgA-pIgR complex through the IEC cytosol (Giffroy, Courtoy et al.
2001). Once the complex reaches the apical surface of the IEC, proteolytic cleavage
occurs, resulting in the release dimerized IgA containing a portion of the pIgR, known as
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the secretory component, resulting in a complex identified as secretory IgA (sIgA)
(Johansen and Kaetzel 2011). sIgA interacts with a wide range of viral, bacterial, and
parasitic pathogens that are present at the mucosal surface. Unlike IgG, sIgA does not
induce activation of inflammatory immune cells, acting primarily through neutralization
by binding microbial adhesins, agglutination, and mucus trapping leading to exclusion of
pathogens from the mucosa (Woof and Kerr 2006).

Figure 5.3
IgA Transcytosis. Transport of IgA across epithelium is a complex, highly regulated
process. Recognition of antigens by toll-like receptors (TLRs) expressed by epithelial cells results in
myD88-mediated transcription of PIGR, resulting in expression of polymeric Ig receptor (pIgR) on the
basolateral surface of the epithelial cell. Dimeric IgA binds to PigR, and undergoes transcytosis
through the epithelial cell. Once on the luminal surface of the epithelial cell, dimeric IgA is cleaved
while still carrying the secretory component (SC) (Johansen and Kaetzel 2011).

While the initiation of immunoglobulin-mediated immune responses typically
occurs following antigen recognition, the existence of ‘natural’ antibodies that are
produced by B-1 B cells have been identified (Lutz, Binder et al. 2009). These
antibodies, which are mostly IgM but also include IgG and IgA, are characterized by
germline-encoded genes in the variable region leading to stable, partially-restricted
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reactivity pattern (Cukrowska, Sinkora et al. 1996). Production of these antibodies has
been shown to be induced following recognition of IL-4 produced by natural killer T
cells, but appears to be non-responsive to T cell major histocompatibility complexmediated signaling (Kamijuku, Nagata et al. 2008). The role of natural antibodies in the
recognition of self, altered self, and external antigens is an important first-response to
external invasion, but also in maintaining systemic homeostasis (Simon and Spath 2003).
While some studies have started to unravel the regulatory mechanism behind natural
antibody production, there remain several uncertainties providing areas of exploration for
further research.
5.2

RESULTS

5.2.1

Serum & Fecal Immunoglobulins in Naïve IP-/- Mice
Studies performed in our laboratory have shown that IP-/- mice have altered

inflammatory responses (Jaffar, Wan et al. 2002; Jaffar, Ferrini et al. 2007; Jaffar, Ferrini
et al. 2011). Further experiments were performed to determine if these effects were a
consequence of specific immunological defects in the IP-/- mouse. Previously unpublished
work done in our laboratory suggested that naïve IP-/- mice displayed decreased
production of immunoglobulins of several isotypes (Teri Girtsman, Ph.D. Thesis).
Specifically, naïve IP-/- mice displayed significantly reduced serum levels of IgG2b (93%
reduction), IgA (70%), IgG2a (60%), and IgG1 (41%), in addition to a non-significant
reduction in serum levels of IgE (43%) and IgG3 (38%) when compared to naïve
C57BL/6 (WT) mice. No differences in serum levels of IgM were described when
comparing IP-/- and WT mice. Since these immunoglobulin levels were analyzed in naïve
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mice and were not elicited by any overt immunization, they most likely represent innate
or ‘natural’ antibodies (Ochsenbein and Zinkernagel 2000).
A hallmark feature of mucosal immunity is the induction of a humoral immune
response and subsequent production of various classes of immunoglobulins. In terms of
secretory immunoglobulins, IgA has been previously described to comprise the majority
of secretory immunoglobulins produced in humans, followed by the various IgG
subclasses as well as IgM (Mestecky J 2005). The results described in Dr. Girtsman’s
thesis suggested that mice lacking prostacyclin signaling had significantly reduced serum
levels of ‘natural’ immunoglobulins that are specifically associated with mucosal
immunity. Therefore, we attempted to characterize more fully the role of prostacyclin
signaling in the regulation of mucosal-associated antibody production.
5.2.1.1 Naive IP-/- Mice Display Decreased Systemic Production of IgA & IgG2b
In an attempt to replicate the results described in Dr. Girtsman’s thesis, we
measured the serum antibody levels in IP-/- and WT mice as described in Chapter 2
Methods Section 2.0.8.1. Measurement of serum antibody levels revealed that IgG2b,
IgA, and IgG1 were significantly decreased when compared to WT mice (26 µg/ml
compared to 414 µg/ml, 126 µg/ml compared to 413 µg/ml, 447 µg/ml compared to 800
µg/ml, respectively), as well as a non-significant decrease in IgG2c (449 µg/ml compared
to 734 µg/ml)(Figure 5.4). In contrast to Dr. Girtsman’s data, we observed a nonsignificant increase in serum IgM and IgG3 levels in IP-/- mice when compared to WT
mice (953 µg/ml compared to 567 µg/ml and 615 µg/ml to 219 µg/ml,
respectively)(Figure 5.4). While there are some discrepancies in the serum antibody
levels observed in naïve IP-/- mice between this and Dr. Girtsman’s work, comparison of
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the data suggests that naïve IP-/- mice consistently display decreased serum antibody
levels of IgG2b and IgA when compared to WT mice.

Figure 5.4
Naïve IP-/- Mice Display Reduced Serum Levels of IgG1, IgG2b, and IgA. Serum
was collected via cardiac puncture from naïve IP-/- and WT mice and IgM, IgG1, IgG2b, IgG2c, IgG3,
and IgA levels were determined by ELISA. Data are mean (n= 4 – 5) and are representative of two
independent experiments. *p < 0.05, compared with WT group.
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5.2.1.2 Naive IP-/- Mice Display Decreased Bronchoalveolar and Fecal Secretion of
IgA
As described in section 5.2.1.1, IP-/- mice display significantly decreased serum
levels of IgA. However, IgA is recognized to be the primary immunoglobulin present at
mucosal locations including lymph nodes, small & large intestines, salivary glands, and
bronchus- & nasal-associated lymphoid tissue (BALT/NALT)(Macpherson, McCoy et al.
2008). This close association with mucosal surfaces directly correlates with the high
levels of IgA present in external secretions including nasal fluid, saliva, bronchoalveolar
lavage fluid (BALF), and fecal excretions (Mestecky J 2005). While systemic IgA is
found primarily in a monomeric form, IgA present at mucosal sites is primarily in a
dimeric form consisting of two monomeric IgA subunits linked via a polypeptide referred
to as the J chain (Koshland 1985). Recognition and binding of J chain by the polymeric
immunoglobulin receptor (pIgR), which is expressed on the basolateral surface of
epithelial cells, leads to transportation of dimeric IgA across the mucosal barrier
(Vaerman, Langendries et al. 1998). Following transport to the apical surface of the
epithelial cell, the IgA-J chain-pIgR complex is cleaved from the epithelial cell and
maintains a portion of the pIgR remains attached and is known as the secretory
component (Woof and Mestecky 2005). The majority (50-90%) of IgA present at
mucosal surfaces and in external secretions displays this secretory component and is
classified as secretory IgA (sIgA) (Woof and Mestecky 2005). In order to quantify sIgA,
our lab had previously developed a specific ELISA described in Chapter 2 Methods
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Section 2.0.8.2 in which anti-secretory component antibody was used for sample capture
and anti-IgA was used for sample detection (Jaffar, Ferrini et al. 2009).
For this study, we focused on the production of sIgA at two mucosal sites,
specifically the airways and gastrointestinal tract, by measurement of sIgA levels in the
BALF and fecal extract, respectively. Measurement of sIgA present in BALF revealed
that naïve IP-/- mice had markedly decreased BALF when compared to naïve WT mice
(Figure 5.5). Similarly, measurement of fecal sIgA revealed that naïve IP-/- mice had
significantly decreased fecal sIgA when compared to WT mice (Figure 5.5). These
results suggest that loss of prostacyclin signaling has a critical effect on sIgA production
at two distinct mucosal locations.

Figure 5.5
Naïve IP-/- Mice Display Reduced sIgA Production. Bronchoalveolar lavage fluid
and fecal content was collected from naïve IP-/- and WT mice and sIgA levels were determined by
ELISA. Data are mean (n= 6) and are representative of three independent experiments. *p < 0.05,
compared with WT group.

5.2.1.3 Immunohistological Examination of IgA+ B Cells in Naïve IP-/- Mouse
Intestinal Lamina Propria & Peyer’s Patches
The development of an IgA-mediated immune response can be divided into two
distinct phases occurring in similar, yet distinct locations within the mucosa. The
induction phase occurs primarily in mucosa-associated lymphoid tissues (MALT) and
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mucosa-draining lymph nodes, while the effector phase occurs primarily in the lamina
propria and surface epithelia of mucosal surfaces (Brandtzaeg, Kiyono et al. 2008). It has
been described since the 1970s that Peyer’s patches (PP) are MALT structures present in
the small intestine that are the main site of sIgA induction in humans, rodents, and
rabbits, and that stimulation of IgA+ plasmablasts in PP leads to recirculation and homing
to other mucosal sites outside the gastrointestinal system (Craig and Cebra 1971; Pierce
and Gowans 1975).
With the knowledge that naïve IP-/- mice appear to have significantly decreased
production of fecal IgA as described in Chapter 5 section 5.2.1.2, we examined the
intestinal mucosa to further analyze the underlying cause of IgA deficiency. Histologic
examination of the small intestinal tissue from naïve IP-/- and WT mice revealed that IP-/mice displayed a severely reduced presence of IgA+ B cells in the lamina propria when
compared to WT mice (Figure 5.6). Additional histologic examination of PP from naïve
IP -/- and WT mice revealed a similarly marked reduction in the presence of IgA+ B cells
when compared to WT mice (Figure 5.6).
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Figure 5.6
Naïve IP-/- Mice Display Reduced IgA+ B Cells in the Lamina Propria and
Peyer’s Patches. Histological examination of the lamina propria and Peyer’s patches of naïve IP-/- and
WT mice using immunofluorescence microscopy. (A) Intestinal cross-section of the small intestine
lamina propria. IgA+ B cells were stained with anti-IgA (green). (B) Intestinal cross-section of the
small intestine lamina propria (20X). (C) Peyer’s patches of the small intestine (60X). Sections were
stained with anti-CD45R/B220 (blue) and anti-IgA (red).
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Flow cytometry analysis of naïve IP-/- and WT PP revealed a marked reduction in
B220+IgA+ cells in naïve IP-/- mice compared to WT mice (7.6% compared to
16%)(Figure 5.7). No differences were observed when examining B220+IgM+ cells in
naïve IP-/- mice compared to WT mice (~11% in both strains)(Figure 5.7). These results
suggest that loss of prostacyclin signaling affects not only the presence of IgA+ B cells at
effector sites such as the intestinal lamina propria, but that the primary cause of the IgA
deficiency observed in naïve IP-/- mice could be a result of the reduced presence of IgA+
B cells present in PP resulting from a decreased inductive capability.
Wild-Type

78.4%

16.0%

IP-/-

7.60%

B220

65.1%

0.05%

0.33%

Wild-Type

75.1%

11.2%

IP-/-

11.0%

B220

69.7%

IgA

0.06%

0.19%

IgM
Figure 5.7
Flow Cytometry Analysis of Naïve IP-/- Mice Display Reduced IgA+ B Cells in
Peyer’s Patches. Peyer’s patches from naïve IP-/- and WT mice were excised from the small intestine
and mechanically and chemically dissociated. Peyer’s patch cells were stained with anti-B220 (APC),
anti-IgA (FITC), and anti-IgM (PE) and analyzed for receptor and immunoglobulin expression using a
BD FACSAria flow cytometer.
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5.2.2

Characterization of Altered Intestinal Secretory IgA Production in Naïve

IP-/- Mice
5.2.2.1 No Alteration in Peyer’s Patch Development or Structure is Observed in Naïve
IP-/- Mice
Development of PP in the gastrointestinal tract occurs during embryogenesis,
after approximately 16 days in mice, and is controlled by IL7R+CD3-CD4+CD45+ cells
known as lymphoid tissue inducer cells (LTIs)(Yoshida, Honda et al. 1999). These LTIs
are responsible for the recruitment and attachment of VCAM-1+ and ICAM-1+ stromal
cells in the intestinal wall as a structural base for the formation of PP (Lamichhane,
Azegami et al. 2014). Studies utilizing a variety of transgenic knockout-mice have
demonstrated that deficiency in LTI-produced lymphotoxin-α & -β, as well as loss of
LTI-expressed lymphotoxin-β receptor and IL-7R results in lack of PP development
(Alimzhanov, Kuprash et al. 1997; Futterer, Mink et al. 1998; Yoshida, Honda et al.
1999). Similar to other secondary lymphoid tissues such as the spleen and lymph nodes,
PP are organized into follicles comprised of B-cell rich germinal centers and T-cell rich
intrafollicular regions, although unlike lymph nodes and spleen, the PP germinal centers
are found even under homeostatic conditions due to the constant stimulation by
commensal bacteria present in the intestinal lumen (Kunisawa, Kurashima et al. 2012).
As PP are the main inductive sites for IgA-mediated immune responses, a reduction in
the number of PP present in the small intestine or alteration in the gross follicle structure
could be responsible for the marked reduction of IgA+ B cells present in the lamina
propria of the intestines of naïve IP-/- mice described in Chapter 5 section 5.2.1.3.
However, examination of PP in the small intestines of naïve IP-/- mice revealed no
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significant differences in the total number of PP when compared to WT mice (data not
shown). The binding of peanut agglutinin (PNA) by B cells to characterize PP germinal
centers has been described previously (Butcher, Rouse et al. 1982), and
immunofluorescence microscopy utilizing PNA staining revealed that germinal center
formation was unaffected when comparing IP-/- and WT mice (Figure 5.8). The failure to
generate intestinal lymphoid tissues such as PP might have been a consequence of
alterations in LTI cells, but these results suggest loss of prostacyclin signaling does not
adversely affect the ability of LTI cells to induce generation of intestinal lymphoid
tissues. Additionally, these results suggest that loss of prostacyclin signaling does not
result in reduced formation or gross structural defects of PP in the small intestine that
could be responsible for the reduced IgA observed in the fecal secretions of naïve IP-/mice.

WT

IP-/-

Figure 5.8
Naïve IP-/- Mice Display No Alteration in Peyer’s Patch Germinal Center
Formation. Histological examination of Peyer’s patch germinal centers in IP-/- and WT mice using
immunofluorescent microscopy. Sections were stained with peanut agglutinin (PNA)(red), antiCD45R/B220 (green), and DAPI (blue)(40X)
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5.2.2.2 Naïve IP-/- Mice Display Decreased Intrafollicular CD3+ Cells in Peyer’s
Patches
Although there were no observable differences in the total number or gross
structural organization of naïve IP-/- mouse PP as described in Chapter 5 section 5.2.2.1,
alterations in the presence of specific immune cell populations required for the initiation
of an IgA-associated immune response could be responsible for the reduction in IgA
observed in naïve IP-/- mice. In addition to the T and B cell populations that comprise
approximately 95% of the immune cells present in the PP, dendritic cells are found in the
subepithelial dome region in addition to the intrafollicular region and are involved in the
recognition and presentation of intestinal antigens to T and B cells present in the PP
(Milling, Yrlid et al. 2010). Utilizing immunofluorescent microscopy, we found that the
PP of naive IP-/- mice displayed a marked reduction in CD3+ cells in the inter-follicular
region when compared to WT mice, while no noticeable differences in B220+ cells were
observed in the germinal centers (Figure 5.9).
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IP-/-

Figure 5.9
Naïve IP-/- Mice Have Decreased Numbers of CD3+ cells in Peyer’s Patch
Intrafollicular Regions. Histological examination of Peyer’s patch germinal centers in IP-/- and WT
mice using immunofluorescent microscopy. Sections were stained with anti-CD3 (pink) and antiCD45R/B220 (green)(20X)

Interestingly, specific analysis of CD3+ cells present in the PP utilizing FACS indicated
that while there was a slight decrease in the number of CD3+CD4+ cells present in the PP,
a more substantial decrease was observed in the number of CD3+CD8+ cells present in the
PP of naïve IP-/- mice when compared to naïve WT mice (Figure 5.10). Although CD8+ T
cells are traditionally recognized to suppress Ig production in B cells (van Vlasselaer,
Gascan et al. 1992), more recent work has shown that IFN-γ produced by CD8+ T cells
can preferentially induce B cell class switching from IgG1 to IgG2a and IgG2b (Mohr,
Cunningham et al. 2010). These results suggest that alterations in the CD3+ cells in the
PP could be a potential cause of the IgA deficiency observed in naïve IP-/- mice.
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Figure 5.10
FACS Analysis of Naïve IP-/- Mice CD3+ Cells in Peyer’s Patches. Peyer’s patches
-/from naïve IP and WT mice were excised from the small intestine and mechanically and chemically
dissociated. Peyer’s patch cells were stained with anti-CD3 (AF647), anti-CD4 (FITC), and anti-CD8
(FITC) and analyzed for receptor expression using a BD FACSAria flow cytometer.

5.2.2.3 Naïve IP-/- Mice Display No Alteration in the Number of ILC3 Cells Present in
Peyer’s Patches
As described in more detail in Chapter 4 section 4.2.1.1, naïve IP-/- mice display
increased systemic expression of activating receptor NKp46 (Figure 4.9). While NKp46
is primarily recognized as a natural killer cell activating receptor, in the last few years
much attention has been focused on describing, characterizing, and classifying new
populations of NK-related innate immune cells (Walker, Barlow et al. 2013) (Spits, Artis
et al. 2013). These cells, known as innate lymphoid cells (ILCs), play a critical role in
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the regulation of several mucosal inflammatory responses, including asthma and Crohn’s
disease (Geremia, Arancibia-Carcamo et al. 2011; Halim, Krauss et al. 2012). The
current classification system divides ILCs into 3 distinct groups based on cytokine
production, surface receptor expression, and transcription factor expression (Spits, Artis
et al. 2013). Several well-described innate lymphocytes populations, such as natural
killer cells and LTIs, have been recognized to share several distinctive characteristics of
ILCs and have been included in the ILC classification.
In terms of intestinal immunity, Group 3 ILCs (ILC3s) have been shown to be the
most prominently involved ILC population (Luci, Reynders et al. 2009). The Group 3
ILC family is comprised of NKp46+ ILC3s, NKp46- ILC3s, and LTIs, classified
primarily on the requirement of IL-7 for development, expression of transcription factor
RORγt, and production & responsiveness to Th17-associated cytokines (Walker, Barlow
et al. 2013). Of particular interest, splenic NKp46+ ILC3s have been demonstrated to
reside in the splenic marginal zone and produce IgA-promoting factors APRIL and BAFF
(Magri, Miyajima et al. 2014). The ability to influence IgA production, when taken into
consideration with the alterations in NK cell populations described in Chapter 4, make
NKp46+ ILC3s an intriguing possibility for involvement in the IgA deficiency observed
in naïve IP-/- mice.
In order to determine the possible role of NKp46+ ILC3s, we analyzed Peyer’s
patches of naïve WT and IP-/- mice utilizing FACS for alterations in cellular markers
typically associated with Type 3 ILCs. As observed in Chapter 4 Results section 4.2.1.1,
naïve IP-/- mice displayed a markedly increased number of NKp46+ cells in the PP when
compared to naive WT mice, which were evenly distributed between NK1.1+NKp46+ and
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NK1.1-NKp46+ groups (Figure 4.9). Further examination of NKp46+ cells from naive
IP-/- and WT mice PP revealed that there was no expression of ILC3-associated surface
markers IL23r, CD127, or intracellular expression of transcription factor RORγt observed
in either mouse strain (Figure 5.11). These results suggest that, while NKp46+ cells are
increased in the PP of naïve IP-/- mice, these cells are likely to be NK cells, not ILC3s,
based on expression of ILC3 cellular markers. The role of these NK cells in the IgA
deficiency observed in naïve IP-/- mice remains to be determined.
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Figure 5.11
FACS Analysis of Naïve IP-/- ILC3 Cells in Peyer’s Patches. Peyer’s patches from
-/naïve IP and WT mice were excised from the small intestine and mechanically and chemically
dissociated. Peyer’s patch cells were stained with anti-NKp46 (PE, APC), intracellular anti-RORγt
(APC), anti-IL-23r (PE), and anti-CD127 (IL-7r)(APC) and analyzed for receptor and transcription
factor expression using a BD FACSAria flow cytometer.
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5.2.2.4 In vitro Stimulation of Peyer’s Patches from Naïve IP-/- Mice with IL-23
Results in Decreased Production of IL-22
The main effector cytokine of group 3 ILCs is recognized as IL-17 (Spits, Artis et
al. 2013). However, NKp46+ ILC3s have been shown to produce IL-22, not IL-17,
following stimulation with IL-23 (Cella, Fuchs et al. 2009). IL-22 is a member of the IL10 family of cytokines, and exerts an important role in intestinal defense and epithelial
barrier integrity (Tumanov, Koroleva et al. 2011). In order to determine whether IL-22
production in the PP was impacted by loss of prostacyclin signaling, we performed in
vitro stimulation of dissociated PP with IL-23 as described in Chapter 2 Methods Section
2.0.7.1. Stimulation of PP with IL-23 resulted in significantly decreased production of
IL-22 in naïve IP-/- mice when compared to WT mice (125 pg/ml compared to 325
pg/ml)(Figure 5.12). Additionally, we attempted to measure IL-17 production in
dissociated PP following IL-23 stimulation, but IL-17 levels were found to be below the
threshold of detection. These results suggest that loss of prostacyclin signaling leads to a
reduction of IL-23-derived IL-22 production in the PP that could have potential
deleterious effects on intestinal immunity.
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Figure 5.12
Peyer’s Patches from Naive IP-/- Mice Display Reduced Production of IL-22 in
Response to IL-23 Stimulation. Peyer’s patches from naïve IP-/- and WT mice were excised from the
small intestine and mechanically and chemically dissociated. Peyer’s patch cells were stimulated with
recombinant IL-23 (20 ng/ml) for 24 h and supernatants analyzed for IL-22 production by ELISA. Data
are mean ± SEM (n=6) in triplicate and are representative of two independent experiments. *p < 0.05,
compared with WT mice

5.2.3

Depletion of Natural Killer Cells Does Not Affect Natural IgA or IgG2b in

Naïve IP-/- Mice
As described in Chapter 4, the altered natural killer cell population found in naïve
IP-/- mice demonstrated an effective ability to regulate the development of asthma, a
classically defined Th2-associated disease. Regulation of Th2 effector function by this
altered lymphocyte population could therefore be a possible mechanism underlying the
immunoglobulin deficiency described in Chapter 5 section 5.2.1.1. In order to examine
this hypothesis, depletion of NK cells utilizing anti-NK1.1 mAb PK136 was performed in
naïve WT and IP-/- mice as described in Chapter 2 Methods Section 2.0.5.1. ELISA
analysis of serum and fecal IgA levels in both IP-/- and WT mice revealed that depletion
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of NK1.1+ cells did not significantly alter sIgA production when compared to nondepleted control mice of either strain (Figure 5.13). These results suggest that NK cells
are not responsible for the sIgA deficiency observed in naïve IP-/- mice.
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Figure 5.13
Systemic Depletion of NK Cells Does Not Alter Serum or Fecal IgA Levels.
Naïve IP-/- and WT mice received intraperitoneal (i.p.) injection of PK136 (250 µg) on day 0, followed
by subsequent i.p. injection on day 3, 6, 10, and 13. Serum and fecal samples were collected on day 14
and analyzed by ELISA. Data are mean (n=6; n=5) and are representative of three independent
experiments. *p < 0.05, compared with WT mice

5.3

DISCUSSION
Early characterization of IP-/- mice revealed that total serum immunoglobulin

levels were markedly reduced compared to WT mice. It is important to note in this study
that both IP-/- and WT mice were maintained germ-free in techniplast isolators, and
should be considered specific pathogen free, however they are likely to retain undefined
commensal intestinal microflora. Consequently, serum immunoblobulin levels of naïve
mice are likely to reflect the release of natural antibodies as well as antibodies elicited by
residual microflora. Natural antibodies have been shown to play a critical role in the
protection of mucosal surfaces through neutralization, maintenance of B cell homeostasis,
binding and clearance of bacterial pathogens, and recognition of self-antigens
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(Ochsenbein, Fehr et al. 1999; Ehrenstein and Notley 2010; Panda, Zhang et al. 2013).
Consequently, understanding the regulatory processes underpinning the production of
natural antibodies has potential to greatly expand potential health outcomes. While the
role of prostaglandins in controlling antigen-specific B cell responses has been well
characterized, the role of prostaglandins in the regulation of non-specific natural antibody
production remains unresolved.
In this study, we attempted to elucidate the effects of prostacyclin on the serum
antibody levels. Natural antibodies have been previously described as non-specific
immunoglobulins which are predominantly IgM, but may also include IgG or IgA, that
are constitutively produced by B cells in the absence of antigenic stimulation
(Cukrowska, Sinkora et al. 1996). Consistent with previously unpublished work
performed in our lab, IP-/- mice displayed attenuated production of natural antibodies.
Analysis of serum antibody levels in naïve IP-/- mice revealed that IgG2b, IgG2a, and IgA
were dramatically reduced in comparison to WT mice. Additionally, secretory IgA levels
in fecal contents were also found to be significantly reduced in IP-/- mice. The
production of IgA by IgA+ plasmablasts located in the PP and LP of the intestinal mucosa
is likely a major contribution to serum IgA levels (Craig and Cebra 1971; Pierce and
Gowans 1975). Consistent with the findings that intestinal production of IgA was
decreased in IP-/- mice, a reduced presence of IgA+ B cells in both the LP and PP was
observed. As total B cell numbers remained unchanged between strains, these results are
suggestive of alterations in the capacity of intestinal B cells to undergo class-switching
from IgM, putatively as a result of deficiencies in prostacyclin signaling. Indeed, work
performed by Roper et al indicated that prostaglandins, specifically PGE2, have the
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capacity to induce B cell class-switching in the production of IgG1, although the
mechanism by which this occurs is still under scrutiny (Roper, Graf et al. 2002).
Supporting this hypothesis, we observed no differences in intestinal IgM+ B cells,
suggesting that naïve B cells are not undergoing differentiation into IgA or IgG2bproducing B cells. In this context, it is interesting to note that both IgA and IgG2b
isotype switching is dependent on TGF-β and both isotypes are absent in mice lacking
TGF-β (Borsutzky, Cazac et al. 2004; Park, Seo et al. 2005).
Since several different mechanisms could be responsible for the regulation of B
cell responses in the intestinal mucosa, we attempted to elucidate specific alterations in
the IP-/- mouse that could lead to altered antibody production. While the formation of PP
in the intestinal epithelium is not a strict requirement for the induction of mucosal IgA
responses to oral antigens, loss of PP has been demonstrated to have deleterious affects
on the intestinal IgA response to bacterial pathogens (Yamamoto, Rennert et al. 2000;
Hashizume, Togawa et al. 2008). Examination of the gross structure of PP revealed that
loss of prostacyclin signaling does not lead to any alterations in overall development of
PP formation or number present in the intestinal mucosa. Similarly, structural formation
of PP in IP-/- mice appeared to be unaffected since the number and size of germinal
centers within the PP was normal when visualized using peanut agglutinin. However,
determination of the cellular population comprising PP revealed that IP-/- mice have
reduced numbers of intrafollicular CD3+ lymphocytes. As CD4+ T cells are critical for
the activation and development of B cell responses, alterations in this population could
result in attenuated intestinal IgA production. Interestingly, analysis of T cell populations
within IP-/- PP revealed that the observed decrease in CD3+ T cells was CD8+ T cells, not
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CD4+ T cells. While CD8+ T cells are typically recognized to suppress immunoglobulin
production, recent work has demonstrated that CD8+ T cell-derived IFN-γ can
preferentially induce the production of IgG2a and IgG2b, and the results of our study
suggest a potential role for prostacyclin signaling in regulating CD8+ T cell responses
responsible for the induction of B cell class-switching (Mohr, Cunningham et al. 2010).
It is unclear how our finding of altered CX3CL1 production in IP-/- mice described in
Chapter 4 (Figure 4.20 and Figure 4.32) impacts the intestinal mucosa. However, it is
interesting to note that CX3CL1 is a chemotactic factor for both CD8+ T cells and NK
cells (Nishimura, Umehara et al. 2002). Conceivably, these types of cells are depleted
from the PP as a consequence of CX3CL1-mediated migration to the intestinal lumen.
However, further analysis of intestinal CD8+ T cell populations in the intestinal mucosa
of IP-/- mice will be needed to clearly establish the regulatory capabilities of prostacyclin
signaling in this regard.
While Th2-associated responses are classically involved in the differentiation and
development of B cell responses, factors derived from other immune cell populations also
can influence intestinal IgA responses. In the past few years, the field of immunology
has expanded greatly through the publication of studies involving the classification,
characterization, and immunoregulatory role of innate lymphoid cells (ILCs) (Walker,
Barlow et al. 2013) (Spits, Artis et al. 2013). Group 3 ILCs (ILC3s) have been
implicated to prominently regulate intestinal immune responses, and splenic ILC3s
expressing NKp46 have been demonstrated to produce IgA-promoting factors APRIL and
BAFF, which are responsible for T-cell independent B cell activation and differentiation
(Luci, Reynders et al. 2009; Magri, Miyajima et al. 2014). In Chapter 4 of this
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dissertation, we demonstrated that IP-/- mice have systemically increased expression of
NKp46, including in the PP (Figure 4.9). Although these cells were identified as NK
cells in the airway, the presence of increased NK1.1-NKp46+ cells in the PP could
indicate potential alterations in intestinal ILC3s. However, further characterization of
this NKp46+ population based on several ILC3-specific surface and transcriptional
markers revealed that these immune cells were unlikely to be ILC3s. It is possible that
alterations in the ILC3 population exist in the IP-/- mouse, as a high density of the
intestinal ILC3 population is present in the intestines exist in the LP and as IELs.
However, attempts to isolate cells from these locations proved to be unsuccessful, and
further studies involving these sites do represent an area of potential further development.
The regulation of asthma, a classically defined Th2-associated disease, by the altered NK
cells described in Chapter 4 of this dissertation, raises the interesting potential that NK
cells present in the airway and intestinal mucosa could be responsible for the decreased
production of natural antibodies through an as-of-yet undefined mechanism. However,
depletion of NK cells in both IP-/- and WT mice failed to lead to any significant
alterations in serum or fecal IgA levels.
Stimulation of dissociated IP-/- mouse PP with recombinant IL-23 resulted in
significantly decreased production of IL-22. As IL-22 exerts an important role in the
maintenance of intestinal defense and epithelial barrier integrity, deficiencies in IL-22
production have the capacity to greatly influence the intestinal mucosa (Tumanov,
Koroleva et al. 2011). However, IL-23-induced production of IL-22 is displayed by a
wide variety of immune cells in the intestinal mucosa, including Th17, Th22, γδ T cells,
NK cells, and ILC3s including LTIs (Zenewicz, Abraham et al. 2010). Prostaglandins,
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specifically PGE2, have been implicated to play a role in enhancing IL-22-mediated
signaling in the intestines, and PGI2 has been shown to promote the development of γδ T
cells in the airway that have the potential to produce IL-22 (Jaffar, Ferrini et al. 2011;
Martin, Beriou et al. 2014). Further studies will need to be completed in order to identify
the specific immune cell populations that are affected by loss of prostacyclin signaling
resulting in attenuated IL-22 production, and the specific mechanism in which
prostacyclin mediates regulation.
In summary, this study demonstrated that IP-/- mice display attenuated production
of antibodies in both the serum as well as the intestinal mucosa, representing a novel look
at the role of prostacyclin signaling on antibody production in the absence of a known
pathogen. Although further studies are needed to determine the exact mechanism
underlying this attenuation, this study suggests a previously unrecognized role for
prostaglandin signaling in the regulation of mucosal and systemic humoral immune
responses.
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Chapter 6
Conclusions
Mucosal barriers represent the most critical interface for the interaction between
the immune system and environmental pathogens. The regulation of immunological
function at these sites, through the actions of both exogenous and endogenous mediators,
should therefore be considered key to understanding how responses to environmental
pathogens are sequestered. In this dissertation, we attempted to elucidate the role of two
specific inflammatory mediators, S-nitrosoglutathione and prostaglandin I2, in the
regulation of immunity in the airways and gastrointestinal tract. Strong functional
parallels exist between PGI2 and nitric oxide (and by inference SNOs) since both are
potent inhibitors of platelet aggregation and vasodilation (Mitchell, Ali et al. 2008). Our
findings offer novel insights into how these vital inflammatory mediators regulate
immunological responses, and pave the way for new opportunities for therapeutic
approaches targeting mucosal-associated diseases.
The steady increase in the prevalence of asthma in developed and developing
countries over the past several decades represents a substantial public health crisis. The
heterogeneous nature of the disease has created difficulties in our ability to fully focus
our therapeutic options to lessen the impact and incidence of disease. Thus, a need has
been predicated for a deeper understanding of the basal mechanisms responsible for the
pathogenesis and resolution of asthma. Allergic asthma has been classically
characterized as a chronic inflammatory disorder driven by predominant activation of a
Th2-mediated adaptive immune response. However, attempts to regulate the Th2associated immune response have not proven effective at reversing the disease process as
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expected. Our data attempts to bridge our understanding of both the adaptive and innate
immune responses in the pathogenesis of asthma by expanding our knowledge of the
regulatory mediators S-nitrosoglutathione and prostaglandin I2.
Inhibition of S-nitrosoglutathinoe reductase with the specific inhibitor, SPL-334,
significantly reduced the development of allergic airway inflammation in a mouse model
of allergic asthma. This was the first demonstration that this class of inhibitor can limit
allergic airway inflammation. We speculate that this reduction is a consequence of
increased airway concentrations of S-nitrosoglutathione, which has been shown to
reverse allergic airway inflammation in response to allergen challenge. Limitations of
our study arise from the fact that we did not measure the total levels of SNOs in the
airway, or determine the cellular prevalence of S-nitrosoglutathione. Additionally,
SPL-334 was found to be relatively insoluble, making administration of the drug difficult,
and lack of access to GSNOR-/- mice as a comparative tool to analyze the efficacy of
SPL-334. Undoubtedly, resolution of these issues would be key to a more detailed
understanding of the molecular mechanism underpinning the attenuated inflammation
seen following SPL-334-mediated inhibition of S-nitrosoglutathione reductase.
Examination of the immunological properties of IP-/- mice revealed that the PGI2
receptor plays an important role in regulating the expression of NKp46 by NK cells, as
well as controlling the number of NK cells residing in the lung. This is the first time that
it has been shown that PGI2 signaling plays an important role in the immunobiology of
NK cells. In part, this may result from dysregulated expression or shedding of CX3CL1,
possibly as a consequence of either dendritic cells or endothelial cells lacking IP
expression. The resolution of the role of CX3CL1 signaling on the properties of
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pulmonary NK cells and allergic inflammation could be accomplished through the use of
CX3CL1-mCherry and CX3CR1-gfp reporter mice. Certainly, pulmonary NK cells in
IP-/- mice were shown to be responsible for attenuated development of allergic airway
inflammation following exposure to house dust mite allergen, although the mechanism
responsible remains to be resolved. These results suggest a previously unknown role for
prostaglandin I2 in the regulation of NK cell effector function, and also suggest a
previously underappreciated capacity for NK cell regulation of asthma pathogenesis.
Determining the effectiveness of specific IP antagonists in suppression of allergic
inflammation, in addition to the impact of CX3CL1 release in the airway is a high
priority and may form the basis for novel therapeutic approaches.
Our third study addressed how intestinal humoral immune responses are regulated
through the actions of prostaglandin I2. The observation that IP-/- mice displayed a
significant reduction in immunoglobulin production in the periphery and gastrointestinal
tract was unexpected. While we were unable to resolve the mechanism underlying this
effect, the potential role of CX3CL1 in modulating the reduced intestinal IgA response is
worthy of future investigation, as CX3CL1 has been shown to play a critical role in the
sampling of intestinal luminal antigens by dendritic cells (Niess, Brand et al. 2005).
In summary, the three complementary studies described in this dissertation
provide insight as to events that underpin mucosal inflammatory processes. Future
studies will focus on the examination of the relative role of NK cells and CX3CL1 in the
immunological defects described in the airway and gastrointestinal tract of IP-/- mice,
leading to greater understanding of the molecular and cellular processes responsible for
protection against environmental pathogens.
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